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HIV epidemic
Worldwide around 35 million people are living with HIV of which approximately 16 
million (almost 50%) are female. Of these women 1.5 million gave birth to a child in 
2013.[1] HIV can be transmitted from mother to child. The highest chance of this mother-
to-child transmission (MTCT) of HIV-1 occurs during delivery (10-20%), but there is also a 
chance of transmission during pregnancy (5-10%). Furthermore, during the breast feeding 
period an additional risk of 10-20% has been observed.[2]
Without intervention the chance of MTCT of the virus is 25-40% during pregnancy and 
delivery. This risk can be reduced to <2% if the mother and infant are treated with an-
tiretroviral therapy.[2] This great reduction of MTCT is driven by two mechanisms: 
1) minimizing the chance of infection during a possible blood-blood contact during 
delivery because of suppression of the virus in the mother by treating the mother 
(and achieving an undetectable viral load in blood).
2) some antiretrovirals cross the placenta barrier and reach the foetus, protecting the 
foetus against the virus at the moment of possible blood-blood contact.[3]
Treatment of HIV
At this moment 24 different antiretrovirals are available, disrupting different phases of 
the reproduction cycle of the virus. This leads to an allocation into six different classes of 
antiretroviral medication: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), 
non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PI), integrase 
inhibitors (II), entry inhibitors (EI) and fusion inhibitors (FI). Antiretroviral drugs are generally 
used in combinations of three or more drugs from more than one class to optimally 
suppress the virus and prevent drug resistance. This is called “combination AntiRetroviral 
Therapy”: cART. Table 1 lists all available antiretrovirals per class and also includes 
two “boosting” agents (ritonavir and cobicistat). These compounds inhibit the CYP3A4 
enzyme, and through this mechanism increase the exposure of antiretrovirals which are 
substrates for the CYP3A4 enzyme. This approach reduced the number of tablets or 
capsules to be used of the CYP3A4 substrates.
cART is also recommended for the treatment of pregnant women with HIV. When a 
woman is already using cART for her own health when she becomes pregnant this 
treatment regimen is mostly continued during pregnancy. However, treatment guidelines 
for middle- and high income countries  recommend to prevent the use of efavirenz during 
conception and early pregnancy due to potential teratogenicity.[3,6] Treatment-naive HIV 
infected pregnant women should start cART early in the second trimester with cART in 
the same regimen as non-pregnant patients. The preferred regimens consist of two NRTIs 
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with either a boosted PI or NNRTI. The European guideline includes the option to add 
raltegravir to the combination therapy if the viral load is not undetectable in the third 
trimester.[6] 
In the choice of a regimen for a pregnant woman many factors should be included: 
co-morbidities, convenience, adverse effects, drug interactions, resistance testing results, 
pharmacokinetics, information on safety for mother and foetus and experience with use 
in pregnancy. Physiological changes in pregnancy may lead to pharmacokinetic alter-
Table 1. Drugs for HIV treatment, available in 2015[4,5]
Class Mechanism of action Drugs
Nucleoside/nucleotide 
reverse transcriptase 
inhibitors
NRTI
NRTIs interrupt the HIV replication cycle via competitive inhibition of 
HIV reverse transcriptase and termination of the DNA chain. NRTIs are 
administered as prodrugs, requiring host cell entry and phosphorylation.
Abacavir
Didanosine
Emtricitabine
Lamivudine
Stavudine
Tenofovir
Zidovudine
Non-nucleoside reverse 
transcriptase inhibitors 
NNRTI
NNRTIs inhibit HIV-1 reverse transcriptase by binding and inducing the 
formation of a hydrophobic pocket proximal to, but not overlapping the 
active site.
Efavirenz
Etravirine
Nevirapine
Rilpivirine
Protease inhibitors
PI
HIV protease inhibitors function as competitive inhibitors that directly 
bind to HIV protease and prevent subsequent cleavage of polypeptides.
Atazanavir
Darunavir
Fosamprenavir
Indinavir
Lopinavir
Ritonavir
Saquinavir
Tipranavir
Boosters, CYP3A4 
inhibitors
Inhibitors of the cytochrome P450 3A4 liver enzyme, reducing the 
metabolism of CYP3A4 substrates.
Ritonavir
Cobicistat
Integrase inhibitors
II
HIV integrase is responsible for the transport and integrated attach-
ment of proviral DNA to host-cell chromosomes, allowing subsequent 
transcription by host enzymes of messenger and viral RNA and 
translation of viral proteins essential for the assembly of virus particles. 
IIs competitively inhibit the strand transfer reaction by binding metallic 
ions in the active site.
Dolutegravir
Elvitegravir
Raltegravir
Entry inhibitors (CCR5 
binding), EI
Binding the CCR5 co-receptor selectively and reversibly, blocking the V3 
loop interaction and inhibiting fusion of the cellular membranes.
Maraviroc
Fusion inhibitors
FI
Fusion inhibitors are peptides that bind to gp41  extracellularly to 
prevent the fusion of HIV envelope to the CD4 or other target cell wall.
Enfuvirtide
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ations, i.e. lower plasma levels of drugs and may necessitate increased dosages, more 
frequent dosing, or boosting, especially of protease inhibitors.[3] The next paragraph 
summarizes the mechanisms behind these pharmacokinetic changes.
Physiological changes in pregnancy affecting pharmacokinetics
Several physiological changes during pregnancy may influence absorption, distribution, 
metabolism and/or excretion of drugs. Increased gastric pH can decrease gastric ab-
sorption of weak acids and increase absorption of weak bases. Slower intestinal motility 
might influence absorption, in most cases increasing absorption. An increased volume of 
distribution during pregnancy can lead to a lower peak concentration (Cmax) at steady 
state. Changes in protein concentrations in the blood (albumin and alpha 1 glycopro-
tein acid) may lead to higher unbound concentrations of highly protein bound drugs. 
Hepatic clearance is dependent on protein binding, activity of metabolic enzymes and 
liver blood flow, all of which change during pregnancy. Protein binding decreases, 
metabolic enzyme activity is induced for most enzymes and liver blood flow increases. 
All factors can lead to increased clearance of drugs during pregnancy. Glomerular 
filtration rate and renal blood flow are increased during pregnancy, possibly decreas-
ing in the third trimester, an effect which also increases clearance of renally excreted 
drugs. The influence of pregnancy on tubular secretion and reabsorption is not known, 
but changes are suggested as pregnancy influences the renal handling of endogenous 
substances such as uric acid and glucose. The influence of pregnancy on transporters 
is getting more attention lately, because this might be an additional factor influencing 
excretion of drugs.[7-10]
Most of the alterations mentioned above lead to lower plasma concentrations of drugs 
during pregnancy, and possibly to below the effectiveness threshold level. A decrease 
in exposure during pregnancy has been described to be the case for several antiretro-
viral drugs, especially protease inhibitors,[11,12] leading to recommendations to increase 
the dose during the third trimester of pregnancy. Sub-therapeutic concentration of an-
tiretroviral agents is of particular concern as this not only may lead to development of 
resistance in the woman but also to HIV MTCT. It is therefore of great importance that 
our knowledge on the pharmacokinetics of antiretroviral medications in pregnancy is 
extended. This thesis contributes to this increased knowledge.
Pharmacokinetics of antiretroviral medication in pregnancy
This thesis starts with Chapter 2: “Pharmacological considerations on the use of an-
tiretrovirals in pregnancy” which summarizes and discusses publications concerning 
pharmacokinetic changes of antiretroviral drugs during pregnancy which were recently 
14 Chapter 1
published. In this review the articles published in 2012 were described.
At that time, for the majority of antiretrovirals information on pharmacokinetics during 
pregnancy was either not available, very limited, or contradictory. As changes in 
pharmacokinetics should be included in the choice of the antiretroviral regimen during 
pregnancy, we felt that there was a need to explore this further.
Pharmacokinetic data in pregnancy (or safety data) are not collected by the pharma-
ceutical industry during the development of a new drug. Pregnant women are simply 
excluded from registrational trials. Post-marketing studies investigating pharmacokinetic 
changes of drugs during pregnancy are set up by independent, academic, groups. 
In the US a study has been set up by the International Maternal Pediatric Adolescent 
AIDS Clinical Trials Network (IMPAACT) to study pharmacokinetics of antiretroviral drugs 
during pregnancy (P1026 protocol, clintrials.gov reference NCT00042289). The popu-
lation studied within this network is mainly black or Hispanic, with only a limited number 
of white patients included. Because the IMPAACT group includes a limited number of 
patients per compound in the study, and the population studied probably differs from the 
European population, we felt there was a need for an additional study. After successfully 
performing a proof of concept study, investigating the pharmacokinetics of saquinavir/
ritonavir in pregnant women, presented in chapter 3 of this thesis, an initiative was taken 
in 2008 to set up a network of hospitals investigating pharmacokinetics in pregnancy 
in Europe. A protocol entitled “Study on Pharmacokinetics of newly developed AN-
tiretroviral agents in HIV-infected pregNAnt women (PANNA)” was  developed by the 
Department of Pharmacy of the Radboud university medical center. Investigators treating 
HIV infected pregnant women, interested in pharmacokinetics and having the facilities 
to perform pharmacokinetic studies, located at different hospitals in Europe were invited 
to participate. A study group, consisting of infectologists, internists, gynaecologists and 
pharmacologists gave input in the set-up of the study. The first patients were recruited 
in 2009 and in 2015 the PANNA network comprises of 21 hospitals in 7 European 
countries (The Netherlands, Belgium, Germany, UK, Spain, Italy, Ireland), with central 
management at the Department of Pharmacy of the Radboud university medical center 
Nijmegen, the Netherlands. 
The study was conducted in compliance with the principles of the “Declaration of 
Helsinki”. Informed consent was obtained from each participant before entering the 
study. Approval of the Medical Ethics Committee from each individual centre involved 
and the national authorities if applicable was obtained. The study is registered at Clini-
calTrials.gov under number NCT00825929.
A selection of antiretrovirals to be studied was made based on the limited availability or 
absence of pharmacokinetic information in pregnancy. Compounds initially under inves-
tigation were: etravirine, efavirenz (UK/Ireland only), emtricitabine, tenofovir, atazana-
vir, darunavir, fosamprenavir, tipranavir, indinavir, raltegravir, maraviroc, enfuvirtide and 
maraviroc. In a later stage abacavir, rilpivirine, elvitegravir, cobicistat and dolutegravir 
were added.
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Pregnant women using (at least) one of the antiretrovirals indicated in the protocol (pre-
scribed by their treating physician) can be included. If they use more than one compound 
from the list, all compounds will be used for analysis. Blood samples are taken for a full 
pharmacokinetic curve in the third trimester of pregnancy (preferably around week 33), 
during delivery a cord blood and matching maternal sample are collected and after 
delivery (preferably 4-6 weeks) a full pharmacokinetic curve is taken (postpartum curve). 
The postpartum curve serves as the control curve representing the non-pregnant situation. 
The women are their own control, which decreases the variation due to which the 
number of patients to be included in the study can be limited. For each compound we 
aim to collect data from 16 women. Pharmacokinetic parameters are calculated using 
the non-compartmental analysis. The comparison between the third trimester pharmaco-
kinetic parameters and postpartum pharmacokinetic parameters is done using analysis 
of variance for paired samples, or using a t-test for paired samples.
Next to the pharmacokinetic information, safety and efficacy data are collected. At each 
visit blood samples are taken for haematology and biochemistry analysis and for viral 
load and CD4 T cell counts which are performed at the local hospital. The major part 
of this thesis comprises of the first results of the PANNA study. The study is still ongoing, 
but some medication arms have been closed and analysed, amendments have been 
drafted to include new antiretrovirals to the list of medication to be investigated.
In this thesis we present the results of this study for two protease inhibitors: atazanavir/r 
(ritonavir) in chapter 4 and darunavir/r in chapter 5; two NRTIs: tenofovir and emtricit-
abine in chapter 6 and the integrase inhibitor raltegravir (chapter 7). For rilpivirine no 
information was reported in the public domain, therefore we published the pharmaco-
kinetics and placental passage of the first two patients included using this compound in 
the PANNA study as a case report, see chapter 8 of this thesis.
Some antiretrovirals under study are rarely used in pregnancy, for example maraviroc. 
The PANNA network included seven patients over a period of 5 years. The P1026 
study, initiated by the IMPAACT group, encountered the same problem. This led to a 
co-operation between the two networks, starting with a joint presentation of the prelimi-
nary data at CROI 2013, resulting in a joint paper describing the pharmacokinetics and 
placenta passage of maraviroc, presented in chapter 9.
Physiologically based pharmacokinetic modelling
Executing these pharmacokinetic studies involves much time, effort and commitment of 
the investigators as well as the patients participating in such a study, and these studies 
are expensive to perform.
Physiologically based pharmacokinetic (PBPK) modelling is a mathematical (computer) 
technique to predict absorption, distribution, metabolism and excretion (ADME) of for 
example medication, based on physicochemical properties and in vitro biotransforma-
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tion. The model consists of different compartments corresponding to the different organs 
and tissues, connected by blood or lymph flows. Recently, a PBPK model including 
physiological changes in relation to duration of pregnancy (pregnancy PBPK model) 
has been developed by Simcyp. The pregnancy PBPK model can be used to predict 
exposure to drugs during pregnancy at any gestational age, and eventually predict 
exposure of increased doses of medication, and indicate the gestational age at which 
a dose increase should be suggested. The foeto-placental unit (combination of foetus, 
placenta, amniotic fluid, membranes and umbilical cord) is included as a perfusion-limit-
ed compartment running in parallel with the other maternal compartments.[13] 
The data derived from the PANNA study were used to verify whether darunavir pharma-
cokinetic parameters in pregnancy can reliably be predicted by the SimCYP pregnancy 
PBPK model, see chapter 10.
In conclusion, the aim of this thesis was:
to describe pharmacokinetic alterations of specified antiretroviral agents during 
pregnancy, and to indicate efficacy, safety and cord blood/maternal ratios.
17Introduction 
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Abstract
Purpose of review: Treatment with combination antiretroviral therapy during pregnancy 
reduces the chance of mother to child transmission of HIV. Physiological changes during 
pregnancy can lead to lower exposure to antiretrovirals, possibly resulting in virological 
failure. For most antiretrovirals, data on exposure during pregnancy and transplacental 
passage is limited. This review summarizes the most recent information on pharmacoki-
netics (including transplacental passage), efficacy, as well as the safety of antiretrovirals 
during pregnancy.
Recent findings: Intensive-sampling pharmacokinetic studies as well as observational 
studies using sparse sampling were performed to explore the exposure to antiretrovirals 
during pregnancy. Transplacental passage, efficacy (viral load at delivery and infection 
status of the newborn) and safety information were evaluated for several antiretrovirals.
Summary: For most nucleoside/nucleotide reverse transcriptase inhibitors and protease 
inhibitors, recent research shows a decreased exposure during pregnancy. However, the 
advantage of a general dose increase during pregnancy still remains unclear. For newer 
compounds and efavirenz, limited or no data on pharmacokinetics during pregnancy or 
transplacental passage are available, while the mechanisms of transplacental passage 
also remain unknown. For safety reasons, it will be important to monitor pregnancy 
outcomes in resource-limited settings during the implementation of the WHO guidelines 
(including the use of efavirenz during pregnancy).
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Introduction
Treatment with antiretrovirals, especially when used as combination antiretroviral therapy 
(cART), dramatically reduces the chance of mother to child transmission (MTCT) of HIV 
from 20% to less than 1%. Current perinatal guidelines recommend to start cART at 
12-14 weeks of pregnancy, or earlier in case of a CD4 count below 350-500 cells/
µL. Preferred agents to include in cART are: lamivudine, zidovudine, nevirapine, ritona-
vir-boosted lopinavir or atazanavir/r.[1,2] According to the US Department of Health 
& Human Services (DHHS) and British HIV Association guidelines, or triple therapy 
including nevirapine or efavirenz[3] may be used according to the WHO guidelines.
Physiological changes occurring during pregnancy can alter exposure to drugs. Examples 
include increased gastric pH, volume of distribution, glomerular filtration and cardiac 
output, decreased protein binding and alteration of cytochrome P450 activity. Recently, 
a meta-analysis of these changes during pregnancy was published.[4] The changes 
lead to lower exposure to antiretrovirals during (late) pregnancy in most cases. In turn, 
subtherapeutic drug levels could lead to virological failure and development of resistant 
virus and eventually to MTCT of HIV. In some studies, antiretroviral dose was increased 
in the third trimester of pregnancy to compensate for lower maternal exposure. Also, 
therapeutic drug monitoring (TDM) is recommended to check antiretroviral levels and 
perform dose increases on an individual level. Besides considerations with regard to 
maternal exposure, antiretrovirals can pass the blood-placenta barrier and might cause 
teratogenicity, induce premature birth or cause low birth weight. Yet, placenta passage 
of antiretrovirals can also ensure infant pre-exposure prophylaxis.
During clinical development exposure of pregnant women to new drugs is avoided, 
whereas after reaching the market they will be used by pregnant women. Hence, 
post-marketing studies are being performed focusing on pharmacokinetics during 
pregnancy, including transplacental passage. Also, the effects of antiretroviral use on 
MTCT, preterm delivery and teratogenicity are important issues here.
We now give an update of the most recent (since 2012) publications on these topics.
Pharmacokinetics and efficacy of antiretrovirals during pregnancy
An extensive review has recently been published,[5] covering pharmacokinetic studies on 
antiretrovirals in pregnancy until 2012. This earlier review concluded that, to optimize 
antiretroviral therapy during pregnancy, pharmacological changes during pregnancy 
and transplacental transfer should be taken into account. TDM of antiretroviral exposure 
in pregnant women was mentioned as an intervention to optimize therapy.
Two other reviews were published in 2012 on this subject.[6,7] Furthermore, Eley et al. 
published a meta-analysis of pharmacokinetic data of atazanavir during pregnancy.[8]
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In the following section, an overview of recent studies published on pharmacokinetics 
and efficacy of antiretrovirals during pregnancy is given for each antiretroviral class; a 
summary of the results and conclusions can be found in Table 1.[9,10-12,13,14-17,18-20,21,22,23]
Nucleoside/Nucleotide reverse transcriptase inhibitors
Two intensive-sampling pharmacokinetic studies, collecting pharmacokinetic curves 
during pregnancy (second and/or third trimester) and postpartum (in the same women), 
were published: emtricitabine[9] was described by the IMPAACT group and tenofovir 
and emtricitabine pharmacokinetics by the PANNA network.[10] Both studies observed 
decreased exposure (by approximately 25%) to these NRTIs during pregnancy, but 
conclude that dose adaptation seems not to be necessary during pregnancy. This con-
clusion was based on absence of an association with virological failure or MTCT,[10] or 
C24h exceeding the IC50 in all individuals.
[9] The clinical relevance of IC50 is uncertain, 
as it only reflects 50% inhibitory concentrations, whereas 100% inhibition of the virus is 
the aim in vivo.
Benaboud et al. reported two population-pharmacokinetic studies, describing lam-
ivudine[11] and tenofovir[12] in pregnancy. The developed population-pharmacokinetic 
models were based on blood samples obtained just before dosing (Ctrough) of pregnant 
women and non-pregnant women (controls).
The lamivudine exposure observed was close to the exposure of non-pregnant women 
and no dosage adjustment was advised.[11] For tenofovir, a 39% increase of clearance 
was observed during pregnancy. To guarantee similar Ctrough as nonpregnant adults, an 
increase in tenofovir dose should be considered for women from the second trimester to 
delivery.[12] Strength of these studies is that they use TDM data of non-pregnant HIV-infect-
ed women as control, and not only reference values in literature that are mostly based 
on pharmacokinetic studies in male patients or healthy volunteers. No information was 
given on MTCT and dosing advice was based on (not yet clinically validated) popula-
tion-pharmacokinetic models.
Non-Nucleoside Reverse Transcriptase Inhibitors
An intensive-sampling pharmacokinetic study was published on the pharmacokinetics 
of efavirenz 600mg once daily (q.d.) during pregnancy. Cressey et al.[13] compared 
second and third trimester efavirenz pharmacokinetic curves to postpartum curves of the 
same patients (n=25). This is of great interest because WHO treatment guidelines include 
efavirenz, tenofovir and emtricitabine as triple therapy to be used during pregnancy.
They found a slight increase of oral clearance and decreased predose and Ctrough 
concentrations in the third trimester. Efavirenz exposure during pregnancy after standard 
dosing remained in the therapeutic range. A limitation of this study is that the majority 
of patients were Thai (83%), and one MTCT took place, without known reason. These 
pharmacokinetic data support the use of standard efavirenz dosing during pregnancy.
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Protease Inhibitors
Calza et al.[14] compared trough lopinavir concentrations of the 400/100mg lopinavir/r 
tablet in pregnant women (n=21) vs. non-pregnant women (n=20). In this study, a slight 
but non-significant decrease in lopinavir Ctrough was found during the third trimester of 
pregnancy. Only virologically suppressed women could take part, possibly excluding 
women with subtherapeutic lopinavir levels. Furthermore, the number of patients included 
was very low for interindividual comparisons. Else et al.[15] compared the exposure 
of lopinavir soft gel capsules (SGCs) with the melt-extruded tablet during pregnancy. 
Despite a significant reduction in exposure during late pregnancy, the tablet formulation 
showed adequate concentrations (and higher than the SGC).
Patterson et al.[16] reported changes of unbound lopinavir plasma concentrations during 
different stages of pregnancy. The dose of lopinavir/r was empirically increased to 
500/125mg twice daily (b.i.d.) after week 30 of pregnancy. Pharmacokinetic curves 
were collected (n=12), at second and third trimester (400/100mg and 500/125mg 
b.i.d.) and postpartum. A less-than-proportional increase in exposure was seen after 
dose increase; the reason is not clear. Lopinavir free fraction did not significantly change 
during the second and third trimesters or postpartum, regardless of dose. Fayet-Mello 
et al.[17] also described unbound lopinavir plasma concentrations during pregnancy. 
They performed sparse sampling during pregnancy and postpartum in 42 women 
using 400/100mg lopinavir/r b.i.d. Total lopinavir concentrations were moderately 
decreased during pregnancy (31-39%), whereas unbound concentrations were not 
significantly altered (lopinavir free fraction was higher during pregnancy). Unbound 
lopinavir concentrations (but not the total concentrations) reported in the studies differ 
to some extent. This difference might be due to different analysis methods. Patterson et 
al. used a rapid equilibrium dialysis, whereas Fayet-Mello et al. used ultrafiltration. Fur-
thermore, the unbound concentrations were close to the lower limit of quantification and 
could possibly be less accurate.
All studies mentioned above conclude that for treatment-naive patients with wild-type 
virus, a dose increase of lopinavir is not necessary during pregnancy (using the tablet 
formulation). However, for treatment-experienced patients, generally needing higher an-
tiretroviral concentrations, TDM during pregnancy is advised.[15]
Atazanavir has been upgraded to the preferred agent for use during pregnancy in the 
July 2012 revised DHHS perinatal guidelines.[1] Similar to other protease inhibitors, lower 
exposure during pregnancy has been reported for atazanavir. This is also described in 
the current product characteristics of atazanavir.[18]
A systematic review reports results of 13 studies performed on atazanavir during 
pregnancy up to April 2012.[8] Pharmacokinetic studies (nine) as well as studies on 
safety and efficacy were reported, including one study with an increased dose during 
the third trimester (400/100mg q.d. atazanavir/r). The increased dose resulted in ther-
apeutic concentrations, but also a doubling of maternal grade 3-4 hyperbilirubinaemia. 
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As current cART includes compounds possibly reducing atazanavir C24h (i.e. tenofovir), 
a dose increase during the third trimester may be required. If available, TDM is recom-
mended to guide dose adaptations.
Recently, an intensive-sampling PK study applying higher atazanavir/r doses during 
pregnancy was published.[19] Pharmacokinetic curves were recorded in the second 
(300/100mg q.d.), third trimester after dose increase to 400/100mg q.d. and post-
partum at the original dose. Postpartum atazanavir levels were higher than in nonpreg-
nant adults. After dose increase, median atazanavir area under the curve (AUC) was 
similar to that seen in non-pregnant historical controls taking the standard dose. Con-
comitant tenofovir use seemed to reduce atazanavir exposure during the second and 
third trimester. These data suggest that a higher atazanavir/r dose should be used in the 
third trimester of pregnancy and is also to be considered during the second trimester, 
especially when tenofovir is coadministered and no TDM is available.
A study with fosamprenavir/r 700/100 mg b.i.d. in pregnant women, performing in-
tensive-sampling pharmacokinetics in the second (n=6) and third (n=9) trimester and 4 
weeks postpartum (n=9) was reported.[20] Amprenavir exposure was significantly lower 
in the second (35% lower) and third trimester (25% lower). For all patients viral load 
at delivery was <200 copies/mL and no MTCT was observed. Therefore, dose ad-
justment does not seem to be required for fosamprenavir/r b.i.d. administration during 
pregnancy. However, in pregnant women with significant protease inhibitor mutations, 
close virologic monitoring is suggested with the use of fosamprenavir.
A prospective, intensive-sampling pharmacokinetic study of indinavir/r 400/100mg 
b.i.d. in Thai pregnant women was performed by Cressey et al.[21] PK curves were 
collected in the second (n=13), third trimester (n=26) and postpartum (n=26). During 
pregnancy indinavir exposure was significantly reduced and approximately 30% of 
women did not achieve a target Ctrough (0.1 mg/L), and none did postpartum. Nineteen 
percent of the women had a viral load of more than 40 copies/mL at delivery; no 
vertical transmission occurred. Increasing the dose of indinavir/r during pregnancy to 
600/100 mg b.i.d. may be preferable to ensure adequate drug concentrations. No 
analysis was done linking high viral loads and plasma concentrations.
A study with limited pharmacokinetic sampling during the second and third trimesters, 
and 6 weeks postpartum was done in 16 pregnant women receiving 1250mg nelfinavir 
b.i.d.[22] Pharmacokinetic analysis of total and unbound nelfinavir and the M8 metabolite 
was performed. Compared with postpartum, AUC of total nelfinavir was reduced by 
46% in the third trimester, total M8 by 83%, unbound nelfinavir by 39%, and unbound 
M8 by 79%. Despite this major reduction in exposure, no MTCT occurred. No dose 
recommendation was given on the basis of this finding, as the number of patients in the 
study was low and only limited sampling was performed.
Zorrilla et al.[23] published a study with intensive-sampling (second and third trimester and 
postpartum) in 11 women using darunavir/r 600/100mg b.i.d. The AUC0-12h for total 
darunavir was 17-24% lower during pregnancy compared to postpartum, for unbound 
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darunavir the AUC0-12h was only 7-8% lower during pregnancy (n=6). All 12 infants were 
HIV-negative. The authors suggest that, because of the nonclinically relevant change 
in unbound (active) darunavir, dose adjustment is not required for pregnant women 
receiving darunavir/r 600/100mg b.i.d.
In addition, a case has been reported of a pregnant woman failing on 600/100mg 
darunavir/r b.i.d. in late pregnancy. Darunavir Ctrough values were lower than expected 
and etravirine (200mg b.i.d.) and maraviroc (150mg b.i.d.) were added to darunavir/r 
to ensure adequate treatment.[24]
Integrase Inhibitors
Croci et al.[25] described a case of a woman using lopinavir/r b.i.d. and raltegra-
vir 400mg b.i.d. during pregnancy. In the third trimester a raltegravir Ctrough of 0.21 
mg/L was reported. The baby was born not HIV-infected at 39 weeks gestational 
age. Exposure, based on a single trough sample, to raltegravir in the third trimester was 
similar to nonpregnant historical controls in this case. More pharmacokinetic studies are 
needed to confirm this finding.
Entry Inhibitors
In 2012 a poster was presented by the IMPAACT group and PANNA network at CROI 
2013 describing the first intensive-sampling pharmacokinetic data during pregnancy, 
including placenta passage information. Maraviroc exposure during pregnancy (third 
trimester) was 21% lower than postpartum (n=9). To make valid dosing recommenda-
tions, more data are needed.[26]
Transplacental passage
An extensive review was published in 2011, covering information available on trans-
placental passage of antiretrovirals as well as concentrations in amniotic fluid.[27] Most 
of the studies described in the pharmacokinetics section of this review also assessed 
transplacental passage. The results are summarized in Table 2.
Two recent papers described transplacental passage. Van Hoog et al.[28] summarized 
information on transplacental passage collected between 2003 and 2010 for nevirap-
ine, nelfinavir and lopinavir.
Transplacental passage is not only influenced by physical-chemical properties of drugs, 
but drug transporters located in the placenta can also play a role in the passage of 
drugs across the placenta. The current knowledge on expression and function of ABC 
and SLC transporters in the trophoblast has been summarized.[29] Olagunju et al.[30] 
reviewed potential effects of pharmacogenetics on maternal, fetal and infant antiret-
roviral drug exposure during pregnancy and breastfeeding. The potential of SNPs in 
transplacental passage was described in detail for nevirapine, efavirenz, lopinavir and 
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ARV, antiretroviral; CI, confidence interval; CV, coefficient of variation; EI, entry inhibitors; GM, geometric mean; IQR, in-
ter-quartile range; n, number; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase 
inhibitor; PI protease inhibitor; SD, standard deviation
Table 2. Transplacental passage of antiretrovirals
ARV
Cord blood : maternal blood 
ratio n ref
NRTIs
tenofovir 0.82 (0.64-1.10) median (range) 14 [10]
tenofovir 1.13 1 [24]
emtricitabine 1.63 (0.46-1.82) median (range) 10 [10]
emtricitabine 1.66 1 [24]
NNRTIs
efavirenz 0.49 (0.37-0.74) median (range) 25 [13]
nevirapine 0.67 (±0.15) median ± IQR 17 [28]
etravirine 0.51 1 [24]
PIs
lopinavir 0.24 (±0.21) median ± IQR 42 [28]
lopinavir total 0.17 ± 0.09 mean±SD 6 [15]
lopinavir unbound 0.31±0.09 mean±SD 6 [15]
total ritonavir 0.13 ±0.08 mean±SD 6 [15]
lopinavir total 0.16 (85%) mean CV% 16 [17]
lopinavir unbound 0.43 (83%) mean CV% 16 [17]
atazanavir - TDF 0.14 (0.05-0.84) median (range) >30 [19]
atazanavir + TDF 0.16 (0.03-4.08) median (range) >30 [19]
indinavir 0.12 (0.05-0.23). median (range) 19 [21]
nelfinavir 0.14(±0.36) median ± IQR 20 [28]
amprenavir 0.267 (0.241, 0.297) GLS mean (95% CI) 7 [20]
darunavir 0.15 (range 0.014-0.36) median (range) 9 [23]
darunavir 0.15 1 [24]
ritonavir 0.32 1 [24]
EI
maraviroc 0.33 (0.03-0.56) median (range) 6 [26]
maraviroc 0.37 1 [24]
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atazanavir, as well as raltegravir. There is still insufficient knowledge about the pharma-
cogenetics possibly influencing antireroviral exposure in pregnant women.
Safety of antiretroviral use during pregnancy
In general, a doubling of the percentage of preterm births (<37 weeks gestational age) 
is seen in HIV-infected women compared with non-HIV-infected women. Whether this is 
due to HIV infection, the use of cART in general, or more specifically the use of protease 
inhibitors, is not clear. An analysis over time (1990–2009) indicates that the use of cART 
seems to contribute to this increase, as the percentage of prematurity in HIV-infected 
women was higher in 2005–2009 (routine, mainly protease inhibitor based cART) than 
in 1990–1993 (no therapy).[31]
As treatment duration during pregnancy increases (also in resource-limited settings), the 
issue of risks of adverse effects of cART during pregnancy (such as prematurity and 
congenital abnormalities) is becoming more important. Western countries do have fa-
cilities to handle prematurity, but in resource-limited settings this might be an important 
safety issue. Some articles warn about these safety concerns when implementing the 
new WHO guidelines to treat all HIV-infected patients (also during pregnancy) with 
efavirenz.[32,33]
A prospective study (in the US) in 183 HIV-infected pregnant women, all using cART, 
report that the increase of small-for-gestational-age (SGA) births (compared with the 
non-HIV-infected population) in pregnant women with HIV is related to the severity of 
HIV disease and not to antiretroviral therapy.[34] As there was no control group (without 
cART), it is unclear how this conclusion could be drawn.
In French cohorts (n=13 271), a remarkable increase was reported in premature deliver-
ies when regimens recommended in pregnancy changed: 9.2% during 1990–1993 (no 
therapy), 9.6% during 1994–1996 (mostly zidovudine monotherapy) to 12.4% during 
1997–1999 (dual-nucleoside analog therapy) and 14.3% during 2005–2009 (routine 
cART therapy).[31] Prematurity was associated with cART, compared to zidovudine mon-
otherapy, when accounting for other factors. In 2005–2009, the prematurity rate was 
higher with boosted than with non-boosted protease inhibitor therapy (14.4% versus 
9.1%). It should be noted that the non-boosted protease inhibitor used was nelfinavir and 
the majority of the patients using a boosted protease inhibitor used lopinavir/r.
Birth defects in pregnancies with exposure to antiretroviral drugs in Italy (1257 pregnan-
cies) were reported over 2001–2011.[35] A birth defect prevalence of 3.2% for exposure 
during the first trimester was found (compared to 3.4% for no antiretroviral exposure 
during the first trimester). No associations were found between birth defects and an-
tiretroviral therapy, main drug classes or individual drugs. Preterm delivery occurred in 
20.9% of pregnancies.
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Nucleoside/nucleotide reverse transcriptase inhibitors
Possible renal and bone/growth problems in newborns, exposed intrauterinally have 
been investigated in several articles, recently. With the use of tenofovir as preexposure 
prophylaxis, conceptions during tenofovir use might increase.
Two articles report tenofovir use to be well tolerated during pregnancy. Pregnancies 
and infant outcomes of the DART trial (Uganda/Zimbabwe, period 2003–2009) have 
been described.[36] There was no evidence that tenofovir exposure during the intrauterine 
period (n=111) had any adverse effects on pregnancy outcomes or on congenital, renal, 
bone, or growth abnormalities up to age 4 years of age.
In a prospective study, bone status of infants exposed to antiretrovirals (n=38) was 
compared with bone status of unexposed children from HIV-negative mothers (n=94).[37] 
Antiretroviral exposure in utero seems not to negatively affect bone metabolism and bone 
development, and changes in bone quantitative ultrasonography measurements during 
the first year of life in antiretroviral-exposed individuals are similar to those occurring in 
healthy controls.
No difference was seen between bone development of infants intrauterinally exposed 
to tenofovir (n=15) and not-exposed to tenofovir (n=23). Only a small group of children 
was exposed to tenofovir, and follow-up was only 1 year; however, a sensitive method 
quantifying bone status was used.
In contrast, Siberry et al.[38] found a lower mean height (0.41 cm shorter) and head 
circumference (0.32 cm smaller) at 1 year of age for infants exposed to tenofovir in 
utero (n=449) versus infants exposed to non-tenofovir-containing regimen (n=1580), in-
dependent of early and late exposure in pregnancy. The significance of this finding is 
uncertain, but this underscores the need for studies with a sufficiently large number of 
patients.
Non-nucleoside reverse transcriptase inhibitors
Because of the increased risk of potentially life-threatening hepatotoxicity in women with 
high CD4 T cell counts, nevirapine should be started in pregnant women with CD4 T 
counts >250 cells/µL only if benefit clearly outweighs risk.[1]
A systematic review and meta-analysis of the safety of nevirapine use during pregnancy 
was performed.[39] The analysis included 20 studies representing 3582 pregnant 
women. Adverse events reported were severe hepatotoxicity (3.2%), severe rash in 3.3% 
of patients. Around 6% of the patients discontinued nevirapine due to an adverse event. 
Pregnant women with a high CD4 T cell count may be at increased risk of adverse 
events, but evidence supporting this association is weak.
Efavirenz is suspected to cause teratogenicity based on animal studies and retrospec-
tive case reports showing that efavirenz may be associated with neural tube and/or 
central nervous system abnormalities. As WHO treatment guidelines include efavirenz, 
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tenofovir and emtricitabine as triple therapy during pregnancy, safety information on 
the use during pregnancy is important. The US Antiretroviral Pregnancy Registry (APR) 
did not find an increased prevalence of overall birth defects with first-trimester efavirenz 
exposure compared to the overall US population.
A case report of bilateral oblique clefts and extremity anomaly in an infant after intrauter-
ine efavirenz exposure was recently published.[40] The mother used efavirenz (along with 
atorvastatin) at the time of conception until 5 weeks postconception, when she switched 
to nelfinavir and zidovudine/lamivudine. The relation between efavirenz exposure and 
this congenital anomaly cannot be confirmed, nor rejected. 
Protease inhibitors
Results of the APR were published in 2012,[41] with more than 200 first trimester exposures 
to atazanavir reported (the threshold for performance of comparative analyses). A total 
of 698 pregnant women were exposed, 425 in the first trimester. Rates of birth defects 
after atazanavir exposure (2.3%) are not different from those noted for other antiretro-
virals, nor from the reference population of the APR. As this is a voluntary registry, the 
number of anomalies found might be underreported.
Integrase inhibitors
Raltegravir is used in special cases during pregnancy only, that is in women presenting 
with HIV in late pregnancy with a high viral load or patients with no other options 
left. Recently, safety data on single and multiple cases were reported on regimens 
containing raltegravir as well as at least two other antiretrovirals.[25,42-46] They all report 
a viral load decline of approximately 1 log/week, being very effective in reaching an 
undetectable viral load around delivery. In total, 22 cases were described, with one 
case of likely in utero MTCT (maternal viral load at delivery was 64 copies/mL, delivery 
by caesarean section). Most case reports did report raltegravir use to be well tolerated 
during pregnancy, except for one case of increased serum aminotransferases during 
pregnancy.[45] In this patient, after 11 days of treatment with raltegravir, a substantial 
reduction in viral load was achieved, but she had a 23-fold increase in serum ALAT and 
a 10-fold increase in serum ASAT. Both returned to normal upon raltegravir discontinua-
tion. No congenital abnormalities were reported.
These articles suggest that raltegravir could be an option for women presenting with 
HIV late in pregnancy or having no treatment options left, being very effective in fast 
decreasing viral load. However, further studies are required to establish safety and 
pharmacokinetics of raltegravir during pregnancy.
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Conclusion
Physiological changes during pregnancy show a general trend to lower exposure to an-
tiretrovirals, with the largest decrease for boosted protease inhibitors. Increased fraction 
of unbound concentrations does not seem to compensate completely for this decrease. 
However, virological failure or MTCT has not yet been associated with lower concen-
trations in pregnancy. This apparent discrepancy can be explained by the fact that the 
large majority of pregnant women harbour wild-type virus and antiretroviral Ctrough, even 
when reduced by 23-35%, remains in the therapeutic range for this specific group of 
patients. Increasing the dose of lopinavir and atazanavir has been shown to effectively 
compensate for decreased exposure during pregnancy. Increasing the dose can be 
done guided by TDM in the second and third trimester, in the presence of tenofovir 
(boosted atazanavir) and in particular when patients have a history of virological failure 
on a previous cART regimen. For newer compounds and efavirenz, limited or no data on 
pharmacokinetics during pregnancy or transplacental passage are available.
The mechanisms of transplacental passage are not elucidated to date; further research 
on the role of transporters and placental metabolism is important to predict transplacen-
tal passage of new compounds. With regards to well tolerated use of antiretrovirals 
during pregnancy, monitoring of pregnancy outcomes in resource-limited setting during 
the implementation of the WHO-guidelines, allowing efavirenz during pregnancy, with 
emphasis on prematurity and congenital abnormalities, is important.
Raltegravir induces rapid viral decline during pregnancy and seems a fair option for 
women presenting with HIV in late pregnancy.
Key points
Physiological changes during pregnancy lead to lower exposure to antiretrovirals in most 
cases, especially for protease inhibitors.
The mechanism of transplacental passage should be subject of future research.
Adding raltegravir to cART seems an option for women presenting with HIV in late 
pregnancy.
Exposure to new antiretrovirals (and efavirenz) during pregnancy and transplacental 
passage should be subject of future research, also in resource-limited settings.
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Abstract
Background: Pregnancy affects the pharmacokinetics of most protease inhibitors. 
Saquinavir, when administered in a tablet formulation, is not studied extensively in this 
setting.
Methods: A pharmacokinetic, prospective multicentre trial of HIV type-1-infected pregnant 
women treated with saquinavir (500mg tablets) boosted with ritonavir at a dose of 
1,000/100mg twice daily plus a nucleoside backbone, was conducted. Pharmacoki-
netic curves were recorded for 12 h in the second trimester (week 20 GA ± 2), the third 
trimester (week 33 ± 2) and postpartum (weeks 4-6). Blood was sampled pre-dosing 
and at 1, 2, 3, 4, 6, 8, 10, and 12 h post-dosing. Pharmacokinetic parameters were 
calculated using WinNonlin software version 4.1.
Results: A total of 37 women were included in the analysis. Mean (±SD) values for 
saquinavir area under the curve (AUC0-12h) were 23.47 h⋅mg/L (11.92) at week 20 GA 
(n=16), 23.65 h⋅mg/L (9.07) at week 33 (n=31), and 25.00 h⋅mg/L (11.81) postpartum 
(n=9). There was no significant difference in the saquinavir AUC0-12h when comparing 
the data during pregnancy and postpartum Subtherapeutic plasma concentrations of 
saquinavir (defined as < 0.10 mg/L) were not observed throughout the study. No major 
safety concerns were noted.
Conclusions: Saquinavir exposure in the new tablet formulation generates adequate 
saquinavir concentrations throughout the course of pregnancy and is safe to use; 
therefore, no dose adjustment during pregnancy is needed.
45Pharmacokinetics of saquinavir in HIV-1 infected pregnant women
Introduction
At present, approximately 15.4 million women are infected with HIV, most of them 
of child-bearing age.[1] It is estimated that 39% of the European women with an HIV 
infection have a desire to bear children in the future, which is comparable to women 
without HIV infection.[2]
In order to prevent mother-to-child transmission of the virus, highly active antiretroviral 
therapy has shown to be the most effective strategy[3], reducing the chance of mother-to-
child transmission from 15-40% to <2%.[4] Owing to the teratogenicity of efavirenz and 
the toxicity of nevirapine in women with CD4+ T-cell counts >250 cells/mm3, the class 
of non-nucleoside reverse transcriptase inhibitors (NNRTIs) is contraindicated in most situ-
ations. Therefore, during pregnancy, a protease inhibitor (PI)-based regimen seems to be 
the most rational choice at present and is commonly used in the developed world (42% 
in the US and 65% in Europe).[5,6] At present, it is not clear what PI and at which dose 
results in the best outcome in terms of safety and efficacy during pregnancy.
According to the US Food and Drug Administration classification for medication use 
during pregnancy,[7] no category A drugs exist among the currently available PIs: (fos)
amprenavir, indinavir, and lopinavir are classified as category C, whereas atazanavir, 
darunavir, nelfinavir (NFV) and saquinavir are all categorized as B.[8] Despite this clas-
sification, indinavir and lopinavir in particular, are commonly used in clinical practice.
During pregnancy the human physiology alters, possibly affecting the absorption, distri-
bution, metabolism and excretion of several drugs.[9,10] The most profound changes that 
might interfere with the pharmacokinetics (PKs) are reduced intestinal motility, increased 
gastric pH, a larger plasma volume, decreased protein binding and induced hepatic 
enzymes. These changes all result in potentially lower exposure of certain medication 
during pregnancy. The use of drugs metabolized by the CYP3A4 iso-enzyme pathway 
is of special concern during pregnancy because its activity is substantially increased 
during gestation, resulting in lower drug concentrations and therefore possible decreased 
efficacy.[9,11] All PIs use this pathway to some extent and should be used with caution 
during pregnancy. Several PK studies have shown that, indeed, these changes have a 
significant impact on the PKs of different PIs when used during pregnancy [12]. However, 
it is questionable, whether all PIs are affected to the same extent.
Saquinavir has not yet been extensively studied in pregnancy, and published data for the 
new tablet formulation are lacking. Earlier data with the hard gel capsule (HCG) suggested 
that the concentrations of ritonavir-boosted saquinavir generate adequate concentrations 
during pregnancy.[13] Therefore, we studied the effect of pregnancy on the saquinavir concen-
trations of the new tablet formulation in an saquinavir/r 1,000/100mg twice-daily regimen.
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Methods
This was a multiple-dose, open-label, non-comparative, multicentre phase II trial 
designed to determine the pharmacokinetic profile of saquinavir 500 mg tablet formula-
tion combined with ritonavir (saquinavir/r 1,000/100 mg twice daily) in pregnant HIV 
type-1(HIV-1)-infected women.
The trial was performed in eight hospitals (seven in Europe and one in Thailand) between 
May 2005 and January 2008. Informed consent was obtained from each participant 
before entering the study. The trial was approved by the medical ethical committee from 
each individual centre involved.
Patients could be either treatment naive or treatment experienced, but without saquinavir 
failure or documented resistance in their history. For eligibility, HIV-1-infected women had 
to be between 18 and 40 years of age with a maximal gestational age (GA) of 31 
weeks. Patients were treated with saquinavir 500 mg tablet formulation plus ritonavir 
1,000/100 mg twice daily (with food) plus two nucleoside reverse transcriptase inhibi-
tors (NRTIs). The choice of the two NRTIs was at the discretion of the investigator, with a 
preference for zidovudine plus lamivudine (300/150 mg Combivir®).
Safety and viral load assessments
Inclusion screening consisted of: medical history, physical examination, serum biochem-
istry, haematology and qualitative urinalysis, hepatitis B/C serology, HIV-1 RNA and 
CD4+ T-cell determination. Analyses were performed by local laboratories. Blood 
samples for laboratory safety were further taken at baseline and at 4-8 week intervals. 
During the study, HIV-1 RNA and CD4+ T-cell determination were performed at baseline, 
at weeks 20, 28, 33 at delivery and at 6 weeks postpartum. Patients were asked for 
adverse events at each visit. Retrospectively, the HIV status of the infants was collected 
from the treating physicians. The DAIDS toxicity table (2004) was used to grade the 
reported adverse events. Grade of at least 3 laboratory abnormalities were described.
Pharmacokinetic blood sampling
A 12 h pharmacokinetic curve was recorded after minimally 2 weeks of saquinavir 
treatment. For patients included before GA week 20, a 12 h pharmacokinetic curve was 
recorded during the second trimester at week 20 GA (± 2 weeks) and optionally during 
the third trimester at week 33 (± 2 weeks). For patients included after GA week 20, the 
first curve was recorded at week 33 (± 2 weeks). All patients who continued with the 
saquinavir/r regimen after delivery could consent to have a 12 h pharmacokinetic curve 
recorded at 6 weeks (± 2 weeks) postpartum.
A standard breakfast was served prior to dosing on the pharmacokinetic days, and 4 
mL of blood was collected just before drug intake (pre-dose) and at 1, 2, 3, 4, 6, 8, 
10, and 12 h post-ingestion (9 samples) at all pharmacokinetic study days. Plasma was 
47Pharmacokinetics of saquinavir in HIV-1 infected pregnant women
separated and stored at <-18°C until shipment on dry ice.
Analytical and pharmacokinetic methods
Plasma concentrations of saquinavir and ritonavir were assayed at the Department 
of Clinical Pharmacy of the Radboud University Nijmegen Medical Centre, using a 
validated high-performance liquid chromatography assay with ultraviolet detection.[14] 
The lower limit of quantification was 0.045 mg/L for both ritonavir and saquinavir.
Pharmacokinetic parameters were determined using WinNonlin version 4.1 (Pharsight 
Corporation, Mountain View, CA, USA).  Area under the curve (AUC0-12h), minimum 
concentration (Cmin) defined as the sample taken at 12 h,  maximum concentration (Cmax), 
elimination half-life (T1/2), time of maximum concentration (Tmax ) and clearance (CL/F) 
were determined per individual curve.
Statistical analysis data handling
Drop-outs were defined as patients who dropped out before at least one curve had been 
taken had to stop study medication because of toxicity. Patients not starting saquinavir 
treatment were not included in analyses.
As some visits were optional, percentages were calculated relative to the available 
data. The efficacy data are presented for week 20, 33 GA and 6 weeks postpartum 
for the patients with a recorded pharmacokinetic curve and expressed as proportion 
undetectable HIV-1 RNA plasma (< 50 copies/mL). Virological failure was defined as 
two consecutive viral load measurements >400 copies/mL for patients >6 months on 
treatment.
Pharmacokinetic parameters are reported as arithmetic means with standard deviation. 
As the sample size was rather small, both non-parametric (either Friedman or Wilcoxon 
signed-rank tests) and parametric (paired sample t-test and repeated-measure one-way 
ANOVA) tests were performed for comparioson within the group. As there were no 
large differences between these methods, the results of the t-test are presented in this 
paper for all analyses except for the comparison of the eight patients of whom three 
curves were available. Furthermore, the number of patients with saquinavir Cmin values 
below the target threshold value of 0.1 mg/L[15] was reported.
Results
A total of 40 patients were enrolled in the study from eight different sites. Three patients 
withdrew their informed consent prior to starting saquinavir treatment; they were excluded 
from all analyses. The baseline characteristics of the remaining 37 subjects are depicted 
in Table 1. Among the patients on antiretrovirals (ARVs; n=20), 75% had an undetectable 
viral load (43% of the total group) and the mean ARV treatment duration of 153 weeks. 
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From these 20 patients 13 used a PI-based regimen when entering the study, 7 of which 
were already on a saquinavir-based regimen. The mean duration of saquinavir treatment 
prior to delivery was 19.1 weeks (range 6-40 weeks).
According to the protocol definition six patients dropped out, five before a pharmaco-
kinetic curve was recorded and one patient after the week 20 GA curve. This latter 
patient stopped saquinavir/r due to hepatotoxicity. In the group of five patients who dis-
continued study medication before a pharmacokinetic curve was recorded, two patients 
discontinued the study due to grade 2 nausea and vomiting 2 weeks after study ini-
tiation, two patients withdrew consent before a pharmacokinetic curve was obtained 
and one had a miscarriage. As a result, at least one 12 h pharmacokinetic-curve was 
recorded for a total of 32 patients.
A total of 16 curves were collected at week 20 GA, 31 at week 33 and 9 at 6 weeks 
postpartum. All 3 curves were obtained for 8 patients, the week 20 GA and week 33 
curves were obtained for 15 patients, and the week 33 and 6 weeks postpartum curves 
were available for 9 patients.
Pharmacokinetics
The mean plasma concentration-time profiles of saquinavir for the three different time 
points are presented in Figure 1A, and the summary statistics of the saquinavir phar-
macokinetic parameters are listed in Table 2. With a mean AUC0-12h of 23.47 h⋅mg/L, 
Table 1. Baseline Characteristics
Unless otherwise indicated, all parameters are expressed as means (±SD). ARV, antiretroviral; HIV-1, HIV type-1
Characteristics Value
Patients, n 37
Age, years 29.6 (6.1)
Weight, kg 69.7 (17.1)
Height, cm 163.4 (7.2)
Race
Caucasian, n 12
Black, n 14
Asian, n 9
Other, n 2
Gestational age, weeks 20 2/7 (8 3/7)
CD4+ T-cell count, cells/mm3 440.5 (215.2)
HIV-1 RNA <50 copies/mL, % 43
Plasma HIV-1 RNA log10, copies/mL 3.62 (0.87)
ARV treatment naive, % 46
Mean ARV treatment duration before study, weeks (range) 153 (2-260)
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23.65 h⋅mg/L and 25.00 h⋅mg/L at week 20 GA, week 33 and 6 weeks postpar-
tum, respectively, the exposure to saquinavir appears consistent over time. None of the 
patients had a saquinavir concentration below the therapeutic minimum concentration 
of 0.1 mg/L. The mean plasma concentration-time curves of ritonavir are presented 
in Figure 1B and the summary statistics for ritonavir pharmacokinetic parameters are 
depicted in table 2.
Saquinavir and ritonavir pharmacokinetic parameters for patients who had at least two 
pharmacokinetic curves taken were compared for the different time points (Table 3). No 
statistically significant differences were found for saquinavir between week 20 GA and 
week 33 GA, or between week 33 GA and 6 weeks postpartum. The Cmin, usually 
related to antiviral efficacy, was found to be similar in both groups. In agreement with 
this, a Friedman analysis of the eight patients who had all three curves taken did not 
show a significant difference (p=0.135).
No differences between week 20 GA and week 33 GA were found for ritonavir. By 
contrast, the ritonavir AUC and Cmax, but not the Cmin, were significantly higher postpar-
tum compared to week 33 (9 patients).
The findings above are consistent if compared with the group as a whole. A wide range 
of variation between and within the patients can be observed. This is also reflected in 
the coefficient of variation, which ranged from 39 to 51% for the saquinavir AUC.
Safety and Efficacy
Two patients developed a serious adverse event (SAE). One had a miscarriage at 
11 5/7 weeks pregnancy, two weeks after initiation of the study medication. The 
study physician assessed it was not related to the study drugs because an ultrasound 
before the start of the study medication already showed a growth retardation of the 
embryo. The other SAE was a one night hospital admission due to diarrhoea. The 
patient was receiving treatment for 3 months without diarrhoea, so it was determined 
that the diarrhoea was not related to the study drugs.
Clinical adverse events higher than grade 2 were not observed. One patient developed 
Figure 1. Mean steady-state concentration-time profile of saquinavir and ritonavir
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diabetes gravidarum.
One grade 3 cholesterol increase was documented. Three patients developed at least 
a grade 3 ASAT/ALAT elevation (2 naive to ARV at baseline, one ARV-experienced). 
The first patient had a grade 3 increase in ASAT/ALAT at delivery which was possibly 
related to the study drugs; therefore, the medication was permanently discontinued. The 
second patient already had grade 2 increases at baseline, but she was co-infected with 
hepatitis C. The liver enzyme elevations were assessed as possibly being related to the 
study drugs; however, the medication was continued. The third patient had an increase 
at 33 weeks GA and at delivery. This increase was possibly related to the study drugs, 
but the medication was continued until delivery.
The average GA at delivery was 38 3/7 weeks. Six infants were born before GA of 37 
weeks, but none were earlier than 35 weeks. In total, 29 children tested HIV negative; 
the HIV status of the remaining three children is unknown, because they were lost during 
follow-up.
At, or close prior to delivery, the viral loads of 30 women were available. The viral 
load was detectable in only one of these women (189 copies/mL). At the delivery visit 
this patient received 72 days of treatment, the saquinavir Cmin was 0.781 mg/L at 33 
weeks GA. Among the patients who recorded the pharmacokinetic curves at GA of 20 
weeks (n=15), week 33 (n=31) and 6 weeks postpartum (n=9, 67%, 93% and 100% 
All parameters are expressed as mean (±SD); P-values calculated with the paired samples t-test; AUC, area under the 
curve; Cmax, maximum plasma concentration; Cmin, trough concentration at 12h; GA, gestational age; PP, postpartum; Tmax, 
time of maximum concentration.
Table 2. Pharmacokinetic parameters of saquinavir/r 1,000/100 mg twice daily
Saquinavir Ritonavir
GA week 20 GA week 33 Week 6 pp GA week 20 GA week 33 Week 6 pp
Patients, n 16 31 9 16 31 9
AUC0-12h (h⋅mg/L) 23.47 (11.92) 23.65 (9.07) 25.00 (11.81) 8.57 (5.28) 7.41 (3.95) 11.57 (4.44)
CV (%) 51 39 47 62 53 38
Cmax (mg/L) 3.59 (1.57) 3.67 (1.49) 3.91 (1.79) 1.46 (0.86) 1.13 (0.58) 1.85 (0.77)
CV (%) 44 41 46 59 51 42
Cmin (mg/L) 0.82 (0.55) 0.84 (0.42) 0.78 (0.47) 0.28 (0.19) 0.29 (0.20) 0.31 (0.14)
CV (%) 67 50 60 68 69 45
Half-life (h) 3.72 (1.12) 3.90 (0.93) 3.79 (1.27) 3.48 (0.80) 4.45 (1.75) 3.68 (1.03)
CV (%) 30 24 34 23 39 28
Tmax (h) 3.65 (1.29) 3.36 (1.25) 3.89 (1.91) 3.59 (1.89) 3.70 (1.65) 2.98 (2.09)
CV (%) 35 37 49 53 45 70
CL/F (L/h) 48 (27) 45 (30) 55 (57) 13 (6.3) 13 (6.3) 8.8 (3.9)
CV (%) 57 67 104 49 47 45
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respectively, had undetectable viral load. None of the patients showed a virological 
failure according to our definition.
Discussion
In this study, we evaluated the pharmacokinetics of the new 500 mg tablet formulation 
of saquinavir when boosted with 100 mg of ritonavir in pregnant HIV-1-infected patients, 
at different time points along the gestation period (week 20 and week 33) and after 
delivery (6 weeks postpartum). For all time points, the saquinavir exposure was adequate 
and no sub-therapeutic concentrations, defined as < 0.1 mg/L, were recorded. No dif-
ference was found between the different time points, suggesting that pregnancy had no 
effect on the saquinavir concentrations. The ritonavir exposure seemed more affected 
during pregnancy than the saquinavir concentrations.
PI disposition is thought to be most affected during the third trimester of pregnancy. In 
this phase, close to delivery, viral suppression is considered important in order to reduce 
All parameters are expressed as mean (±SD); P-values calculated with the paired samples t-test; AUC, area under the 
curve; Cmax, maximum plasma concentration; Cmin, trough concentration at 12h; GA, gestational age; PP, postpartum; Tmax, 
time of maximum concentration.
GA week 20 GA week 33 P-value GA week 33 Week 6 PP P-value
Patients, n 15 15 9 9
Saquinavir
AUC0-12h 
(h⋅mg/L)
23.35 (12.33) 24.40 (10.27) 0.710 20.63 (9.47) 25.00 (11.81) 0.379
Cmax (mg/L) 3.53 (1.61) 3.70 (1.73) 0.667 3.12 (1.54) 3.91 (1.79) 0.319
Cmin (mg/L) 0.83 (0.57) 0.92 (0.48) 0.490 0.79 (0.43) 0.78 (0.47) 0.935
Half-life (h) 3.75 (1.15) 3.76 (0.80) 0.951 3.95 (0.97) 3.79 (1.27) 0.814
Tmax (h) 3.69 (1.33) 3.66 (1.60) 0.915 3.41 (1.88) 3.89 (1.91) 0.519
CL/F (L/h) 48 (28) 45 (33) 0.672 54 (39) 55 (57) 0.987
Ritonavir
AUC0-12h 
(h⋅mg/L)
8.40 (5.43) 7.87 (4.80) 0.321 6.73 (1.95) 11.57 (4.44) 0.030
Cmax (mg/L) 1.44 (0.89) 1.23 (0.65) 0.147 1.03 (0.35) 1.85 (0.77) 0.021
Cmin (mg/L) 0.28 (0.19) 0.30 (0.23) 0.320 0.30 (0.22) 0.31 (0.14) 0.920
Half-life (h) 3.49 (0.83) 3.86 (1.24) 0.146 3.94 (0.96) 3.68 (1.03) 0.557
Tmax (h) 3.70 (1.90) 3.76 (2.00) 0.923 4.04 (1.82) 2.98 (2.09) 0.066
CL/F (L/h) 13 (6.4) 13 (4.7) 0.704 13 (4.4) 8.8 (3.9) 0.091
Table 3. Within patient comparison of pharmacokinetic parameters
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mother-to-child transmission to a minimum. Subtherapeutic concentrations in this trimester 
may have a negative effect on drug antiviral efficacy. In this study, we collected 31 
curves for the third trimester (week 33) in order to generate a reliable mean estimate 
of saquinavir exposure, accounting for the large inter-variability in its pharmacokinet-
ics. Although the variability was large, none of the patients had concentrations <0.1 
mg/L. The cut off of 0.1 mg/L is currently considered the most accurate, although other 
studies suggested other cut-offs in the past, or could not prove the correlation. To our 
knowledge this is the first extensive pharmacokinetic study in pregnant women with 
the tablet formulation of saquinavir. Earlier studies with saquinavir in pregnant women 
were either performed with the unboosted soft gel capsule (no longer available)[16] or 
the boosted 200 mg hard gel capsules (HGC).[13] One study  with the new tablet for-
mulation reported only the Cmin.
[17] In the study of Acosta et al.[13] the AUC antepartum 
was 29 h⋅mg/L with a 800/100 mg twice-daily (HGC) dosing in 13 patients, which 
is somewhat higher than the 23.7 h.mg/L we found in our study. In this study, breakfast 
with a higher fat percentage was used at the days of pharmacokinetic monitoring, this 
could explain the higher exposure to saquinavir. Bittner et al.[18] reported a bioequiva-
lence study comparing the HGC with the new tablet formulation in healthy volunteers. 
An AUC0-inf of 26.8 h⋅mg/L saquinavir was reported for the tablet. An AUC of 18.8 
mg/L was calculated (n=11) in another study in the non-pregnant population using the 
new tablet formulation.[19] This reduced exposure could possibly be explained by gender 
differences (only one female was included). It has been suggested that some antiretro-
virals, saquinavir in particular, are affected by sex differences.[20] The postpartum con-
centrations found in our study are expected to be representative for the concentrations 
of the non-pregnant female population. The AUC0-12 determined in our study is similar to 
AUCs found in other studies.
Our within-patient comparison between the ante- and postpartum curves did not show 
a difference in saquinavir exposure. This is consistent with the finding of Acosta et al. [13]; 
however, in that study, a trend toward lower saquinavir exposure during the gestational 
period was observed. It must be noted that our postpartum sample size may be too 
small to be conclusive on the precise effect of pregnancy on the saquinavir concen-
trations. However, saquinavir seems less sensitive to the physiological changes during 
pregnancy than other PIs such as indinavir, nelfinavir and lopinavir, for which, even 
with small sampled studies significant differences were found ante- and postpartum. 
Nelfinavir is the most extensively studied PI during pregnancy, due to its frequent use in 
pregnant women over the past years. All pharmacokinetic studies reported a decreased 
exposure to nelfinavir during pregnancy, which is more pronounced towards the end 
of the gestation.[21,22] Owing to safety and efficacy concerns, nelfinavir is currently rel-
atively contra-indicated in pregnancy and in most guidelines replaced by lopinavir/
ritonavir. However, one may question if lopinavir/ritonavir should be the PI of choice 
during pregnancy. In Stek et al.[23] a comparison within 12 patients on lopinavir/ritonavir 
was made ante- and postpartum. A significant reduction in total exposure of approx-
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imately 33% during pregnancy was observed. Based on this and other studies, an 
increase of the lopinavir/ritonavir dose when no therapeutic drug monitoring is available 
is suggested. The same is true for (unboosted) indinavir with a decrease of 68% in its 
exposure. For atazanavir, the results of two small studies are conflicting.[24,25]
The differences between the individual PIs are difficult to explain considering they all 
use the same metabolic pathway, CYP3A4, which is known to play a major role in the 
changes of drug disposition during gestation.
In our study we found a significant reduction of 36% for ritonavir exposure during 
pregnancy, which did not affect the saquinavir concentrations accordingly. Kilby et al.[26] 
showed in healthy volunteers that lower concentrations of ritonavir do not necessarily 
generate lower concentrations of saquinavir. This relative independence of ritonavir 
exposure could explain why saquinavir plasma concentrations are more stable during 
pregnancy compared to other PIs, despite the reduced exposure of its booster ritonavir. 
The role of the ritonavir reduction in combination with PIs in pregnancy is currently 
difficult to address as most studies do not report the ritonavir concentrations. Additional 
studies looking into this mechanism are warranted before strong conclusions can be 
drawn.
During our study we recorded 3 cases of severe hepatotoxicity, out of which one had 
hepatitis C; consistent with another study of saquinavir use in pregnancy.[27] However, 
the risk of developing severe hepatotoxicity is similar to non-pregnant patients starting 
boosted saquinavir.[28] Moreover, pregnancy in itself is an additional risk factor for devel-
oping hepatotoxicity.[29] Larger studies should be conducted for the different PIs to assess 
if there is additional risk of hepatotoxicity when saquinavir is used during pregnancy.
The antiviral potency was adequate although the sample size was too small and the 
group too heterogeneous to be conclusive. Currently, the use of PIs is recommended and 
considered safe and effective during pregnancy
On the basis of this study, the use of boosted saquinavir tablet in a saquinavir/r 
1,000/100 mg twice-daily regimen can be recommended to be used during pregnancy. 
This treatment generates adequate saquinavir concentrations throughout the course of 
pregnancy and has a solid safety and antiviral efficacy profile.
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Abstract
Background: We studied the effect of pregnancy on atazanavir pharmacokinetics in 
presence and absence of tenofovir.
Methods: This was a non-randomized, open-label, multicentre phase IV study in HIV-in-
fected pregnant women recruited from European HIV treatment centres. HIV-infected 
pregnant women treated with boosted atazanavir (300/100mg or 400/100mg ataza-
navir/ritonavir) as part of their combination antiretroviral therapy (cART) were included in 
the study. 24h pharmacokinetic curves were recorded in the third trimester and postpar-
tum. Collection of a cord blood and maternal sample at delivery was optional.
Results: 31 patients were included in the analysis, 21/31 patients used tenofovir as 
part of cART. Median (range) gestational age at delivery was 39 weeks (36-42). Ap-
proaching delivery 81% (25 patients) had an HIV viral load <50 copies/mL, all <1,000 
copies/mL. Least squares means ratios (90% CI) of atazanavir pharmacokinetic param-
eters third trimester/postpartum were: 0.66 (0.57-0.75) for AUC0-24h, 0.70 (0.61-0.80) 
for Cmax and 0.59 (0.48-0.72) for C24h. No statistical difference in pharmacokinetic 
parameters was found between patients using tenofovir versus no tenofovir. None of 
the patients showed atazanavir concentrations <0.15 mg/L (target for treatment-naive 
patients). One baby had a congenital abnormality, which was not likely to be related to 
atazanavir/ritonavir use. None of the children were HIV-infected.
Conclusions: Despite 34% lower atazanavir exposure during pregnancy, atazana-
vir/ritonavir 300/100mg once daily generates effective concentrations for protease 
inhibitor (PI)-naive patients, even if co-administered with tenofovir. For treatment-expe-
rienced patients (with relevant PI resistance mutations) therapeutic drug monitoring of 
atazanavir should be considered to adapt the atazanavir/ritonavir dose on an individ-
ual basis.
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Introduction
The risk of mother-to-child transmission (MTCT) of HIV has been reduced by the introduc-
tion of combination antiretroviral therapy (cART), reducing the risk from 15-40% in the 
absence of therapy to <2%.[1] Since 2012 Department of Health and Human Services 
(DHHS) perinatal guidelines have classified ritonavir-boosted atazanavir (atazanavir/r) 
as one of the preferred protease inhibitors (PIs) to be used during pregnancy.[2] The 
European AIDS Clinical Society guidelines[3] as well as the British HIV Association guide-
lines for the management of HIV infection in pregnant women report boosted lopinavir, 
saquinavir as well as atazanavir as compounds effective as the third agent in cART in 
pregnancy.[4]
In the US, PIs are the most common third class of drugs (combined with NRTIs) used 
in pregnancy: up to 86% in 2009. In 2009, atazanavir/r use during pregnancy was 
much lower compared to lopinavir/r use (20% versus 55%).[5] The use of atazanavir/r 
during pregnancy may increase because atazanavir/r has been classified as one of 
the preferred PIs to be used in pregnancy. Moreover, atazanavir is classified as FDA 
Pregnancy Category B indicating that animal reproduction studies failed to demonstrate 
risk to the foetus; whereas lopinavir/r is classified as FDA Pregnancy Category C, indi-
cating that animal reproduction studies have shown an adverse effect on the foetus.[2]
Sufficient numbers of first trimester exposures to atazanavir (n=746 up to July 2012) have 
been monitored by the Antiretroviral Pregnancy Register to have power to detect at 
least a twofold increase in risk of overall birth defects, but no such increases have been 
detected to date. A subset of the registry (all cases using atazanavir during pregnancy 
from 2002 onwards) was analysed for possible birth defects.[6] No pattern of birth 
defects suggestive of a common aetiology was observed.
During pregnancy human physiology alters, potentially affecting the pharmacokinetics 
of drugs. These changes include: decreased gastric emptying and motility, increased 
gastric pH, increased total body water and plasma volume, increased hepatic blood 
flow, alteration of cytochrome P450 activity, increased cardiac output, increased 
glomerular filtration and decreased protein binding. In most cases resulting in lower 
exposure of medication during pregnancy,[7-9] this effect seems to be rather strong for 
boosted PIs.[10, 11]
Between 2005 and 2012 several studies were performed investigating the pharma-
cokinetics of atazanavir/r during pregnancy. A systematic review of these studies was 
recently published.[12] Pharmacokinetic studies as well as studies on safety and efficacy 
were reported, including one study with an increased dose during the third trimester 
(400/100mg once daily atazanavir/r). Most studies report lower exposure during 
pregnancy, with area under the curve (AUC) 21% (geometric mean ratio [GMR]) lower 
in the second and 21-33% lower in the third trimester of pregnancy. When combined 
with tenofovir disoproxil fumarate (TDF) in cART the decrease in exposure was even 
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more pronounced (34%).[13] However, not all pharmacokinetic studies performed during 
pregnancy showed decreased exposure: Ripamonti et al. reported an AUC GMR (90% 
CI) of 0.93 (0.79-1.08; third trimester versus postpartum).[14]
Two intensive pharmacokinetic studies investigated an atazanavir dose increase in the 
third trimester of pregnancy. The increased dose (400/100mg once daily) resulted in 
therapeutic concentrations in both studies, but also a doubling of maternal grade 3-4 
hyperbilirubinaemia in one study.[15,16] 
The atazanavir product characteristics state that as atazanavir/r 300/100mg once 
daily may not give sufficient exposure during the second and third trimester, therapeutic 
drug monitoring is recommended and dose increase if necessary. If TDF or an H2-re-
ceptor antagonist is needed, a dose increase to atazanavir/r 400/100mg once daily 
with therapeutic drug monitoring may be considered. Atazanavir/r should not be used 
by pregnant women also using TDF and an H2-receptor antagonist.[17] TDF use may play 
a bigger role in pregnancy, because tenofovir/emtricitabine is considered a preferred 
NRTI backbone during pregnancy according to the recent changes in DHHS perinatal 
guidelines.[2]
Given that information on atazanavir pharmacokinetics during pregnancy and after 
pregnancy was not consistent, TDF was reported to decrease atazanavir levels during 
pregnancy to a greater extent, and atazanavir and TDF are considered preferred agents 
to be used during pregnancy, we studied the effect of pregnancy on atazanavir phar-
macokinetics in presence and absence of TDF.
Methods
This was a non-randomized, open-label, multicentre phase IV study in HIV-infected 
pregnant women recruited from HIV treatment centres in Europe (PANNA network: 
www.pannastudy.com). The PANNA network is a European network of hospitals col-
lecting pharmacokinetic curves of several antiretrovirals (ARVs) during pregnancy in a 
prospective study. In total 17 hospitals are involved in the network; data in this publica-
tion were collected between February 2010 and May 2013.
The study was conducted in compliance with the principles of the Declaration of Helsinki. 
Informed consent was obtained from each participant before entering the study. The 
study was approved by the medical ethical committee from each individual centre 
involved and by the national authorities if applicable. The study was registered at Clini-
calTrials.gov under number NCT00825929.
Here we describe the pharmacokinetics of atazanavir/r in pregnancy compared to 
postpartum, with a focus on concomitant use of TDF. Patient eligibility included being 
HIV-infected, pregnant, at least 18 years of age at screening and treated with a cART 
regimen containing atazanavir for at least 2 weeks before the day of first pharmacoki-
netic curve evaluation (in the third trimester of pregnancy). Patients were excluded if they 
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had a past medical history or current condition that might interfere with drug absorption, 
distribution, metabolism or excretion or presented with grade III/IV anaemia (i.e. Hb 
<4.6 mmol/L or <7.4 g/dL) at screening.
Safety assessments and viral load
Blood samples for safety assessments and viral load were taken at screening and visits 
for pharmacokinetic blood sampling. Patients were asked for adverse events at each 
visit. Birth weight, congenital abnormalities and HIV status of the infants were collected.
Pharmacokinetic blood sampling
Pharmacokinetic curves (samples were taken pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 and 
24h post-medication intake) were recorded during the third trimester (preferably at week 
33) and at least 2 weeks postpartum (preferably 4-6 weeks postpartum). At delivery (if 
possible) a cord blood sample was taken and at the same time a blood sample from 
the mother was taken. A standard breakfast (650kCal; 30g fat) was served prior to 
(observed) dosing on the pharmacokinetic days.
Analytical and pharmacokinetic methods
Concentrations of atazanavir and ritonavir in plasma were analyzed by use of a 
validated (ultra) high-performance liquid chromatography method for the simultaneous 
quantitative determination of several HIV PIs in human plasma.[18] Lower limit of quan-
tification (LLOQ) was 0.090 mg/L for atazanavir and 0.045 mg/L for ritonavir. The 
assays were externally validated through ACTG and KKGT.[19,20]
Pharmacokinetic parameters were determined using a non-compartmental model in 
WinNonlin/Phoenix version 6.3 [Pharsight Corporation, Mountain View, CA, USA]. 
Concentrations below LLOQ occurring before the first measurable concentration were 
set to zero, the first <LLOQ concentration at the end of the curve was set to ½ LLOQ, 
subsequent concentrations were left empty. Area under the curve over a dosing interval 
(AUC0-24h) using the trapezoidal rule, trough concentration (C24h) defined as the sample 
taken at time point 24hr (or extrapolated from the last available concentration, using 
lambda, if the sample was missing), maximum concentration (Cmax), elimination half-life 
(Thalf), time of maximum concentration (Tmax) and apparent clearance (CL/F, being the 
dose/AUCtau) were determined per individual curve.
Statistical analysis data handling
Patients from whom a pharmacokinetic curve was taken during pregnancy were 
included in demographic, safety analyses and descriptive statistics of the pharmacoki-
netic parameters. Demographic data were summarized with descriptive statistics. Quan-
titative data were compared between patients with and without TDF co-treatment using 
the Mann-Whitney U test, categorical data were compared using the chi-square test. 
Pharmacokinetic parameters are reported as geometric means with 95% intervals (for 
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300/100mg atazanavir/r dose only). Least squares means ratios (LSMRs) and 90% con-
fidence intervals (CI) of AUC0-24h, Cmax, C24h, CL/F and Thalf of third trimester versus post-
partum were calculated. For geometric mean calculations patients using 400/100mg 
atazanavir/r were excluded, for the LSMR calculations these patients were included. To 
indicate whether the pharmacokinetic parameters during pregnancy differed statistically 
significantly from the postpartum parameters, a mixed models test (using SPSS) was 
performed on the natural log (ln)-transformed parameters. Pharmacokinetic parameters 
(ln-transformed) with and without TDF co-treatment were compared by an independent 
t-test. The non-parametric test for independent samples: Mann-Whitney U was used to 
determine a difference in pharmacokinetic parameters for patients with and without a 
detectable viral load around delivery. Cord blood/maternal blood concentration ratios 
were determined and described.
Results
Thirty-six patients receiving atazanavir/r during pregnancy were enrolled in the study 
from 13 different sites from the PANNA network. Four of these patients dropped out 
before the first pharmacokinetic curve was taken: three delivered before the intensive 
sampling pharmacokinetic day (the gestational age [GA] was 28 weeks, 33 weeks and 
40 weeks) and one withdrew consent. For one patient all plasma concentrations (for 
both atazanavir and ritonavir) were below LLOQ, indicating that she was not adherent 
to therapy and in that intake of medication was apparently not supervised. These five 
patients were excluded from the analysis.
The characteristics and pregnancy outcome of the remaining patients (n=31) are 
presented in Table 1. Fourteen patients were White, 16 Black and 1 of mixed race. At 
the time of conception, 11 (35%) of the patients were treatment-naive and 13 patients 
used atazanavir/r and continued during pregnancy. The majority of the patients used 
atazanavir/r 300/100mg once daily (94%), 2 patients used atazanavir/r 400/100mg 
once daily. Twenty-one out of 31 patients used TDF. Other NRTIs taken were: emtricit-
abine (n=20), lamivudine (n=10), zidovudine (n=6) and abacavir (n=4). One patient 
also used raltegravir. Non-ARV concomitant substances possibly influencing atazanavir 
exposure was marijuana used by one patient. No statistical differences in subject char-
acteristics were observed between patients with TDF and without TDF in their backbone 
therapy (Table 1).
A total of 31 curves were collected in the third trimester (median 35 weeks GA) and 
26 curves postpartum (median 6 weeks postpartum). Five patients did not have a post-
partum curve for the following reasons: withdrawn consent (n=1); lost to follow-up (n=2); 
changed medication (n=1); plasma atazanavir levels <LLOQ (n=1) probably due to 
non-adherence. 
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Pharmacokinetics
Mean plasma concentration-time profiles of atazanavir 300/100mg once daily with 
separate lines for TDF use and non-TDF use are presented in Figure 1. Summary statistics 
of the pharmacokinetic parameters are listed in Tables 2 and 3.
The AUC0-24h, Cmax, C24h for atazanavir were respectively 34%, 30% and 41% lower 
during pregnancy compared with postpartum (intra-subject comparison) and 55%, 58% 
and 53% lower for ritonavir, respectively. For both compounds the steady-state apparent 
clearance (CLss/F) was increased during pregnancy (53% and 124% for atazanavir 
and ritonavir, respectively) and Thalf tended to be shorter in the third trimester. No statis-
tical difference in atazanavir AUC0-24h, Cmax, C24h, Thalf or CLss/F was found between 
patients (atazanavir 300/100mg only) using TDF versus no TDF in the third trimester or 
postpartum (p>0.15 for all parameter; Table 3). Geometric mean (95% CI) atazanavir 
AUC0-24h in the third trimester was 32.1 (21.1-48.7) h⋅mg/L without TDF and 28.8 (22.2-
37.4) h⋅mg/L with TDF and atazanavir C24h was 0.58 (0.32-1.05) mg/L without and 
0.44 (0.31-0.62) mg/L with TDF co-treatment. Postpartum geometric mean (95% CI) 
atazanavir AUC0-24h was 49.2 (34.7-69.8) h⋅mg/L without TDF and 46.1 (36.2-58.6) 
h⋅mg/L with TDF and atazanavir C24h was 0.90 (0.47-1.71) mg/L without and 0.89 
(0.59-1.32) mg/L with TDF.
None of the patients had atazanavir concentrations below 0.15 mg/L (target for treat-
ment-naive patients) in the third trimester or postpartum. For three patients extrapolated 
third trimester C24h concentrations would have been below 0.15 mg/L (i.e. 0.130, 0.135 
and 0.139 mg/L). The pre-dose concentrations of these patients were well above 0.15 
Figure 1. Mean atazanavir concentration-time profiles
Mean (±SD) concentration versus time curves for HIV-infected pregnant women using 300/100mg ritonavir boosted ata-
zanavir (atazanavir/r) once daily during the third trimester and postpartum. Solid lines represent patients using tenofovir 
disoproxil fumarate (TDF) and dashed lines represent subjects not using TDF.
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mg/L, 2 of these patients used TDF concomitantly.
Eighteen umbilical cord blood (CB) samples were collected with matching maternal 
blood samples. The median time between the reported last dose and delivery was 
12h (range 2-27h); the median time between CB sample and maternal sample was 
3 minutes (0-345 min). In five cord blood samples, atazanavir concentrations were 
undetectable; in one case the time between maternal and cord blood sample was 10h, 
this sample was excluded from descriptive statistics. The median (range) ratio of CB/
maternal blood was 0.20 (0.06-3.05; n=12) for atazanavir. For ritonavir all CB samples 
were <LLOQ. 
 Third Trimestera Postpartuma
LSM Ratio (90% CI)b
Third Trimester/Postpartum p-valuec
Atazanavir (n=29) (n=25)   
AUC0-24h (h⋅mg/L) 29.9 (24.3-36.8) 47.0 (39.1-56.6) 0.66 (0.57-0.75) <0.001
Cmax (mg/L) 2.92 (2.36-3.61) 4.29 (3.67-5.02) 0.70 (0.61-0.80) <0.001
Tmax (h) 3 (0-6) 3 (1-7.9)   
Cpredose (mg/L) 0.60 (0.46-0.79) 0.92 (0.69-1.23)   
C24h (mg/L) 0.48 (0.36-0.65) 0.89 (0.65-1.22) 0.59 (0.48-0.72) <0.001
Thalf (h) 10 (9-12) 12 (10-15) 0.87 (0.76-1.00) 0.109
CLss /F (L/h) 10 (8-12) 6 (5-8) 1.53 (1.34-1.75) <0.001
Ritonavir (n=29) (n=25)   
AUC0-24h (mg⋅L/h) 5.01 (4.09-6.15) 11.68 (9.46-14.42) 0.45 (0.37-0.53)  
Cmax (mg/L) 0.59 (0.46-0.77) 1.50 (1.22-1.86) 0.42 (0.34-0.51)  
Tmax (h) 4.0 (0.00-8.00) 4 (0-7.9)   
C24h (mg/L) 0.036
d (0.028-0.045) 0.08e (0.060-.012) 0.47 (0.36-0.62)  
Thalf (h) 5 (4-6) 5 (5-6) 0.90 (0.78-1.04)  
CLss /F (L/h) 20 (16-24) 9 (7-11) 2.24 (1.88-2.68)  
Table 2. Pharmacokinetic parameters 300/100mg atazanavir/r once daily
a Geometric mean (95% confidence interval); except for Tmax: median (min-max); b LSM (Least squares mean) ratio 
includes one patient using 400/100mg atazanavir/r; c mixed model analysis; d 16 below LLOQ, taken as 1/2 LOQ, i.e. 
0.0225 mg/L; e 5 below LLOQ, taken as 1/2 LOQ, i.e. 0.0225 mg/L
AUC0-24h, area under the curve over a dosing interval; CLss/F, apparent steady-state clearance; Cmax, maximum concen-
tration; Cpredose, predose concentration; C24h, trough concentration defined as the sample taken at time point 24 h (or 
extrapolated from the last available concentration, using lambda, if the sample was missing); Thalf, elimination half-life.
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Efficacy and safety
HIV viral load close to delivery (median 34 weeks GA) was undetectable in 25 (out of 
31) women and detectable in 6 women: 68, 100, 120, 162, 290 and 402 copies/
mL. One patient started cART in the second trimester, the other patients were on cART 
at conception. All of these patients used atazanavir/r 300/100mg once daily and TDF 
concomitantly.
The average GA at delivery was 39 (range 36-42) weeks. Two children were born 
pre-term at 36 weeks and 36 weeks and 3 days. Birth weight of 26 children was 
reported, 2 had a low birth weight (<2500 g), whereas 5 out of 26 were small for 
gestational age (reference 10th percentile of birth weight for GA by gender, US, 1991). 
Twenty-eight children were tested HIV-negative (PCR DNA after delivery) and the status 
of 3 children was unknown. One child had a congenital diaphragmatic hernia resulting 
in respiratory failure, septic shock and death. A relationship with the ARV medication 
used could not be ruled out, however the closure of the pleuroperitoneal canal in the de-
veloping embryo occurs at approximately week 8 of pregnancy and the patient started 
antiretroviral therapy in week 18 of her pregnancy (atazanavir/r even later at week 21). 
Furthermore, this patient also used methadone since 2000 (also during this pregnancy).
Five patients developed a serious adverse event (SAE). One was the congenital ab-
normality described above. Five hospital admissions occurred (3 patients) for several 
reasons: a patient thought the baby was not moving (the baby was born without 
 
Third 
Trimester 
plus TDFa
Third 
Trimester 
without 
TDFa
P 
valueb
Postpartum 
plus TDF
Postpartum 
without 
TDF
P 
valueb
Third 
Trimester / 
Postpartum 
plus TDFc
Third 
Trimester / 
Postpartum 
without TDFc
Atazanavir (n=19) (n=10)  (n=17) (n=8)    
AUC0-24h 
(h⋅mg/L)
28.8
(22.2-37.4)
32.08
(21.1-48.7)
0.624 46.1
(36.2-58.6)
49.2
(34.7-69.8)
0.735 0.65
(0.55-0.78)
0.66
(0.53-0.83)
Cmax 
(mg/L)
2.92
(2.21-3.84)
2.93
(1.95-4.40)
0.985 4.17
(3.42-5.08)
4.58
(3.31-6.34)
0.570 0.72
(0.60-0.86)
0.65
(0.52-0.82)
C24h 
(mg/L)
0.44
(0.31-0.62)
0.58
(0.32-1.05)
0.351 0.89
(0.59-1.32)
0.90
(0.47-1.71)
0.972 0.57
(0.43-0.75)
0.64
(0.47-0.87)
Thalf
(h)
9
(8-11)
12
(8-17)
0.181 12
(10-16)
12
(8-18)
0.768 0.82
(0.68-0.97)
1.00
(0.80-1.26)
Table 3. Pharmacokinetic parameters 300/100mg atazanavir/r in presence and absence of TDF
a Geometric mean (95% confidence interval); except for Tmax: median (min-max); b independent t-test on ln-transformed 
parameters; c LSM (Least squares mean) ratio includes one patient using 400/100mg atazanavir/r
AUC0-24h, area under the curve over a dosing interval; Cmax, maximum concentration; C24h, trough concentration defined as 
the sample taken at time point 24 h (or extrapolated from the last available concentration, using lambda, if the sample 
was missing); TDF, tenofovir disoproxil fumerate; Thalf, elimination half-life.
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problems); early contractions at 31.3 weeks GA (baby was born at GA 38.6 weeks) 
and urinary tract infection; tonic/clonic seizure and headache after delivery. All patients 
recovered. The final SAE was in a patient who had postnatal uterus agony, coagulapa-
thy and postpartum haemorrhage, which prolonged hospital admission. She recovered 
within one week. The local investigators judged these SAEs not to be related to the cART 
given. Nine other patients reported adverse events, all were grade 1 or 2 and not or 
unlikely related to the cART given. No clinically relevant laboratory abnormalities were 
reported.
Pharmacokinetic – efficacy relationship
HIV viral loads were detectable for 6 patients around delivery. The Mann-Whitney U 
test did not reveal significant differences in third trimester atazanavir pharmacokinetic 
parameters (AUC0-24h, Cmax, C24h, Thalf or CLss/F) compared to the pharmacokinetic 
parameters of patients with an undetectable viral load around delivery (Table 3). One 
patient had an extrapolated C24h <0.15 mg/L, with a pre-dose concentration of 0.54 
mg/L. Twenty-eight children were tested HIV-negative (PCR DNA after delivery), the 
status of 3 children was unknown.
Discussion
In this study we evaluated the pharmacokinetics of atazanavir/r in the third trimester of 
pregnancy in absence and presence of TDF in 31 pregnant HIV-infected patients.
In the third trimester of pregnancy a decrease in atazanavir AUC0-24h, Cmax and C24h 
(34%, 30% and 41%, respectively) was observed as well as a marked decrease in 
ritonavir AUC0-24h, Cmax and C24h (55%, 58% and 53%, respectively). Clearance (CLss/F) 
was markedly increased during pregnancy for both compounds (atazanavir 53% and 
ritonavir 124%).
Four previous studies report intensive pharmacokinetics of atazanavir during 
pregnancy.[13,15,16,21] Our findings are in line with other groups reporting a decrease in 
exposure (atazanavir AUC during 300/100mg atazanavir treatment) of 21%,[15] 30% 
without TDF or 34% with TDF[13] in the third trimester of pregnancy versus postpartum 
or historical controls. None of the studies reported a significant decrease of C24h con-
centrations during pregnancy, whereas we did find a statistically significant decrease. 
Despite this significant decrease of atazanavir C24h, no concentrations below the target 
trough concentration of 0.15 mg/L were measured, indicating sufficient exposure for 
PI-naive patients.
For six patients a detectable HIV viral load was reported around delivery, although 
all were <1,000 copies/mL, this might be of concern. Five of these patients were 
treatment experienced and all of them used atazanavir/r 300/100mg once daily and 
TDF. Although all of these patients used TDF concomitantly, no statistically significant 
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difference in pharmacokinetic parameters in the third trimester was observed for these 
patients compared with the patients with an undetectable HIV viral load and none 
showed atazanavir concentrations <0.15 mg/L. None of the children of the patients 
with a detectable viral load were HIV-infected.
In contrast to data reported by Mirochnick et al.,[13] our study showed no statistical dif-
ference in AUC0-24h, Cmax or C24h for patients (atazanavir 300/100mg only) using TDF 
versus no TDF (in the third trimester or postpartum). Although the atazanavir product char-
acteristics[17] and Taburet et al.[22] report decreased exposure to atazanavir if combined 
with TDF, some other studies do not find this effect (for which a mechanism has not been 
discovered).[23,24]
Furthermore, most studies investigating the pharmacokinetics of atazanavir during 
pregnancy[13,15,16] report the postpartum exposure to be unexpectedly higher compared 
to the non-pregnant population. Atazanavir Cmax and AUCs were found to be approx-
imately 26-40% higher, and Ctrough concentrations even twofold higher during the post-
partum period than those observed historically in HIV-infected, non-pregnant patients. 
This finding is not confirmed in our study, as the postpartum atazanavir AUC0-24h of 47.0 
h⋅mg/L and Cmax of 4.29 mg/L observed in this study (with and without TDF combined) 
is in line with historical data: atazanavir AUC0-24h of 44.2 h⋅mg/L and Cmax of 4.47 
mg/L.[17]
The cord blood/maternal blood concentration ratio we found for atazanavir (0.20) is in 
line with the CB/M ratios reported in literature: ranging from 0.13-0.20.[25]
We did not analyse bilirubin concentrations in the mother, nor in the child. As this is a 
known side effect of atazanavir, this would have been interesting for safety purposes. 
However, as the bilirubin concentrations seem to be correlated to high plasma atazana-
vir concentrations, and the plasma atazanavir concentrations postpartum were in the 
“normal range” and during pregnancy even lower, we do not think this is a major 
concern.
The mechanism behind the decreased exposure during pregnancy remains unclear, as 
Cmax is decreased (indicating decreased absorption and/or increased volume of distri-
bution) and the elimination (Thalf) seems to be faster during pregnancy. As this study was 
performed under steady-state conditions, the half-life is difficult to determine accurately. 
We determined total atazanavir concentrations in plasma, not the unbound concentra-
tions. During pregnancy protein binding is decreased, resulting in a higher free fraction, 
possibly (partly) compensating for the lower concentrations during pregnancy.
Despite 34% lower atazanavir exposure during pregnancy, 300/100mg atazanavir/r 
seems to generate effective concentrations for PI-naive patients, even if co-administered 
with TDF. For treatment-experienced patients (with relevant PI resistance mutations) ther-
apeutic drug monitoring of atazanavir should be considered to adapt the atazanavir/r 
dose on an individual basis.
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Abstract
Objective: To describe the pharmacokinetics of darunavir in HIV-infected pregnant 
women in the third trimester and postpartum.
Patients and Methods: This was a non-randomized, open-label, multicentre, phase IV 
study in HIV-infected pregnant women recruited from HIV treatment centres in Europe. 
HIV-infected pregnant women treated with darunavir/r (800/100mg once daily 
or 600/100mg twice daily) as part of their combination antiretroviral therapy were 
included. Pharmacokinetic curves were recorded in the third trimester and postpartum. 
A cord blood sample and maternal sample were collected.
Results: Twenty-four women were included in the analysis (darunavir/r 600/100mg 
twice daily (n=6); 800/100mg once daily (n=17); and 600/100mg once daily (n=1)). 
Geometric mean ratios of third trimester versus postpartum (90% confidence interval) 
were 0.78 (0.60-1.00) for total darunavir AUC0-tau after 600/100mg twice-daily dosing 
and 0.67 (0.56-0.82) for total darunavir AUC0-tau after 800/100mg once-daily dosing. 
The unbound fraction of darunavir was not different during pregnancy (12%) compared 
with postpartum (10%). The median (range) ratio of darunavir cord blood/maternal 
blood was 0.13 (0.08-0.35). Viral load close to delivery was <300 copies/mL in all 
but two patients. All children were tested HIV-negative and no congenital abnormalities 
were reported.
Conclusions: Darunavir AUC and Cmax are substantially decreased in pregnancy for both 
darunavir/r regimens. This decrease in exposure did not result in mother-to-child transmis-
sion. For antiretroviral-naive patients, who are adherent, take darunavir with food and 
are not using concomitant medication reducing darunavir concentrations, 800/100mg 
darunavir/r once daily is adequate in pregnancy. For all other patients 600/100mg of 
darunavir/r twice daily is recommended during pregnancy.
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Introduction
Combination antiretroviral therapy (cART) has been shown to be a highly effective 
strategy for preventing mother-to-child transmission (MTCT) of HIV, reducing the risk from 
15-40% to <2%.[1,2] Boosted darunavir is a preferred agent for antiretroviral-naive adult 
patients in a dose of 800/100mg once daily for patients without mutations associated 
with resistance to protease inhibitors (PIs). For patients with evidence of limited protease 
resistance-associated mutations, the 600/100mg twice-daily dose should be used.[3] 
Darunavir exposure-response data are not sufficient to recommend a minimum trough 
concentration (Ctrough). However, the EC50 are 0.055mg/L for wild type virus,
[4] and 
0.55 mg/L for resistant virus[5] with an EC90 of 0.2mg/L for wild type virus. These targets 
are frequently used for therapeutic drug monitoring purposes.
Department of Health and Human Services (DHHS) perinatal guidelines classify ri-
tonavir-boosted darunavir as an alternative agent to be used during pregnancy. The 
DHHS guidelines as well as the British HIV Association guidelines for the management 
of HIV infection in pregnant women 2012 recommend the 600/100mg twice-dai-
ly dose to be used during pregnancy,[6,7] because 800/100mg darunavir/r once 
daily during pregnancy leads to reduced trough levels, whereas trough levels after the 
600/100mg twice-daily dose seem to be more in line with exposure in non-pregnant 
adults. During pregnancy human physiology alters, potentially affecting the pharmacoki-
netics of drugs.[8,9] These changes mostly result in lower exposure of medication during 
pregnancy, which has been reported for total darunavir, with decreases in AUC0-tau 
and Ctrough ranging from 17-31%,
[10-13] and with a less pronounced decrease in active, 
unbound darunavir (7-8%[10] and 24%[13]), due to changes in protein binding.
Zorilla et al. studied the pharmacokinetics of 600/100mg of darunavir/r twice daily in 
pregnancy in a limited number of patients (n=11) and conclude that, because the change 
in unbound (active) darunavir was not clinically significant, no dose adjustment is required 
for pregnant women receiving darunavir/r 600/100mg twice daily.[10] Capparelli et al. 
presented preliminary results of darunavir/r (600mg twice daily and 800/100mg once 
daily) pharmacokinetics in pregnancy. They concluded that twice-daily dosing should 
be used during pregnancy as the Ctrough of total darunavir was low in the patients on 
darunavir/r 800/100mg once daily: 1.25 (0.15-2.49) mg/L.[11] A 20% reduction of 
total darunavir Ctrough in the third compared with the first trimester was also reported by 
Courbon et al. Some women did not meet the 0.55 mg/L target for treating HIV with 
resistance-associated mutations. The conclusion was that 600/100mg of darunavir/r 
twice daily results in better exposure during pregnancy and can be suggested.[12]
Curran et al. presented the total and unbound darunavir AUCs during pregnancy and 
postpartum of five patients taking 800/100mg of darunavir/r once daily. None of 
the patients had a Ctrough below the IC50 for wild type virus.
[13] Crauwels et al. also 
reported total and unbound darunavir AUCs of 16 patients using this once-daily dose in 
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pregnancy. In the third trimester of pregnancy an AUC decrease of 35% total darunavir 
and 20% of unbound darunavir was observed. Unbound darunavir was >10-fold above 
the wild-type EC50, high viral suppression rates were maintained during pregnancy and 
no MTCT was reported.[14] Both studies concluded that dose adjustment to 600/100mg 
of darunavir/r twice daily in pregnancy would not be necessary.
Safety of darunavir use in pregnancy is summarized in the Antiretroviral Pregnancy 
Registry (APRegistry). Darunavir is a pregnancy category C drug according to FDA 
guidelines, which is defined as: “animal reproduction studies have shown an adverse 
effect on the foetus and there are no adequate and well-controlled studies in humans, 
but potential benefits may warrant use of the drug in pregnant women despite potential 
risks.” The APRegistry contains sufficient numbers of pregnancy outcomes for first trimester 
exposures to darunavir to rule out at least a 2-fold increase in risk of overall birth 
defects (n=212) compared with the reference population. The percentage of defects/
live births was 2.4%, which is not different from CDC’s birth defects surveillance system: 
i.i. 2.72%.[15]
cART might be associated with an increased rate of pre-term delivery (<37 weeks ges-
tational age (GA)).[16,17] Some studies report higher rates of pre-term birth when cART 
contains protease inhibitors, but these results are not consistent.[16,18] Furthermore, no 
strong association was found between antiretroviral use during pregnancy and small 
for GA.[18]
Because the information on pharmacokinetic changes during pregnancy is limited for 
darunavir (especially for the 800/100mg once-daily dose) and the use of protease in-
hibitors during pregnancy is increasing in high- and middle-income countries, we studied 
the effect of pregnancy on darunavir total and unbound plasma concentrations.
Patients and methods 
This was a non-randomized, open-label, multicentre, phase IV study in HIV-infected 
pregnant women recruited from HIV treatment centres in Europe (PANNA network: www.
pannastudy.com). The PANNA Network is a European network of 19 hospitals collect-
ing pharmacokinetic curves of several antiretrovirals during pregnancy in a prospective 
study. Data in this publication were collected by nine hospitals between October 2009 
and January 2014.
The study was conducted in compliance with the principles of the “Declaration of 
Helsinki”. Informed consent was obtained from each participant before entering the 
study. The study was approved by the Medical Ethics Committee from each individual 
centre involved and by the national authorities if applicable. The study is registered at 
ClinicalTrials.gov under number NCT00825929.
Patient eligibility included being HIV-infected, pregnant, at least 18 years of age at 
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screening and treated with a cART regimen containing darunavir for at least two weeks 
prior to the first pharmacokinetic curve evaluation (in the third trimester of pregnancy). 
Patients were excluded if they had a past medical history or current condition that might 
interfere with drug absorption, distribution, metabolism or excretion or presented with 
grade III/IV anaemia (i.e. Hb <4.6 mmol/L or <7.4 g/dL) at screening.
Safety assessments and viral load
Inclusion screening consisted of: medical history, physical examination, serum biochem-
istry, haematology and qualitative urinalysis, HIV-1 RNA load and CD4+ T cell count 
determination. Analyses for safety assessments were performed by local laboratories. 
Blood samples for safety assessments were further taken at the visits for pharmacokinetic 
blood sampling. Patients were asked for adverse events at each visit. Birth weight, con-
genital abnormalities and HIV-status of the infants were collected.
Pharmacokinetic blood sampling
A 12 or 24 hour pharmacokinetic curve was obtained after at least 2 weeks of darunavir 
treatment during the third trimester (preferably at week 33) and at least 2 weeks post-
partum (preferably 4-6 weeks postpartum). At delivery (where possible) a cord blood 
sample and a contemporary maternal blood sample were collected. Total concentra-
tions of darunavir in plasma were analyzed in all samples. Unbound darunavir concen-
trations were analyzed in two samples per curve (1 sample with low and 1 sample with 
high total darunavir concentrations). Samples were analyzed by the laboratory of the 
Pharmacy of the Radboud university medical center.
A standard breakfast (650kCal; 30g fat) commenced prior to (observed) dosing on the 
pharmacokinetic days. A 6 mL venous blood sample was collected into heparin tubes 
just before drug intake (pre-dose) and at 0.5, 1, 2, 3, 4, 6, 8, 12 and (if applicable) 
24h post-medication intake on both pharmacokinetic study days. Plasma was separated 
and stored at <-18°C until shipment on dry ice to the central laboratory for analysis.
Analytical and pharmacokinetic methods
Concentrations of total darunavir and ritonavir in plasma were analyzed by use of a 
validated (ultra)HPLC method for the simultaneous quantitative determination of several 
HIV protease inhibitors in human plasma.[19] The lower limit of quantification (LLOQ) 
was 0.10 mg/L for darunavir and 0.045 mg/L for ritonavir. The assays were externally 
validated through ACTG and KKGT.[20,21]
Protein-bound and -unbound darunavir was separated using an ultrafiltration method 
(using pre-washed Centifree-30K protein binding filters, Amicon). The unbound fraction 
was analysed using the same UPLC method as described above with an LLOQ of 0.015 
mg/L (range 0.015-1.5 mg/L). Unbound concentrations were assessed in a sample 
with a low (total) darunavir concentration and a high (total) darunavir concentration per 
pharmacokinetic curve, if the sample volume was sufficient for the analysis.
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Pharmacokinetic parameters were determined using a non-compartmental model in 
WinNonlin version 6.3 (Pharsight Corporation, CA, USA). Area under the curve over 
a dosing interval (AUCtau, AUC0-12h/AUC0-24h) using the trapezoidal rule, trough concen-
tration (C12h/C24h) defined as the sample taken at time point 12hr or 24hr, maximum 
concentration (Cmax), elimination half life (Thalf), time of maximum concentration (Tmax) 
and apparent clearance (CL/F, being the dose/AUCtau) were determined per individual 
curve.
Statistical analysis data handling
Patients for whom a curve was taken during pregnancy were included in demographic, 
safety analyses and descriptive statistics of the pharmacokinetic parameters. Geometric 
mean ratios (GMR) were calculated for the patients with a curve in the third trimester 
and a postpartum curve. Pharmacokinetic parameters are reported as geometric means 
with 95% intervals. GMRs of AUCtau, Cmax, C12h/24h, CL/F and Thalf of third trimester versus 
postpartum were calculated for both dosing regimens separately using a mixed-effects 
model in WinNonlin/Phoenix. Unbound plasma concentrations and the percentage 
unbound were determined, and mean percentage unbound darunavir was calculated 
for the third trimester and postpartum. Cord blood/maternal blood concentration ratios 
were determined and described.
Results
Twenty-four patients receiving darunavir during pregnancy were enrolled in the study. 
Six patients used 600/100mg of darunavir/r twice daily and 17 used 800/100mg of 
darunavir/r once daily, one patient used 600/100mg darunavir/r once daily (due to 
previous hepatotoxicity and high darunavir concentrations on 800/100mg once daily 
the dose had been reduced by the treating physician, liver function normalised after 
dose reduction). Characteristics of the patients as well as pregnancy outcome summa-
rized for the total group and per dosing regimen are depicted in Table 1. Approximately 
50% of the patients were white; smoking, alcohol use and drug use only appeared in 
the 800/100mg once daily regimen group. The age at delivery was similar between 
both regimens (median age was 31 and 33 years, respectively). Most patients (75%) 
conceived whilst taking cART; however, only 25% were on darunavir at conception. If 
not used prior to conception, darunavir was started mainly during the first and second 
trimester, only three patients (13%) started darunavir in the third trimester, of which only 
one patient was antiretroviral treatment-naive. Darunavir/r and two nucleos(t)ide reverse 
transcriptase inhibitors (NRTIs) was used by nine (50%) of the patients on 800/100mg 
of darunavir/r once daily and by one patient on 600/100mg of darunavir/r twice 
daily. Most other patients used at least four antiretroviral drugs, mainly two NRTIs, 
darunavir/r and raltegravir or maraviroc. One patient used 800/100mg of darunavir/r 
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Screening All n=24
600/100mg DRV/r 
BID n=6
800/100mg DRV/r 
QD n=18a
Age at delivery, years (range) 30 (20-44) 31 (24-41) 33 (20-44)
Caucasian race/ Black race, n (%) 11 (46%)/ 13 (54%) 2 (33%)/ 4 (66%) 9 (50%)/ 9 (50%)
Smoking, n (%) 4 (17%) 0 (0%) 4 (22%)
Alcohol, n  (%) 2 (8%) 0 (0%) 2 (11%)
Drugs, n (%) 1 (4%) 0 (0%) 1 (6%)
Treatment-naive at start pregnancy, n (%) 6 (25%) 1 (17%) 5 (28%)
ARV treatment duration 235 (28-813) 107 (28-127) 384 (60-813)
before pregnancy, median weeks (range)
Conception on darunavir, n (%) 6 (25%) 2 (33%) 4 (22%)
Start darunavir per trimester, n (%) 6 (25%) 1st trimester 2 (33%) 1st trimester 4 (22%) 1st trimester 
9 (38%) 2nd trimester 1 (17%) 2nd trimester 8 (44%) 2nd trimester
3 (13%) 3rd trimester 1 (17%) 3rd trimester 2 (11%) 3rd trimester
Concomitant ARV
    NRTI, n (%)
 3 (50%) zidovudine; 2 
(33%) tenofovir 
13 (72%) tenofovir; 11 
(61%) emtricitabine
 
 
1 (17%) emtricitabine; 
2 (33%) lamivudine 2 (11%) lamivudine 
Integrase inhibitor, n (%)  2 (33%) raltegravir 6  (33%) raltegravir
Fusion/entry inhibitor, n (%) 2 (33%) maraviroc; 1 
(17%) enfuvirtide 2 (11%) maraviroc
NNRTI, n (%)  1 (17%) etravirine  
Third trimester    
Gestinational age, weeks (range) 34 (31-37) 33 (31-36) 34 (32-37)
Weight, kg (range) 80 (65-117) 80 (70-103) 80 (65-117)
Delivery    
Gestational age, weeks (range) 38 (36-41) 38 (37-39) 38 (36-41)
Vaginal delivery, n (%) 6 (25%) 2 (33%) 4 (22%)
Undetectable viral load <50 copies/mL, 
n (%)b
16 (67%), unk 1 (4%) 3 (50%) 13 (72%), unk 1 (6%)
CD4+ T cell count, cells/mm3 (range)b 479 (82-1196), unk2 330 (82-837) 591 (151-1196), unk 2
Pregnancy outcomes    
Birth weight, g (range) 3090 (2060-3718) 3260 (2470-3700) 3075 (2060-3718)
Small for gestational age, n (%)c 6 (25%) 1 (17%) 5 (28%)
HIV infected childs, n 0 0 0
Table 1. Patient characteristics
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as monotherapy. No other concomitant medication was used which could potentially 
influence darunavir or ritonavir exposure.
A total of 21 evaluable darunavir curves were collected in the third trimester (five for the 
twice-daily regimen and 16 for the once-daily regimen) and 13 evaluable postpartum 
curves (five for the twice-daily regimen and eight for the once-daily regimen). Reasons 
for non-evaluable curves in the third trimester were: one patient did not have measurable 
darunavir concentrations in the samples (twice-daily regimen), probably due to non-ad-
herence, and was excluded from pharmacokinetic analysis (third trimester and postpar-
tum); one patient on the once-daily regimen took the darunavir/r medication at night, a 
12-24h curve was collected (this patient was only partly included in the analysis); one 
patient on once-daily regimen used 600/100mg of darunavir/r once daily and was 
only included in the GMR calculations. Additionally six patients did not have a postpar-
tum curve: five withdrew consent and one was lost to follow-up. One patient had only 
a postpartum curve collected until 4 hours after dosing and Cmax was not observed, 
and one patient did not have measurable concentrations in the postpartum curve. For 
some patients the 12h or 24h sample was not collected: one patient on 600/100mg of 
darunavir/r twice daily in the third trimester; four patients on 800/100mg of darunavir/r 
once daily in the third trimester and two patients on 800/100mg of darunavir/r once 
daily postpartum. Curves were taken at median (range) 34 (31-37) weeks GA for the 
third trimester and median (range) 5 (3-14) weeks postpartum.
Screening All n=24
600/100mg DRV/r 
BID n=6
800/100mg DRV/r 
QD n=18a
Postpartum
All n =18
600/100mg DRV/r 
BID n=6
800/100mg DRV/r 
QD n=12a
Time after delivery, weeks (range) 5 (3-14) 5 (4-9) 5 (4-13)
Weight, kg (range) 76 (62-109) 76 (63-109) 76 (62-100)
Undetectable viral load <50 copies/mL, 
n (%) 12 (67%) 3 (50%) 9 (75%)
CD4+ T cell count, cells/mm3, median 
(range)
445 (93-1279), unk 6 385 (93-716) 496 (149-1279), unk 6 
Table 1. - continued Patient characteristics
ARV, antiretroviral; BID, twice daily; QD, once daily; DRV/r: darunavir/ritonavir, NRTI; nucleoside reverse transcriptase 
inhibitor, NNRTI: nonnucleoside reverse transcriptase inhibitor a: Subject using DRV/r 600/100mg QD was included in 
800/100mg QD analysis. b: Undetectable viral load and CD4+ count measured at delivery in 7 subjects. For the other 
subjects (n=17) the viral load and CD4+ count from the third trimester were used. The median time between sampling 
third trimester and delivery, weeks (range) was 4 (0-6) c: Small for gestational age (SGA) was determined as 10th 
percentile of birth-weight-for-age, based on US population-based reference for SGA
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Pharmacokinetics
The mean plasma concentration-time profiles of darunavir in the third trimester and post-
partum are presented by regimen in Figure 1; summary statistics of the PK parameters are 
listed in Table 2 for darunavir and in supplementary Table 1 for ritonavir.
AUCtau was 22% and 34% lower in the third trimester for 600/100mg twice daily and 
800/100mg once daily, respectively. For the twice-daily regimen the 90% CI of the 
GMR ranged from 60-100% and for the once-daily dose this was 56-82% (intra-subject 
comparison). Cmax was 24% and 22% lower during pregnancy and C12h/C24h was 11% 
and 42% lower for twice-daily and once-daily regimen, respectively. Mean protein-free 
fraction of darunavir (95% CI) was 12% (11-13%, 44 samples of 19 patients) in the third 
trimester and 10% (9-11%, 30 samples of 14 patients) postpartum.
For the 800/100mg once-daily regimen one patient (8%) had documented darunavir 
concentrations <0.55 mg/L (EC50 for resistant virus), but >0.055 mg/L (EC50 for wild-type 
virus) in the third trimester. None of the patients on 600/100mg of darunavir/r twice 
daily had observed concentrations below this target. In Figure 2 individual AUCtau and 
Figure 1. Mean concentration-time profiles
Darunavir (DRV) concentrations at steady-state after both the twice-daily (BID) as well as once-daily (QD) dosing regimen.
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C12h/C24h results during pregnancy and postpartum are depicted.
Ritonavir exposure (AUCtau) was markedly decreased during pregnancy: 26% and 41% 
for twice-daily and once-daily regimen, Cmax was even more affected: 37% and 41% 
lower for the twice-daily and once-daily regimen, respectively (Table 3).
Eleven umbilical cord blood samples were collected with matching maternal blood 
samples. The median time between the reported last dose and cord blood sampling 
was 9.1h (range 1.4-19.0h); the median time between cord blood sample and maternal 
sample was 10 minutes (0-79 min). Darunavir concentrations were below the LLOQ in 
three cord blood samples (with matching maternal samples ranging from 0.18-0.79 
 GM (95% CI) GM (95% CI) GM Ratio (90% CI)
 Third Trimester Postpartum
Third Trimester / Post-
partum
Darunavir 600/100mg BID (n=5) (n=5)  
AUC0-12h (h⋅mg/L) 41.0 (27.2-61.8) 52.8 (38.2-73.1) 0.78 (0.60-1.00)
Cmax (mg/L) 4.98 (3.17-7.82) 6.5 (4.36-9.70) 0.76 (0.53-1.11)
Tmax (h) 4 (2-6) 3 (2-4)  
Cpredose (mg/L) 2.68 (1.76-4.08) 3.26 (2.21-4.81) 0.82 (0.70-0.96)
C12h (mg/L) 2.41 (1.20-4.86)
b 2.76 (1.84-4.13) 0.89 (0.58-1.36)
thalf (h) 8.5 (6-12) 7.6 (4.2-13.7) 1.12 (0.79-1.59)
CLss/F (L/h) 15 (10-22) 11 (8-16) 1.28 (1.00-1.66)
Darunavir 800/100mg QD (n=16) (n=8)  
AUC0-24h (h⋅mg/L) 52.9 (44.5-63.0) 76.2 (64.9-89.5) 0.67 (0.56-0.82)
a
Cmax (mg/L) 5.30 (4.49-6.25) 6.75 (5.86-7.77) 0.78 (0.65-0.95)
a
Tmax (h) 3 (1.5-6) 2.5 (1-7)  
Cpredose (mg/L) 1.21 (0.92-1.61) 1.62 (1.06-2.48) 0.77 (0.54-1.10)
a
C24h (mg/L) 1.14 (0.90-1.46)
c 2.05 (1.65-2.55)d 0.58 (0.44-0.78)a
thalf (h) 13 (9-18) 21 (13-34) 0.59 (0.40-0.87)
a
CLss/F (L/h) 15 (13-18) 10.5 (9-12) 1.50 (1.24-1.81)
a
Table 2. Darunavir pharmacokinetic parameters
a GMR includes one patient using 600/100mg QD b 1 value (20%) was missing, no sample taken at 12h after dosing 
c 4 values (25%) were missing, no sample taken at 24h after dosing d 2 values (25%) were missing, no sample taken at 
24h after dosing
87 Pharmacokinetics of darunavir in HIV-1 infected pregnant women
mg/L). Ritonavir concentrations were below LLOQ in all cord blood samples. The median 
(range) ratio of darunavir cord blood/maternal blood was 0.13 (0.08-0.35; n=8).
Efficacy and safety
The median GA at delivery was 38 (range, 36-41) weeks. All children were tested 
HIV-negative (PCR DNA after delivery) and no congenital abnormalities were reported. 
One infant (4%) was born between 36 and 37 weeks GA. Four babies had a low 
birth weight (<2,500 gram: 2,060-2,470 gram). Six children (25%) were small for GA 
(reference 10th percentile of birth weight for GA by gender, US, 1991).[22]
One (maternal) serious adverse event (SAE) was reported: one patient on darunavir 
800/100mg once-daily was hospitalized for 3 days (starting at 34 weeks and 4 days 
GA) because of suspicion of pre-eclampsia, which was not confirmed. The patient was 
released from the hospital and delivered at 37 weeks and 2 days GA. This SAE was 
judged not to be related to darunavir/r treatment. Seven patients reported adverse 
events, all but 1 were grade 1 or 2 and not or unlikely related to the cART given. Severe 
anaemia (due to haemorrhagic delivery) was reported for one subject; she recovered 
and this adverse event was not related to darunavir/r.
 GM (95% CI) GM (95% CI) GM Ratio (90% CI)
 Third Trimester Postpartum
Third Trimester / Postpar-
tum
Darunavir 600/100mg BID (n=5) (n=5)  
AUC0-12h (h⋅mg/L) 4.67 (3.00-7.28) 6.32 (4.54-8.79) 0.74 (0.65-0.84)
Cmax (mg/L) 0.61 (0.38-0.98) 0.96 (0.58-1.60) 0.63 (0.53-0.76)
Tmax (h) 4 (3-8) 4 (2-6)  
C12h (mg/L) 0.22 (0.11-0.41) 0.30 (0.18-0.49) 0.72 (0.56-0.92)
thalf (h) 5.5 (4-7) 5 (4-6) 1.17 (0.95-1.43)
CLss/F (L/h) 21 (14-33) 16 (11-22) 1.35 (1.18-1.55)
Darunavir 800/100mg QD (n=16) (n=8)  
AUC0-24h (h⋅mg/L) 3.11 (2.19-4.42) 5.16 (3.60-7.42) 0.59 (0.42-0.83)
a
Cmax (mg/L) 0.31 (0.23-0.44) 0.56 (0.37-0.83) 0.59 (0.42-0.82)
a
Tmax (h) 4 (1.5-8) 4 (3-7)  
C24h (mg/L) 0.03 (0.02-0.04)
b 0.041 (0.03-0.06)c 0.72 (0.47-1.10)a
thalf (h) 6 (5-7) 6 (5-8) 1.00 (0.75-1.33)
a
CLss/F (L/h) 32 (23-46) 19 (13-28) 1.70 (1.20-2.41)
a
Table 3. Ritonavir pharmacokinetic parameters
a GMR includes one patient using 600/100mg QD; b 13 (81%) below LLOQ, taken as 1/2 LOQ, i.e. 0.0225 mg/L; c 3 
(38%) below LLOQ, taken as 1/2 LOQ, i.e. 0.0225 mg/L
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HIV viral load close to delivery was undetectable (<50 copies/mL) in the majority 
(67%) of the women. However, a detectable viral load was seen in 3/6 women on the 
twice-daily regimen (242, 272 and 1,610 copies/mL) and 4/18 women on once-daily 
regimen (74; 121; 144; 28,711 copies/mL) around delivery.
Pharmacokinetic – Efficacy relationship
As reported above, HIV viral loads were detectable (>50 copies/mL) for 7 patients 
around delivery. See Table 4 for detailed information of these patients. The two patients 
with the high viral load (i.e. 1,610 and 28,711 copies/mL respectively) were probably 
Figure 2. Individual darunavir AUC and Ctrough levels
Open circle and continuous lines: undetectable viral load around delivery (<50 copies/mL) filled squares and broken 
lines: detectable viral load around delivery (>50 copies/mL) DRV/r=darunavir/ritonavir; BID = twice daily; QD = once 
daily
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not adherent; they did not have detectable darunavir concentrations in the plasma 
during the third trimester visit and/or postpartum. All other patients with detectable viral 
load around delivery reported to have been adherent to therapy during that time period. 
In Figure 2 individual AUCs and Ctrough levels are presented for patients with and without 
detectable viral load. For patients reported to be adherent, darunavir AUC and Ctrough 
were similar between patients with or without detectable viral load for the once-daily 
regimen. For the twice-daily regimen the Ctrough and AUCs show a trend towards lower 
concentration and exposure for the patients with a detectable viral load in the third 
trimester of pregnancy.
     darunavir concentrations
DRV cART
cART 
use at 
pregancy 
start
Viral load 
around 
delivery
(copies/mL)
Viral load 
postpartum 
(copies/mL)
3rd trim 
predose 
(mg/L)
3rd trim 
12h or 24h 
(mg/L)
postpar-
tum 12h 
or 24h 
(mg/L)
600/100mg BID lamivudine + 
zidovudine + 
tenofovir
Yes 525 74 1.8 1.6 2.565
600/100mg BID etravirine + 
fuzeon
Yes 1,610
(<50 at 3rd 
trim visit)
16,300 <LLOQ <LLOQ <LLOQ
600/100mg BID lamivudine + 
zidovudine, 
raltegravir 
added after 
3rd trim visit
Yes 242 99 2.9 No sample 3.216
800/100mg QD tenofovir + 
emtricitabine
Yes 121 112 1.136 1.263 1.365
800/100mg QD raltegravir Yes 74 Undet
<50c/mL
1.324 1.222 2.699
800/100mg QD tenofovir + 
emtricitabine 
+ raltegravir
No, start 
in 2nd 
trimester
144  2.252 No sample Not done
800/100mg QD tenofovir + 
emtricitabine
Yes 28711 5673 <LLOQ <LLOQ Not done
Table 4. Detailed information patients with detectable viral load around delivery
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Discussion
In this paper, we describe the pharmacokinetics of darunavir/r in 24 pregnant HIV-in-
fected patients (6 on 600/100mg darunavir/r twice daily and 18 on darunavir/r once 
daily), in the third trimester of pregnancy and after delivery. In the third trimester of 
pregnancy a decrease in total darunavir AUCtau, Cmax and C12h/24h was observed for 
both treatment regimens. Darunavir free fraction was similar during pregnancy and post-
partum. For one patient on 800/100mg darunavir/r once daily (8%) darunavir a Ctrough 
below the EC50 for resistant virus (0.55mg/L) was reported in the third trimester. Trans-
placental passage of darunavir was low: 0.13 (median ratio of darunavir cord blood/
maternal blood), and ritonavir was undetectable in all cord blood samples. Darunavir 
was well tolerated during pregnancy, none of the children was tested HIV-positive and 
no congenital abnormalities were reported. The median GA at delivery was 38 weeks, 
with a range of 36-41 weeks. Six children (25%) were small for GA (reference 10th per-
centile of birth weight for GA by gender, US, 1991),[22] which is higher than observed 
in the US for children born from HIV-infected women (7.3%).[18]
The darunavir postpartum curves reported in this study were comparable to the reference 
pharmacokinetic curves reported in literature for both the 600/100mg twice-daily 
dose[5,23] and the 800/100mg once-daily dose,[4,5,23] indicating that the postpartum 
curves can be used as reference for the normal, non-pregnant, situation.
The decreased exposure (22%) for darunavir/r 600/100mg twice daily in the third 
trimester of pregnancy was in line with the 18% and 26% decrease in AUC observed 
by Zorrilla et al. and Capparelli et al.[10,11] However, in this study, we did not find a dif-
ference in fraction unbound between the pregnant and non-pregnant situation, whereas 
Zorrilla et al. described a slightly higher fraction unbound during pregnancy, resulting in 
a less pronounced decrease in unbound darunavir in pregnancy (appr. 7% decrease 
in AUC).[10]
In this study, for darunavir/r 800/100mg once daily a 33% lower AUCtau was observed 
in the third trimester compared with postpartum. This is also in line with previously 
reported data by Curran et al. and Crauwels et al. (31% and 35% decrease of total 
darunavir AUC)[13,14] and slightly more pronounced than reported by Capparelli et al. 
(24% decrease in AUC).[11] The darunavir pharmacokinetic parameters we describe tend 
to be marginally lower compared with both other studies describing pharmacokinetics 
in pregnancy after 800/100mg of darunavir/r once daily.[11,13] Darunavir Ctrough in the 
third trimester after 800/100mg of darunavir/r once daily reported by Courbon et al.[12] 
(1.08 mg/L) was in line with the levels observed in our study (1.14 mg/L).
In this study, for one patient a C24h concentration below the EC50 for resistant virus (but 
above the EC50 for wild type virus) was reported in the third trimester (800/100mg of 
darunavir/r once daily). This patient had an undetectable viral load around delivery. For 
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the twice-daily dosing regimen the C12h concentrations seem lower in the third trimester 
for patients with a detectable viral load around delivery; however, the C12h concentra-
tions were well above the EC50 for resistant virus for the adherent patients. The number 
of patients is too low to draw conclusions. A clear relationship between low darunavir 
plasma concentrations and detectable viral load could not be demonstrated for these 
dosing regimens.
A limitation of the study is that we determined the unbound darunavir concentrations 
in only a limited number of samples and not for the entire curve, because not enough 
plasma was available to perform the analyses. Another limitation is the fact that we 
did not collect genotyping data; therefore information on possible protease inhibitor 
resistance is not known.
Physiological changes possibly causing lower exposure to darunavir and ritonavir during 
pregnancy are reduced intestinal motility, a larger plasma volume, increased hepatic 
blood flow, decreased protein binding and induced hepatic enzymes. The Cmax for both 
compounds was approximately 20-60% lower in the third trimester, which potentially 
is caused by a larger plasma volume, possibly decreased gastrointestinal absorption 
and/or slower gastro intestinal transit time. For the 800/100mg once-daily dose, the 
darunavir half-life was shorter during pregnancy, indicating a faster elimination (possibly 
due to enzyme induction), which could lead to lower trough levels, especially in case of 
(accidental) prolonged (>24h) dosing intervals. It should be noted that half-life calcula-
tions are less reliable because we only cover a limited period of the terminal half-life in 
this dosing period, especially for the twice-daily dosing regimen. Next to the physiolog-
ical changes, the reduced ritonavir concentrations might imply less boosting, resulting in 
lower darunavir concentrations (and faster elimination). Ritonavir exposure was approx-
imately 26% (twice daily) and 41% (once daily) lower during pregnancy. This is in line 
with the ritonavir AUC decrease reported for 800/100mg of darunavir/r once daily[14] 
and 600mg/100mg of darunavir/r twice daily[10] during pregnancy and also similar 
to results when ritonavir was combined with atazanavir (once daily).[24,25] Assuming 
dose-linear pharmacokinetics for ritonavir, this decrease would be similar to a 50mg 
dose. In a study in healthy volunteers steady state 800/50mg of darunavir/r once 
daily revealed that the darunavir AUC was only approximately 13% lower compared 
to 100mg boosting. Darunavir Cmax was not affected but the largest effect was seen 
on Cmin: 32% lower for the 50mg ritonavir dose. Furthermore, ritonavir concentrations 
decreased more than dose-linear in that study.[26] Although less boosting due to lower 
ritonavir concentrations probably only partly explains the decreased exposure during 
pregnancy, it might explain the more prominent decrease in exposure to darunavir in the 
800/100mg once daily regimen compared to the 600/100mg twice daily regimen.
In conclusion, darunavir AUC and Cmax are substantially decreased in pregnancy 
(22-34%) for both 600/100mg of darunavir/r twice daily and 800/100mg of daruna-
vir/r once daily. This decrease in exposure did not result in mother-to-child-transmission. 
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For antiretroviral-naive patients, who are adherent, take darunavir with food and are 
not using concomitant medication reducing darunavir concentrations, 800/100mg of 
darunavir/r once daily is adequate in pregnancy. For all other patients, 600/100mg of 
darunavir/r twice daily is recommended during pregnancy.
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Abstract
Objective: To describe the pharmacokinetics of tenofovir and emtricitabine in the third 
trimester of pregnant HIV-infected women and at postpartum.
Design: A nonrandomized, open-label, multicentre phase IV study in HIV-infected 
pregnant women recruited from HIV treatment centres in Europe.
Methods: HIV-infected pregnant women treated with the nucleotide/nucleoside analogue 
reverse transcriptase inhibitors (NRTIs) tenofovir disoproxil fumarate (300mg; equivalent 
to 245mg tenofovir disoproxil and/or emtricitabine (200mg) were included in the study. 
Twenty-four-hour pharmacokinetic curves were recorded in the 3rd trimester (preferably 
week 33) and postpartum (preferably week 4-6). Collection of a cord blood sample 
and maternal sample at delivery was optional. Pharmacokinetic parameters were cal-
culated using WinNonlin software version 5.3. Statistical analysis was conducted using 
SPSS version 16.0.
Results: Thirty-four women were included in the analysis. Geometric mean ratios of 
3rd trimester vs. postpartum [90% confidence interval (CI)] were 0.77 (0.71-0.83) 
for tenofovir AUC0-24h; 0.81 (0.68-0.96) for tenofovir Cmax and 0.79 (0.70-0.90) for 
tenofovir C24h, and 0.75 (0.68-0.82) for emtricitabine AUC0-24h; 0.87 (0.77-0.99) for 
emtricitabine Cmax and 0.77 (0.52-1.12) for emtricitabine C24h. The viral load close to 
delivery was less than 200 copies/mL in all but one patient, the average gestational 
age at delivery was 38 weeks. All children were tested HIV negative and no congenital 
abnormalities were reported.
Conclusions: Although pharmacokinetic exposure of the NRTIs tenofovir disoproxil and 
emtricitabine during pregnancy is approximately 25% lower, this was not associated 
with virological failure in this study and did not result in mother-to-child transmission.
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Introduction
In 2010, approximately 17.5 million women were infected with HIV, most of who were 
of child bearing age.[1] It is estimated that 39% of the European women infected with 
HIV have a desire for childbearing in the future, which is comparable to HIV-uninfected 
women.[2] This has also been reported for women infected with HIV in the USA[3] and 
South Africa.[4]
Combination antiretroviral therapy (cART) has been shown to be a highly effective 
strategy for preventing mother-to-child transmission (PMTCT) of HIV, reducing the risk 
from 15-40% to less than 2%.[5] The US Department of Health and Human Services 
(DHHS) guidelines recommend the inclusion of one or more nucleoside analogue 
reverse transcriptase inhibitors (NRTIs) with good transplacental passage in the cART 
regimen, when feasible.[6] The most commonly used NRTIs are zidovudine (ZDV) and 
lamivudine (3TC), mainly because of the vastly greater clinical experience with these 
compounds during pregnancy. However, an overview of antiretroviral prescribing during 
pregnancy between 1995 and 2009 showed an increase of tenofovir disoproxil/
emtricitabine use to approximately 30%, whereas ZDV/3TC use during pregnancy 
decreased from approximately 90% to 70%.[7] This reflects the recommendations for 
first-line NRTI back-bone (tenofovir disoproxil/emtricitabine combination) in non-pregnant 
adults.[8] All four NRTIs cross the placenta well.[9-14] The current summary of product 
characteristics of Truvada®[15] states that its use may be considered during pregnancy, if 
necessary. Safety issues on the use of antiretrovirals during pregnancy concern exposure 
of the mother, influence on pregnancy duration and teratogenicity. cART use (especially 
protease inhibitor based) during pregnancy has been reported to be associated with 
an increased rate of pre-term delivery (<37 weeks gestational age (GA)) in European 
studies.[16] Most North American studies have not shown this association.[17,18]
The antiretroviral pregnancy registry interim report (up to 31 Jan 2012) did not detect a 
two-fold increase in risk of overall birth defects: the prevalence of birth defects of both 
tenofovir disoproxil and emtricitabine was 2.3%,[19] compared with 2.1% prevalence of 
major birth defects in the European general population.[20] Two individual cases of py-
electasis in children born from mothers receiving tenofovir disoproxil-containing therapy 
during pregnancy have been described.[21] In a macaque model, perinatal exposure to 
very high doses of tenofovir disoproxil resulted in bone toxicity in some offspring.[22] This 
has not yet been reported in humans,[23,24] nor in another macaque model.[25] In studies 
with emtricitabine during pregnancy, no emtricitabine-related congenital anomalies were 
reported [26,27] and emtricitabine animal studies do not indicate reproductive toxicity.[28]
Human physiology alters during pregnancy, potentially affecting the pharmacokinetics 
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of drugs,[29-31] mostly resulting in lower exposure of medication during pregnancy.
Pharmacokinetic parameters of chronic exposure to tenofovir (TFV) during pregnancy 
have been presented as abstracts at conferences only. It was concluded that exposure 
during pregnancy is lower, but with area under the curves (AUCs) not below the 10th per-
centile of nonpregnant patients (2 mg⋅h/L) for most women.[10] In studies of single-dose 
tenofovir disoproxil given for HIV PMTCT at onset of labour, doses of 600mg and 
900mg tenofovir disoproxil, which are higher that for chronic administration (300mg), 
have been used.[14,27] For the 600mg dose, plasma concentrations were similar to those 
observed after chronic administration of 300mg tenofovir disoproxil fumarate in non-
pregnant adults[12,14] and with an initial dose of 600mg tenofovir disoproxil fumarate in 
nonpregnant adults.[11] A population study of 186 women (of whom 46 were pregnant), 
with a sparse sampling method, showed  39% higher apparent clearance of tenofovir 
in the pregnant women.[32]
Pharmacokinetic parameters of chronic exposure to emtricitabine have been reported as 
lower during pregnancy, but the magnitude of the decrease appears to be small, 10%[33] 
to 18%.[26] When 400mg is administered at labour initiation, the plasma concentrations 
appear higher than after chronic administration of 200mg emtricitabine in non-pregnant 
adults.[34]
As information on pharmacokinetic changes during pregnancy is limited (especially 
for chronic use during pregnancy) and the use of tenofovir disoproxil and emtricitabine 
during pregnancy is increasing, we studied the effect of pregnancy on tenofovir and 
emtricitabine pharmacokinetics.
Methods
This was a nonrandomized, open-label, multicentre phase IV study in HIV-infected 
pregnant women recruited from HIV treatment centres in Europe (PANNA network: 
www.pannastudy.com). The PANNA network is a European network of hospitals col-
lecting pharmacokinetic curves of several antiretroviral drugs during pregnancy in a pro-
spective study. In total, 17 hospitals are involved in the network, data in this publication 
were collected by 10 hospitals between November 2008 and January 2012.
The study was conducted in compliance with the principles of the “Declaration of 
Helsinki”. Informed consent was obtained from each participant before entering the 
study. The study was approved by the medical ethical committee from each individual 
centre involved and by the national authorities if applicable. The study is registered at 
ClinicalTrials.gov under number NCT00825929.
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Patient eligibility included being HIV infected, pregnant, at least 18 years of age at 
screening and treated with a cART regimen containing tenofovir disoproxil and/or 
emtricitabine for at least 2 weeks before the day of first pharmacokinetic curve eval-
uation (in the third trimester of pregnancy). Patients were excluded if they had a past 
medical history or current condition that might interfere with drug absorption, distribution, 
metabolism or excretion (such as renal failure or hepatic failure) or presented with grade 
III/IV anaemia (i.e. Hb <4.6 mmol/L or <7.4 g/dL) at screening.
Safety assessments and viral load
Inclusion screening consisted of: medical history, physical examination, serum biochem-
istry, haematology and qualitative urinalysis, HIV-1 RNA load and CD4 T cell counts. 
Analyses for safety assessments were performed by local laboratories. Blood samples 
for safety assessments were further taken at the visits for pharmacokinetic blood sampling 
and at delivery (if they delivered at the hospital). Patients were asked for adverse events 
at each visit, the DAIDS toxicity table (2004) was used to grade the reported adverse 
events.  The HIV-status of the infants was collected.
Pharmacokinetic blood sampling
A 24-hour pharmacokinetic curve was recorded after at least two weeks of tenofovir 
disoproxil and/or emtricitabine treatment during the third trimester (preferably at week 
33) and at least 2 weeks postpartum (preferably 4-6 weeks postpartum). At delivery (if 
possible) a cord blood sample and a blood sample from the mother were taken. Con-
centrations of tenofovir and emtricitabine in plasma were analyzed by the laboratory of 
the Pharmacy of the Radboud University Nijmegen Medical Centre.
A standard breakfast (650kCal; 30g fat) was served prior to (observed) dosing on the 
pharmacokinetic days. Six mL of blood was collected just before drug intake (predose) 
and at 0.5, 1, 2, 3, 4, 6, 8, 12 and 24h after medication intake (10 samples) at all 
pharmacokinetic study days. Plasma was separated and stored at -18°C or lower until 
shipment on dry ice to the central laboratory for analysis.
Analytical and pharmacokinetic methods
Concentrations of tenofovir and emtricitabine in plasma were analysed by use of a 
validated reversed phase high-pressure liquid chromatography (HPLC) method with flu-
orescence detection.
Sample preparation for tenofovir consisted of a liquid-liquid extraction. The solution was 
injected onto a SymmetryShield RP 18 column (3.5 mm, 150 x 4.6 mm). The flow rate 
was set at 1.0 mL/min and tenofovir was detected by use of a fluorescence detector (Lex-
citation=232 nm, Lemission=420 nm). Tenofovir lower limit of quantification (LOQ) was 0.015 
mg/L. The linear calibration ranges in plasma were 0.015-1.5 mg/L.
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Sample preparation for emtricitabine consisted of a solid-phase extraction. 190 µL of 
the solution was injected onto an Atlantis CP18 column (5 mm, 150 x 4.6 mm). The 
flow rate was set at 1.0 mL/min. Emtricitabine was detected by use of a fluorescence 
detector (Lexcitation=244 nm, Lemission=356 nm). Emtricitabine LOQ was 0.030 mg/L. The 
linear calibration ranges in plasma were 0.03-5.0 mg/L. The assays were externally 
validated through ACTG.[35]
Pharmacokinetic parameters were determined using a noncompartmental model in 
WinNonlin version 5.3 (Pharsight Corporation, Sunnyvale, California, USA). Area under 
the curve (AUC0-24h) using the trapezoidal rule, the trough concentration (C24h) defined 
as the sample taken at time point 24hr (or extrapolated if the sample was missing), 
maximum concentration (Cmax), elimination half-life (Thalf), time of maximum concentration 
(Tmax) and apparent clearance (CL/F, being the dose/AUC0-24h) were determined per 
individual curve.
Statistical analysis data handling
Patients for whom a curve was taken during pregnancy were included in demographic, 
safety analyses and descriptive statistics of the pharmacokinetic parameters. Geometric 
mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated for the patients 
with a curve in the third trimester and a postpartum curve. Pharmacokinetic parame-
ters are reported as geometric means with 95% CIs. GMRs of AUC0-24h, Cmax, C24h, 
CL/F and Thalf of third trimester vs. postpartum were calculated. To indicate whether the 
pharmacokinetic parameters during pregnancy differed statistically significantly from the 
postpartum parameters a paired t-test was performed on the log-transformed parame-
ters. Cord blood/maternal blood concentration ratios were determined and described.
Results
Thirty-four patients receiving tenofovir disoproxil and/or emtricitabine during pregnancy 
from 10 different sites from the PANNA network were enrolled in the study. The charac-
teristics of the patients and pregnancy outcome are depicted in Table 1. Sixteen patients 
were white, 17 black and 1 was of mixed race. Eleven (32%) of the patients were 
treatment naive at conception and 23 were already on cART before pregnancy. Thir-
ty-one out of 34 patients used Truvada®. Other NRTIs used were: zidovudine (n=2) and 
lamivudine (n=1). Twenty-four of the patients were on a boosted protease inhibitor based 
cART; six were on a nonnucleoside reverse transcriptase inhibitor (NNRTI) based cART; 
four were on the integrase inhibitor raltegravir; one was on raltegravir+protease inhibitor 
and one was on maraviroc+protease inhibitor. No other concomitant medication was 
used which could possibly influence tenofovir or emtricitabine exposure.
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Table 1. Subject characteristics
median (range) or n (%)
Age at delivery [years, median (range)] 32 (19-44)
Race/ethnicity [n (%)]  
White 16 (47%)
Black 17 (50%)
Other 1 (3%)
Smoking [n (%)] 7 (21%)
Alcohol use [n (%)] 4 (12%)
Truvada® use [n (%)] 31 (91%)
Treatment naive at pregnancy start [n (%)] 11 (32%)
ARV treatment duration before pregnancy [months, median (range)] 50 (2-135)
Concomitant antiretrovirals [n (%)]  
Protease inhibitors 24 (71%)
 
11 atazanavir/r; 10 darunavir/r; 2 lopina-
vir/r; 2 saquinavir/r; 1 fosamprenavir/r
NNRTI 6 (18%)
 4 nevirapine; 2 efavirenz 
Raltegravir 2 (6%)
Rategravir + PI 1 (3%)
Maraviroc + PI 1 (3%)
Third trimester (n=34)  
Gestational age [weeks, median (range)] 33 (28-38)
Weight [kg, median (range)] 75 (49-123)
HIV-RNA undetectable <50 [n (%)] 28 (83%) / <200: 33 (97%)
CD4 cell count [cells/µL, median (range)] 545 (120-1333)
Creatinine concentration [µmol/L, median (range)] 54 (33-71)
Creatinine clearance (Cockcroft) [mL/min, median (range)] 171 (110-292)
Post partum (n=28)  
Time after delivery [weeks, median (range)] 5 (3-9)
Weight [kg, median (range)] 70 (43-114)
HIV-RNA undetectable <50 [n (%)] 23 (82%) / <200: 28 (100%)
CD4 cell count [cells/µL, median (range)] 588 (130-1210)
Creatinine concentration [µmol/L, median (range)] 67 (50-86)
Creatinine clearance(Cockcroft) [mL/min,median (range)] 124 (82-190)
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Figure 1. Mean concentration-time profiles
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*HIV DNA polymerase chain reaction (PCR) test.
median (range) or n (%)
Pregnancy outcomes  
Gestational age [weeks, median (range)] 38 (36-41)
Caesarian section [n (%)] 20 (65%): 3 unknown
Birth weight [g, median (range)] 3070 (2190-4350)
Infant VL undetectable [n (%)]* 34 (100%)
Table 1. - continued Subject characteristics
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A total of 34 tenofovir curves were collected in the third trimester (median 33 weeks 
GA) and 27 curves postpartum (median 5 weeks postpartum). For emtricitabine, a total 
of 27 curves were collected in the third trimester and 24 postpartum. For four patients 
who had been treated with tenofovir disoproxil and emtricitabine insufficient plasma 
remained to determine the emtricitabine concentrations. Seven patients did not have 
a postpartum curve due to several reasons: withdrawn consent (n=2), lost to follow-up 
(n=3), changed medication (n=1) and insufficient plasma for analysis (n=1).
Pharmacokinetics
The mean plasma concentration-time profiles of tenofovir and emtricitabine in the third 
trimester and postpartum are presented in Figure 1; summary statistics of the pharma-
cokinetic parameters are listed in Table 2. The AUC0-24h, Cmax, C24h of tenofovir were, 
respectively, 23, 19 and 21% lower during pregnancy compared with postpartum (intra-
subject comparison). For emtricitabine, the AUC0-24h, Cmax, C24h were 25, 13 and 23% 
GM Ratio (90% CI)
Third Trimester* Postpartum*
Third Trimester / 
Postpartum P-value**
Tenofovir (n=34) (n=27) (n=27)
AUC0-24h (mg⋅L/h) 2.46 (2.23-2.66) 3.17 (2.86-3.52) 0.77 (0.71-0.83) <0.001
Cmax (mg/L) 0.28 (0.24-0.31) 0.33 (0.29-0.39) 0.81 (0.74-0.89) 0.001
Tmax (h) 1.0 (0.5-4.0) 1.1 (0.5-4.0)
Cpredose (mg/L) 0.049 (0.043-0.056) 0.060 (0.050-0.073) 0.81 (0.68-0.96)
C24h (mg/L) 0.052 (0.047-0.059) 0.066 (0.058-0.076) 0.79 (0.70-0.90) 0.003
T1/2 (h) 15 (14-16) 15 (13-17) 1.00 (0.87-1.15) 0.987
CLss/F (L/h) 55 (51-61) 43 (39-48) 1.30 (1.20-1.40) <0.001
Emtricitabine (n=27) (n=24) (n=24)
AUC0-24h (mg⋅L/h) 9.56 (8.99-10.48) 13.0 (11.8-14.3) 0.75 (0.68-0.82) <0.001
Cmax (mg/L) 1.79 (1.57-1.99) 2.02 (1.78-2.30) 0.87 (0.77-0.99) 0.048
Tmax (h) 2.0 (0.5-4.0) 2.0 (1.0-6.0)
Cpredose (mg/L) 0.057 (0.051-0.084) 0.115 (0.088-0.150) 0.57 (0.44-0.73)
C24h (mg/L) 0.052 (0.043-0.073) 0.073 (0.054-0.098) 0.77 (0.52-1.12) 0.232
T1/2 (h) 6 (5-7) 6 (5-6) 1.05 (0.91-1.21) 0.570
CLss/F (L/h) 21 (19-22) 15 (14-17) 1.34 (1.22-1.47) <0.001
Table 2. Pharmacokinetic parameters
AUC, area under the curve; CI, confidence interval; Gm, geometric mean
* Geometric mean (95% confidence interval); except for Tmax: median (minimum-maximum)
** paired t-test on log-transformed data
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lower, respectively. For both compounds the CLss/F is increased during pregnancy (30 
and 34% increased for tenofovir and emtricitabine, respectively), whereas the Thalf was 
not affected. The paired samples t-test revealed a significant difference for tenofovir and 
emtricitabine AUC0-24h, Cmax and CLss/F as well as tenofovir C24h between the third 
trimester and postpartum.
In Figure 2 the individual AUC0-24h for tenofovir and emtricitabine during the third 
trimester and postpartum are depicted, a subdivision was made for the concomitant 
use of NNRTI, protease inhibitor and/or integrase inhibitor. No difference between the 
different cART regimens was observed for tenofovir or emtricitabine exposure.
Sixteen umbilical cord blood (CB) samples were collected with matching maternal blood 
samples. In one cord blood sample (and the matching maternal sample), emtricitabine/
tenofovir concentrations were undetectable. The median time between the reported last 
dose and delivery was 8.5h (range 0-32h) and the median time between cord blood 
sample and maternal sample was 3 minutes (0-75 min). The median (range) ratio of cord 
blood/maternal blood was 0.82 (0.64-1.10; n=14) for tenofovir and 1.63 (0.46-1.82; 
n=10) for emtricitabine.
Efficacy and safety
HIV viral load close to delivery (median 34 weeks gestational age) was detectable in 
seven women (72- 272 copies/mL). The average gestational age at delivery was 38 
(range 36-41) weeks. All children were tested HIV-negative and no congenital abnor-
malities were reported. Four of the infants (12%) were born between 36 and 37 weeks 
gestational age. Three babies had a low birth weight (<2,500 gram).
Three patients developed a serious adverse event (SAE). One patient had a hospital 
admission because she thought the baby was not moving, the baby was born without 
problems (36.5 weeks gestational age); one patient had a transfusion with packed 
cells to treat anaemia 24h postpartum, anaemia was attributed to blood loss during/
Figure 2. Individual area under the curve plot
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after delivery; and one patient had a postnatal uterus atony, coagulation problems and 
massive blood loss. All patients recovered. These SAEs were judged by the local inves-
tigator not to be related to the cART given. Nine other patients reported adverse events, 
all were grade 1 or 2 and not or unlikely related to the cART given. These adverse 
events included: back pain; oesophagus pain; inflammation right eye; urinary tract 
infection; common cold; gestational diabetes; blood loss during pregnancy; vomiting 
and nausea; anemia (2); bronchitis; infection to caesarean section wound; 400mL 
blood loss at vaginal delivery and coryza.
Creatinine concentrations and Glomerular Filtration Rate (GFR; using the Cockroft-Gault 
formula) were determined in the third trimester and postpartum (see Table 1). During 
pregnancy creatinine concentrations were lower (median 54 versus 67 µmol/L) and 
estimated GFR higher (171 mL/min versus 124 mL/min) compared to postpartum.
Pharmacokinetic – Efficacy relationship
HIV viral loads were detectable (>50 copies/mL) for seven patients around delivery. Five 
out of the seven patients with a detectable viral load were on cART before pregnancy 
(one on NNRTI-based cART and four on protease inhibitor-based cART) and two started 
treatment during pregnancy (protease inhibitor-based cART); the treatment duration was 
24 and 28 weeks at delivery for these two patients. Adherence was checked by asking 
whether the patients had been taking their medication according to prescription for the 
last 2 weeks before the measurement. All patients reported to have been adherent to 
therapy during that time period.
Third trimester tenofovir, geometric means (95% CI) for AUC0-24h were 2.39 (2.17-2.64) 
mg⋅h/L and 2.72 (2.03-3.65) mg⋅h/L for patients with undetectable and detectable viral 
loads around delivery, respectively. For third trimester emtricitabine, geometric means 
(95% CI) for AUC0-24h were 9.41 (8.66-10.2) mg⋅h/L (patients with undetectable viral 
load) and 10.08 (7.83-13.0) mg⋅h/L (patients with detectable viral load) respectively. In 
Figure 3, the individual tenofovir and emtricitabine AUC0-24h, Cmax and C24h are depicted 
for patients who had a detectable viral load around delivery compared with the patients 
who had an undetectable viral load around delivery. For all these parameters, the 
values are comparable between these two groups.
Discussion
In this study we evaluated the pharmacokinetics of tenofovir and emtricitabine, in the 
majority of cases combined in Truvada®, in 34 pregnant HIV-infected patients, at the 
third trimester of pregnancy and after delivery. In the third trimester of pregnancy, a 
decrease in tenofovir AUC0-24h, Cmax and C24h (23%, 19% and 21% respectively) was 
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observed as well as a decrease in emtricitabine AUC0-24h, Cmax and C24h (25%, 13% and 
23% respectively). The clearance (CLss/F) was markedly increased during pregnancy 
for both compounds (tenofovir 30% and emtricitabine 34%). 
Tenofovir and emtricitabine are mainly excreted unchanged in urine, indicating that 
renal clearance is the major route of elimination. It is known that renal clearance 
is increased during pregnancy,[36] in line with our findings that estimated creatinine 
clearance increased during pregnancy by around 40%. Although possibly influencing 
the decreased exposure during pregnancy found in this study, this was not translated 
into shorter half-life of tenofovir and emtricitabine. The half-life was determined during a 
dosing interval, which is possibly not a correct estimate, because the last sample was 
taken 24h after dosing, this means that the entire elimination phase was not covered.
Other physiological changes during pregnancy are reduced intestinal motility, increased 
Figure 3. Comparison of individual pharmacokinetic parameters for patients with and without detectable viral load 
around delivery; UD: undetectable viral load; DET: detectable viral load.
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gastric pH, a larger plasma volume, increased hepatic blood flow, decreased protein 
binding and induced hepatic enzymes. The Cmax decreased by 19% for tenofovir 
and 13% for emtricitabine, potentially implying the influence of larger plasma volume 
and possibly decreased gastrointestinal absorption. However, the absorption was not 
delayed, as Tmax was similar during and after pregnancy for both compounds.
Protease inhibitors are known to increase tenofovir concentrations.[37] In this study, the 
tenofovir AUC0-24h for patients on an NNRTI regimen are similar to these on a protease 
inhibitor regimen. Possible explanations for this finding could be: a decrease in boosting 
effect during pregnancy because of the lower exposure to protease inhibitors during 
pregnancy;[9,38,39] furthermore the number of patients using a nonprotease inhibitor 
regimen in this study was low (only 18%), reducing the power to detect a difference.
There is no efficacy threshold level for tenofovir or emtricitabine blood concentrations. In 
previous studies with tenofovir disoproxil, a threshold of 2 mg⋅h/L for AUC0-24h
[6] (being 
the 10TH percentile of non-pregnant controls) was used and an AUC0-24h threshold for 
emtricitabine of at least 7 mg⋅h/L (≤ 30% reduction from the normal controls).[26] Using 
these thresholds, the study showed that 26% of the patients receiving tenofovir disoproxil 
did not meet the threshold in the third trimester compared with only 4% of the patients 
in the postpartum period. For the patients on emtricitabine only 4% did not meet the 
threshold in the third trimester compared with 0% postpartum. One of 9 of patients with 
tenofovir AUC0-24h below the threshold had a detectable viral load around delivery, 
compared with six of 25 with AUC0-24h above the threshold. This finding indicates that 
in this study, tenofovir AUC0-24h below the 10
TH percentile of nonpregnant controls was 
not associated with virological failure of the mother and did not result in mother-to-child 
transmission.
The reference tenofovir AUC in nonpregnant adults is 3.324 mg⋅h/L with a Cmax of 0.326 
mg/L, a Cmin of 0.064 mg/L and a Thalf of 12-18h.
[40-42] The reference emtricitabine AUC 
is 10.0 mg*h/L with a Cmax of 1.86 mg/L, a Cmin of 0.09 mg/L and a Thalf of 10h.
[28] 
The tenofovir and emtricitabine postpartum pharmacokinetic parameters found in this 
study are in line with reference values reported in the summary product characteristics. 
This implies that pharmacokinetic parameters recorded 5 weeks after delivery can be 
used as reference values for the nonpregnant situation, that is, the pregnancy induced 
physiological changes were not present anymore.
The decreased emtricitabine AUC and C24h we observed in this study is in line with the 
decrease reported by Stek et al.[26] However, we also observed a decrease in emtricit-
abine Cmax, which was not observed earlier.
For other NRTIs (zidovudine, lamivudine, didanosine and abacavir), pharmacokinetic 
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studies during pregnancy also reported decreased exposure, without a need for dose 
alteration.[43-46]
For both compounds placenta passage is good, concentrations in the cord blood are 
somewhat lower for tenofovir and approximately similar to the concentrations of the 
mother for emtricitabine. This is in line with the findings of other NRTIs.[47] In this review, 
cord blood/maternal ratios for both compounds ranged from 0.60 to 1.6 (with an 
outlier of 6.0 for tenofovir).
HIV viral load was undetectable (<50 copies/mL) for 79% patients around delivery, and 
less than 200 copies/mL for 97% of the patients. A possible explanation for the detecta-
ble viral load could be shorter treatment duration in these patients. The shortest treatment 
duration in these patients was 24 weeks, which should be sufficient to suppress the 
viral load, although both patients were on a protease inhibitor based cART.[48, 49] The 
third trimester exposure to tenofovir and emtricitabine was not lower in patients with a 
detectable viral load (n=7) compared with the patients who had an undetectable viral 
load around delivery.
None of the babies had a detectable HIV viral load and no congenital abnormalities 
were reported. The adverse events observed in this study were judged not be related to 
the antiretroviral drugs taken, but mainly to pregnancy. Although the number of patients 
in this study is limited, the safety information collected is extensive (safety laboratory 
and adverse events were collected at each visit). The safety information from this study 
suggests that the use of Truvada® during pregnancy seems to be safe. This reflects the 
safety reporting on tenofovir use during pregnancy.[23,24,50]
None of the available formula for GFR is accurate during pregnancy: the Cockroft-Gault 
(we used) overestimates the GFR during pregnancy, because the increase in weight is 
an increase in body water and fat but not in body muscle mass.[36] The only reliable 
measure for GFR is creatinine clearance by 24h urine collection, but this information was 
not collected in this study.
One of the strengths of this study is that it includes several antiretroviral drugs in one study 
protocol. Patients using these antiretroviral drugs as part of their cART can be included 
and their treatment is not adapted for the study. Many patients use more than one an-
tiretroviral drug from the list of medication to be investigated. Another advantage of the 
study draws from the PANNA network itself and is the variation in European and non-Eu-
ropean ethnicities available for investigation: approximately 50% white Europeans and 
50% black patients were included.
A limitation of the study is that no pharmacokinetic curve was collected in the second 
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trimester. We focussed on the third trimester as drug disposition of antiretroviral drugs is 
thought to be most affected during this period, because of the prominent physiological 
changes present. Furthermore, in the phase close to delivery, maximum viral suppres-
sion and antiretroviral effectiveness is considered important in order to minimise MTCT. 
Sub-therapeutic concentrations in late pregnancy may have a negative effect on antiviral 
efficacy. This is also a reason for assessing drug exposure during the third trimester of 
pregnancy.
In conclusion, although pharmacokinetic exposure of the NRTIs tenofovir disoproxil and 
emtricitabine during pregnancy is approximately 25% lower, this was not associated 
with virological failure in this study and did not result in mother-to-child transmission.
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Abstract
Background: The use of raltegravir in HIV-infected pregnant women is important in the 
prevention of mother-to-child HIV transmission (MTCT), especially in circumstances when 
a rapid decline of HIV RNA viral load is warranted or when preferred antiretroviral 
agents cannot be used. Physiological changes during pregnancy can reduce antiret-
roviral drug exposure. We studied the effect of pregnancy on the pharmacokinetics of 
raltegravir and its safety and efficacy in HIV-infected pregnant women. 
Methods: An open-label, multi-centre, phase IV study in HIV-infected pregnant women 
receiving raltegravir 400 mg twice daily, was performed (PANNA Network). Steady-
state pharmacokinetic profiles were obtained in the third trimester and postpartum along 
with cord and maternal delivery concentrations. Safety and virological efficacy were 
evaluated.
Results: Twenty-two patients were included of which 68% started raltegravir during 
pregnancy. Approaching delivery, 86% of the patients had an undetectable viral load 
(<50 copies/mL). None of the children were HIV-infected. Exposure to raltegravir was 
highly variable. Overall AUC and C12h plasma concentrations in the third trimester were 
on average 29% and 36% lower compared to postpartum: Geometric mean ratios 
(90% confidence interval) were 0.71 (0.53-0.96) for AUC0-12h and 0.64 (0.34-1.22) for 
C12h. The median (IQR) ratio of raltegravir cord/maternal blood was 1.21 (1.02-2.17; 
n=9).
Conclusions: Raltegravir was well tolerated during pregnancy. The pharmacokinetics 
of raltegravir showed extensive variability. The observed mean decrease in exposure 
to raltegravir during third trimester compared to postpartum is not considered to be 
of clinical importance. Raltegravir can be used in standard dosages in HIV-infected 
pregnant women.
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Introduction
An estimated 1.4 million pregnant women infected with HIV give birth annually 
worldwide, of which the majority live in Sub-Saharan Africa.[1] Mother-to-child HIV trans-
mission (MTCT) is the most common route of HIV-infection among infants and children. 
Each day, approximately 1,000 infants acquire HIV due to MTCT during pregnancy, 
delivery or breastfeeding. 
Combination antiretroviral therapy (cART) is the standard of care for the prevention of 
perinatal transmission. The main goal of cART is maximal suppression of HIV replica-
tion. Its implementation together with other effective interventions has led to dramatic 
declines in the number of perinatally HIV-infected children from 15-40% to <2%. Absent 
or delayed prenatal care, acute primary infection in late pregnancy, and the continued 
increase in incidence of HIV infection in women of childbearing age are among the 
most important obstacles to fully eliminate perinatal transmission in the United States and 
other resource-rich countries.[2] 
In current US and European treatment guidelines for HIV-1 infection in pregnancy, 
preferred combined antiretroviral agents include two nucleoside/nucleotide reverse tran-
scriptase inhibitors (NRTIs) in combination with the protease inhibitors (PIs) lopinavir or 
atazanavir boosted with ritonavir or the non-nucleoside reverse transcriptase inhibitor 
(NNRTI) nevirapine. Regimens including the HIV-1 integrase inhibitor raltegravir can be 
considered for use in special circumstances because information on the pharmacokinet-
ics and the safety of raltegravir in pregnancy is limited. Examples of these special cir-
cumstances could be pregnant women who present late in care (>28 weeks gestational 
age) or whose HIV RNA load is not undetectable at third trimester.[2-4] HIV integrase 
inhibitors such as raltegravir have demonstrated to rapidly reduce HIV RNA load with 
shorter times to achieve virological suppression compared to agents from other drug 
classes.[5] Case reports and small case series suggest that raltegravir could play an 
important role when a rapid decline in maternal plasma HIV RNA is needed to prevent 
MTCT during delivery or as an alternative antiretroviral drug in complex treatment-expe-
rienced HIV-infected pregnant women.[6-17] In a pilot study including 28 pregnant HIV-
infected women, which was presented as abstract at a conference, the use of raltegravir 
seemed safe in both women and infants.[18] 
Pregnancy is associated with considerable physiological changes such as changes in 
gastrointestinal, hepatic, and renal function as well as alterations in the expression and 
activity of transport proteins and metabolic enzymes. Pregnancy may influence the phar-
macokinetic profile of antiretroviral agents and lead to decreased drug exposure. Sub-
optimal drug exposure can result in HIV RNA rebound, the selection of resistant virus and 
an increased risk of HIV-1 transmission to the infant.[19,20] Published information on the 
pharmacokinetics of raltegravir during pregnancy is limited.[21,22] Watts et al. describe 
a 50% reduction in median exposure to raltegravir during pregnancy compared with 
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postpartum and a large variability in raltegravir pharmacokinetics. The authors report 
that 92% of women had an HIV RNA load of <400 copies/mL at delivery and none of 
the infants were confirmed to be infected. Additional well-controlled studies are needed 
to confirm that raltegravir can be used safely in this special patient population. We 
studied the effect of pregnancy on the pharmacokinetics of raltegravir and its safety and 
efficacy in pregnant HIV-infected women.
Methods
Study design and participants
This multi-centre, phase IV study was designed as a non-randomised, open-label trial in 
HIV-infected pregnant women and coordinated by the PANNA network study group. 
The PANNA network is a European network of 19 hospitals in seven countries with 
the primary aim to collect pharmacokinetic data during pregnancy on antiretroviral 
agents for which no or limited data are available (www.pannastudy.com). We enrolled 
HIV-infected pregnant women (aged at least 18 years) who were on a cART regimen 
containing raltegravir 400 mg twice daily. Patients were eligible for inclusion if they 
were on raltegravir treatment for at least two weeks prior to the first pharmacokinetic 
assessment in the third trimester of pregnancy. Exclusion criteria were a medical history 
or current condition that might interfere with drug absorption, distribution, metabolism 
or excretion (such as renal failure or hepatic failure), and grade III/IV anaemia (i.e. Hb 
<4.6 mmol/L or <7.4 g/dL). The study was conducted in compliance with the principles 
of the “Declaration of Helsinki”. Informed consent was obtained from each participant 
before undergoing any protocol-specified procedures. The study was approved by the 
appropriate medical ethical committee of each centre and by the national authorities 
where applicable. The trial is registered at ClinicalTrials.gov, number NCT00825929.
Procedures
Inclusion screening consisted of clinical evaluations (medical history and physical exami-
nation) and laboratory assays (serum biochemistry, haematology, qualitative urinalysis, 
HIV-1 RNA load and CD4 T cell count). Blood samples for safety and efficacy as-
sessments were obtained on pharmacokinetic sampling days and analysed at local 
laboratories. Adverse events were recorded at each visit and graded according to the 
Division of AIDS (DAIDS) toxicity table (2004). Infant birth weight, gestational age at 
birth, congenital abnormalities and HIV infection status were collected. Safety outcomes 
were maternal adverse events and congenital abnormalities. Efficacy outcomes were 
an undetectable HIV RNA load (<50 copies/mL) measured at or prior to delivery, and 
infant HIV infection status measured by HIV DNA Polymerase Chain Reaction test.
Pharmacokinetic assessment took place in the third trimester (approximately at week 
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33) and at least two weeks postpartum (approximately 4-6 weeks postpartum). Blood 
samples for pharmacokinetic assessment were collected during a 12-hour period at 
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8, 12 hours after observed intake of 400 mg of 
raltegravir after a standard breakfast (650kCal; 30g fat). Where possible umbilical 
cord blood (CB) and matching maternal blood samples were obtained at delivery to 
assess placental transfer. Plasma was separated and stored at ≤-18°C until shipment 
on dry ice to the laboratory of the Pharmacy of the Radboud university medical center 
(Nijmegen, The Netherlands). Concentrations of raltegravir in plasma were analyzed 
using validated reversed phase high-pressure liquid chromatography (HPLC) with fluores-
cence detection. The linear calibration ranges in plasma were 0.014-10.0 mg/L with a 
lower limit of quantification (LLOQ) of 0.014 mg/L. The raltegravir assay was externally 
validated through the International Interlaboratory Quality Control Program for Measure-
ment of Antiretroviral Drugs in Plasma as well as by the Proficiency Testing program of 
the ACTG/IMPAACT group.[16, 23]
Statistical analysis
Pharmacokinetic parameters were determined using a non-compartmental model in 
WinNonlin/Phoenix version 6.3 (Pharsight Corporation, CA, USA). Based on the in-
dividual plasma concentration-time data, the following pharmacokinetic parameters of 
raltegravir were determined: the area under the plasma concentration-time curve from 
0 to 12 hours after intake using the trapezoidal rule (AUC0-12h), the trough concentration 
(C12h) defined as the sample taken at 12 hours, the maximum plasma concentration of 
the drug (Cmax), the time to reach Cmax (Tmax), the apparent volume of distribution (V/F), the 
apparent oral clearance being the dose divided by AUC0-12h (CLss/F) and the apparent 
elimination half life (Thalf). Patients from whom a curve was taken during pregnancy were 
included in demographic, safety analyses and descriptive statistics of the pharmacoki-
netic parameters. Pharmacokinetic parameters are reported as geometric means with 
95% confidence intervals (CI). We calculated geometric means ratios (GMRs) and 90% 
CI of raltegravir pharmacokinetic parameters of third trimester versus postpartum using 
a mixed effects model in WinNonlin/Phoenix. Cord blood/maternal blood plasma 
concentration ratios were determined and described. 
Results
Twenty-two HIV-infected pregnant women receiving raltegravir 400 mg twice daily 
were enrolled in 10 European hospitals during 2010 to April 2014. The characteristics 
of the study population are presented in Table 1. Four patients (18%) were diagnosed 
with HIV after conception at 12, 16, 18 and 23 weeks of gestational age respectively. 
Of the 18 pregnant women who were already aware of their HIV-positive status, 14 
were on cART at the time of conception with a median duration of approximately five 
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Characteristics (n=22)
Age at delivery (years) 33 (29-36)
Race/ethinicity
White 9 (41%)
Black 12 (55%)
Other 1 (5%)
Smoking 0 (0%)
Alcohol use 0 (0%)
Drug use 0 (0%)
ARV treatment at start of pregnancy 14 (64%)
Median ARV treatment duration before pregnancy (weeks) 257 (110-440)
Start raltgravir
Before conception 7 (32%)
1st trimester 2 (9%)
2nd trimester 6 (27%)
3rd trimester 7 (32%)
Concomitant ARVs
NRTI 15 (68%) [11 (50%) tenofovir + emtricitabine; 3 
(14%) tenofovir; 1 (5%) zidovudine + lamivudine]
Protease inhibitors• 13 (59%) [8 (36%) DRV/r; 3 (14%) ATV/r; 2 (9%) 
LPV/r] 
NNRTI 2 (9%) etravirine
Entry inhibitor 2 (9%) maraviroc
Third trimester (n=22)
Gestational age (weeks) 33 (32-35)
Weight (kg) 73 (67-79)
HIV RNA detectable >50 copies/mL 3 (14%) [74 copies/mL; 144 copies/mL; 242 
copies/mL]
CD-4 count (copies/uL)# 622 (240-756)
Delivery (n=22)
Gestational age (weeks) 38 (38-39)
Caesarian section# 11 (52%)
HIV RNA detectable closest to delivery >50 copies/mL 3 (14%) [144 copies/mL; 242 copies/mL; 290 
copies/mL]
Time between HIV RNA measurement and delivery (weeks) 3 (0-4) 
Table 1. Patient characteristics and pregnancy outcomes
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Table 1. - continued Patient characteristics and pregnancy outcomes
Data are n(%) or median and interquartile range (IQR)
ARV, antiretroviral; ATV/r, atazanavir/ritonavir; DRV/r, darunavir/ritonavir; LPV/r, lopinavir/ritonavir; 
(N)NRTI, (non)nucleoside reverse transcriptase inhibitor; PCR, polymerase chain reaction.
• One subject stopped DRV/r before delivery; Available for: #21 patients, † 17 patients
‡ Small for gestational age was determind as below the 10th percentile of the fetal-infant growth chart by Fenton .[25]
Characteristics (n=22)
Postpartum (n=18)
Time after delivery (weeks) 5 (4-6)
Weight (kg) 64 (59-72)
HIV RNA detectable >50 copies/mL† 2 (12%) [99 copies/mL; 650 copies/mL]
CD-4 count (cells/uL) 585 (266-806)
Pregnancy outcomes
Birth weight (grams) (n=22) 3115 (2628-3360)
Small for gestational age‡ 3 (14%)
Infant HIV DNA PCR test negative 22 (100%)
Figure 1. Geometric mean (+upper 95% confidence interval) raltegravir concentration-time profiles during the third 
trimester of pregnancy (open squares) and postpartum (filled circles).
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years (257 weeks). Seven patients (32%) were using raltegravir 400 mg twice daily 
prior to conception. If not used prior to conception raltegravir was started mainly during 
the second (27%) and third (32%) trimester of the pregnancy. Only two patients (9%) 
started a raltegravir-based regimen during the first trimester, of which one patient was still 
unaware of her pregnancy at that time. Various indications for raltegravir in this special 
patient population were presented: raltegravir was started either as part of the first cART 
Figure 2. Individual raltegravir AUC0-12h (A) and C12h (B) parameters during the third trimester of pregnancy and postpar-
tum.
Symbols: Filled square  is a detectable (≥50 copies/mL) and an open circle  is an undetectable (<50 copies/mL) 
HIV RNA load close to delivery.
Third trimestera (n=21) Postpartuma (n=18)
GM ratio (90% CI) of third 
trimester: postpartum (n=17)
AUC0-12h (h⋅mg/L) 5.00 (3.56-7.01) 7.11 (4.91-10.30) 0.71 (0.53-0.96)
Cmax (mg/L) 1.43 (0.93-2.22) 1.76 (1.10-2.80) 0.82 (0.55-1.23)
Tmax (h) 1.98 (0-11.3) 2.03 (0-7.97)
C12h (mg/L) 0.077 (0.043-0.137) 0.120 (0.074-0.193) 0.64 (0.34-1.22)
thalf (h) 2.55
b (1.88-3.45) 2.53c (1.91-3.36) 1.04 (0.73-1.47)
CLss/F (L/h) 80.1 (57.0-112) 56.2 (38.8-81.4) 1.41 (1.04-1.90)
V/F (L) 311b (159-607) 205c (115-367) 1.24 (0.67-2.27)
Table 2. Pharmacokinetic parameters raltegravir during third trimester of pregnancy and postpartum
AUC, area under the curve; CI, confidence interval; GM, geometric mean.
aAll values are GM (95% CI) except for Tmax [median (minimum–maximum)].
bAvailable for 15 patients; cAvailable for 14 patients.
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regimen to obtain a rapid decline in HIV RNA viral load with raltegravir as 4th agent; 
or added to the current regimen to optimize or intensify treatment in patients with a de-
tectable viral load; or used as alternative to a preferred antiretroviral agent due to side 
effects (gastro-intestinal or hyperbilirubinemia). Concomitant HIV and non-HIV medica-
tion which could possibly influence raltegravir exposure was the use of ritonavir boosted 
atazanavir in three patients, the use of acid reducing agents (ranitidine 150 mg twice 
daily or sodium alginate as needed) in two patients, the use of a calcium carbonate 
supplement in two patients, and the use of a magnesium supplement in one patient. All 
potential drug-interacting agents were used during both pharmacokinetic assessments.
Pharmacokinetic assessment in third trimester took place at a median (IQR) gestational 
age of 33 (32-35) weeks. A total of 21 evaluable raltegravir pharmacokinetic curves 
were obtained. One pharmacokinetic profile sampling was stopped at 3 hours at the 
volunteer’s request and these plasma concentrations could only be partly included in 
the analysis. Pharmacokinetic assessment postpartum took place at a median (IQR) of 
5 (4-6) weeks after delivery and resulted in 18 evaluable pharmacokinetic postpartum 
curves. Four patients did not have a postpartum curve because they withdrew consent. 
The mean plasma concentration-time profile of raltegravir in the third trimester and post-
partum are presented in Figure 1 and summary statistics of the pharmacokinetic param-
eters are listed in Table 2.
Exposure to raltegravir, which is expressed as AUC0-12h, was 29% lower in the third 
trimester compared to postpartum by intrasubject comparison. Cmax and C12h were on 
average 18% and 36% lower during pregnancy. The apparent elimination half-life of 
raltegravir did not appear to be influenced by pregnancy. One patient in the third 
trimester (and none postpartum) had a C12h plasma concentration below the suggested 
threshold of 0.020 mg/L which was associated with failure to achieve an undetectable 
HIV RNA load in treatment-naive patients in the QDMRK study.[24] Raltegravir pharma-
cokinetics was highly variable which is best seen in the large 90% confidence intervals 
around the GMR in Table 2 and graphically in Figure 2. Figure 2 shows the individual 
changes in AUC0-12h (A) and C12h (B) of raltegravir in the third trimester of the pregnancy 
compared with postpartum. Although a mean decrease in raltegravir exposure (29%) 
and C12h plasma concentrations (36%) in the third trimester was observed, considerable 
variation in the amount and direction of the effect is seen as well as variation between 
individual patients. Eleven out of 17 patients with complete paired pharmacokinetic 
curves (65%), showed a decrease in raltegravir exposure in third trimester compared 
with postpartum. 
Nine umbilical cord blood (CB) samples were collected with matching maternal blood 
samples. The median (IQR) time between the reported last dose and CB sampling if 
available was 10 h (7-11 h); the median (IQR) time between CB sample and maternal 
sample was 0 minutes (0-4 min). The median (IQR) ratio of raltegravir CB/maternal 
blood was 1.21 (1.02-2.17; n=9).
No congenital abnormalities were reported. Five patients reported a total of ten adverse 
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events which were considered not or unlikely to be related to the cART given. Seven 
events were grade 1 or 2. Grade 3 neuropatic pain was reported as a serious adverse 
event not related to the use of raltegravir. Other grade 3 adverse events were severe 
anaemia due to haemorrhagic delivery and varicella lesions.
Twenty-two infants were born and they were all tested HIV-negative. Three infants (14%) 
were small for gestational age (below 10th percentile of fetal-infant growth chart by 
Fenton) [25], which is higher than observed in the US for children born from HIV-infected 
women (7.3%).[26] Other pregnancy outcomes are shown in Table 1 as well as the results 
of the maternal HIV RNA viral load measurements. In summary 3/22 patients (14%) 
failed to achieve an undetectable HIV RNA viral load (<50 copies/mL) close to delivery 
(144, 242 and 290 copies/mL) when measured a median (IQR) of 3 (0-4) weeks 
before delivery. The patient with a C12h level below the threshold of 0.020 mg/L in third 
trimester had an HIV RNA viral load of 74 copies/mL measured in third trimester and 
an undetectable viral load on the day of delivery. Adherence, based on self-reporting, 
was good in all patients.
Discussion
In this study we evaluated the effect of pregnancy on the pharmacokinetics of raltegravir 
and its safety and efficacy in 22 HIV-infected women. In the third trimester of pregnancy 
systemic exposure (AUC) to raltegravir was on average 29% lower compared with 
postpartum. However, pharmacokinetics of raltegravir was highly variable and exposure 
was not consistently decreased in third trimester compared with postpartum. Of the 17 
women with paired pharmacokinetic curves six (35%) had a higher AUC0-12h in the third 
trimester. A similar effect of pregnancy on C12h plasma levels was observed, leading 
to an average decrease of 36% of the plasma levels seen postpartum. The magnitude 
of the observed effect is not considered to be of clinical importance. Similar effects 
of drug-interacting agents on the pharmacokinetics of raltegravir are described in the 
product information leaflet without special recommendation to adjust the dosage of 
raltegravir.[27] Viral suppression was good in our population with an HIV RNA load 
<400 copies/mL in all women and <50 copies/mL in 84% of women prior to delivery. 
The women (14%) who failed to have an undetectable viral load prior to delivery had 
adequate C12h levels in third trimester. Only one patient had a C12h level below 0.020 
mg/L in third trimester, which is considered to be too low for adequate virological 
response in treatment-naive patients.[24] She had an undetectable viral load on the day 
of delivery.
The decrease in AUC (29%) in third trimester compared with postpartum was in line 
with the observations in a previous study with intensive pharmacokinetics of raltegravir 
during pregnancy from Watts et al..[21] They describe a more pronounced decrease 
of approximately 50% in AUC in the third trimester compared with postpartum. Given 
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the high rate of viral suppression at delivery and the lack of a clear pharmacokinetic/
pharmacodynamic relationship in non-pregnant adults, the authors suggest that a higher 
dose of raltegravir is not necessary during pregnancy. Watts et al. reported a median 
AUC of 5.4 h⋅mg/L (n=41) in third trimester, which is comparable to the geometric 
mean AUC in third trimester (5.00 h⋅mg/L ) found in our study. The postpartum median 
AUC reported by Watts et al. was higher than the AUC we found: 11.6 h⋅mg/L (n=38) 
measured 3-14 weeks postpartum versus 7.11 h⋅mg/L. This difference probably causes 
the more pronounced decrease between third trimester and postpartum found by Watts 
et al.. Raltegravir C12h levels in third trimester were comparable: 0.064 mg/L reported 
by Watts et al. and 0.077 mg/L in our study. The postpartum curves in our study are 
consistent with intensive pharmacokinetic profiles in non-pregnant HIV-infected patients 
in the twice-daily treatment arm of the QDMRK study.[24] Geometric mean AUC and 
C12h (n=20) of raltegravir are 5.84 h⋅mg/L and 0.114 mg/L respectively in the QDMRK 
study compared to 7.11 h⋅mg/L and 0.120 mg/L postpartum (n=18) in our study. This 
would suggest that the pharmacokinetic parameters collected at a median of 5 weeks 
postpartum in our study can be used as reference for the non-pregnant situation. Patient 
characteristics, drug-drug interactions, time of postpartum pharmacokinetic assessment 
and the large inter-subject variability in raltegravir pharmacokinetics could have contrib-
uted to the differences in pharmacokinetic parameters of raltegravir postpartum between 
Watts et al. and our study. The large inter-subject and intra-subject variability in raltegra-
vir pharmacokinetics observed in our study is well recognised by others in non-pregnant 
populations.[28,29] 
There are many physiological changes during pregnancy that could alter distribution, me-
tabolism and clearance of antiretroviral drugs used in pregnancy.[19,20] During pregnancy 
the apparent volume of distribution increases with subsequent decreases in peak plasma 
concentrations, which was observed in our study as well. Alterations in drug elimina-
tion clearance during pregnancy can affect steady-state concentrations. Raltegravir is 
primarily metabolized by uridine diphosphate glucuronosyltransferase (UGT)1A1. The 
potential effect of pregnancy on UGT1A1 activity has been evaluated and is believed to 
be increased during pregnancy.[19,30] Jeong et al. suggest that the induction of UGT1A1 
expression by rising progesterone levels in pregnant women may be responsible for the 
increase in clearance of UGT1A1 substrates.[31] This hypothesis is not supported by our 
study in which the apparent elimination half-life of raltegravir in the third trimester was 
similar to postpartum.
Raltegravir was well tolerated during pregnancy and all of the children were tested 
HIV-negative. Only nine babies were exposed to raltegravir during the first trimester, with 
no birth defects reported. To assess prevalence rates of birth defects in infants exposed 
to raltegravir compared to non-exposed infants, more experience of raltegravir in human 
pregnancy is needed. Placental transfer of raltegravir is efficient with a median ralte-
gravir CB/maternal plasma ratio of 1.21 in agreement with previous reports.[12,13,21,32,33] 
Unfortunately the collection of neonatal blood samples to describe the washout phar-
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macokinetics and safety of in utero exposure to raltegravir was not part of this study. 
UGT1A1 neonatal enzyme activity is still immature after birth and leads to prolonged 
elimination of raltegravir post-delivery. In newborns whose mothers were exposed to 
raltegravir during pregnancy raltegravir is slowly metabolized with an elimination half 
life that is highly variable.[9,12,33]
In conclusion, raltegravir was well tolerated during pregnancy in our study popula-
tion. Raltegravir pharmacokinetics showed extensive inter- and intra-individual variability. 
Our findings show a mean decrease in exposure to raltegravir during third trimester 
compared with postpartum which is not considered to be of clinical importance. Ralte-
gravir in combination with other antiretroviral agents was effective in preventing MTCT 
by reducing and/or maintaining HIV RNA viral load at an undetectable (<50 copies/
mL) or low level (<400 copies/mL). Our data support the use of raltegravir in standard 
dosages in HIV-infected pregnant women for the prevention of MTCT.
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Introduction
Generally, no information is available about new drugs during pregnancy owing to 
exclusion of pregnant women from clinical trials. For the new antiretroviral drug rilpivirine 
no safety or pharmacokinetic information during pregnancy is available to date.[1] Rilpi-
virine is a once-daily dosed nonnucleoside reverse transcriptase inhibitor, available as 
a single 25mg tablet (Edurant®) and also coformulated with tenofovir and emtricitabine 
(Eviplera®) to accomplish a one tablet/day regimen. Rilpivirine is indicated for the 
treatment of HIV type 1 infection in combination antiretroviral for treatment (cART)-naive 
adult patients with a viral load of 100,000 HIV-1 RNA copies/mL or less.[2]
A European network studies pharmacokinetics and transplacental passage of newly 
developed antiretrovirals during pregnancy (PANNA, http://www.pannastudy.com/
ClinicalTrials.gov NCT00825929). It is a non-randomized, open-label, multicentre 
phase IV study, see Colbers et al.[3] for the methods used. Here, we describe two cases 
of rilpivirine use during pregnancy from the PANNA study.
Case one
Case 1 was a 19-year-old black woman, abstinent from nicotine and alcohol use, 
was diagnosed with HIV in 2011, when she immediately started Eviplera®. Concep-
tion occurred after approximately 14 weeks of Eviplera® use. When pregnancy was 
established, Eviplera® was interrupted (week 5 gestational age). This was restarted in 
week 25 gestational age (viral load 3543 copies/mL) and continued for the rest of the 
pregnancy and after delivery.
In week 32 gestational age a pharmacokinetic curve was recorded (Figure 1A): AUC0-24h 
was 1.25 mg⋅h/L; Cmax was 0.07 mg/L, C0h was 0.04 mg/L, thalf was 30h. Viral load 
was undetectable (<50 copies/mL). At week 38 gestational age, she was admitted to 
the hospital because of irregular contractions. This hospital admission was reported as 
SAE, judged not to be related to Eviplera® use.
Vaginal delivery took place at 39 weeks and 5 days gestational age; viral load was 
undetectable. A healthy girl (no congenital abnormalities), 3620gr, 53cm, head circum-
ference 34cm, APGAR score of 10 after 1, 5, 10 min, was born. An HIV DNA PCR test 
2 weeks after delivery was negative.
At delivery, a cord blood (rilpivirine 0.016 mg/L) sample and maternal sample (rilpivirine 
0.021 mg/L) were collected 16 hours after the last maternal rilpivirine intake. The cord 
blood/maternal blood ratio was 0.74.
Forty-five days after delivery, a postpartum pharmacokinetic curve was collected, which 
represents the normal situation. AUC0-24h was 1.79 mg⋅h/L; Cmax was 0.11 mg/L, C0h 
was 0.07 mg/L, thalf was 43h.
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Case two
Case 2 was a 24-year-old white woman, smoking more than 10 cigarettes/day, no 
alcohol use, was diagnosed with HIV in 2010. In September 2011, she started cART: 
atazanavir/ritonavir 300/100mg daily (q.d.) and zidovudine/lamivudine (Combivir®); 
in August 2012, she switched to Eviplera®. At conception she was using Eviplera® for 
10 weeks.
At week 32 gestational age a pharmacokinetic curve was taken (see Figure 1B): 
AUC0-24h was 1.42 mg⋅h/L; Cmax was 0.14 mg/L, C0h was 0.04 mg/L and thalf was 
33h. Viral load was undetectable.
Nonelective Caesarian section (due to non-progressing dilatation) was performed at 
38 weeks and 5 days gestational age. Two weeks before delivery, viral load was 77 
copies/mL; 4 weeks after delivery viral load was undetectable again. A healthy girl, 
2945gr, 51.5cm, head circumference 35.8cm, APGAR score after 1 and 5 min: 8 and 
10, was born. The infant was tested for HIV 1 day and 18 days after birth and the tests 
were negative (DNA PCR).
Thirty-six days after delivery, a postpartum pharmacokinetic curve was collected: 
AUC0-24h was 2.49 mg⋅h/L; Cmax was 0.15 mg/L, C0h was 0.09 mg/L and thalf was 
48h.
Discussion
Exposure (AUC0-24h) during pregnancy was 30-43% lower during pregnancy (compa-
rable to the decrease seen for protease inhibitors). Postpartum AUC0-24h of these two 
cases is in line with the mean steady state AUC0-24h in patients (2.397 mg⋅h/L).
[4] The 
lower exposure during pregnancy is possibly driven by a shorter rilpivirine half-life; 
however, accurate determination of the half-life under steady-state conditions is difficult. 
A suggested rilpivirine target trough concentration is 0.040 mg/L, derived from the 
exposure-response relationship in phase III studies.[5] For both cases the Ctrough concen-
trations in the 3rd trimester and the maternal sample at delivery were 0.040 mg/L or 
less, indicating subtherapeutic exposure during pregnancy. However, no mother-to-child 
transmission of HIV was observed, but should be confirmed by at least 4 months of age. 
A limitation is that no unbound rilpivirine concentrations were determined: lower protein 
binding during pregnancy might (partly) compensate for lower total concentrations. No 
major safety issues were reported for these two cases.
In our case, rilpivirine moderately crosses the placenta and exposure during pregnancy 
is decreased by approximately 30-43%. More data regarding rilpivirine in pregnancy 
are needed to confirm these first findings, but therapeutic drug monitoring for rilpivirine 
during pregnancy is strongly recommended.
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Figure 1. Individual rilpivirine plasma concentrations during and after pregnancy
For C24h the C0h was used because at t=24h no sample was taken.
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Abstract
Objective: To describe the pharmacokinetics of maraviroc in HIV-infected women during 
pregnancy and postpartum.
Methods: HIV infected pregnant women receiving maraviroc as part of clinical care  had 
intensive steady-state 12-hour pharmacokinetic profiles performed during the 3rd trimester 
and at least 2 weeks after delivery. Cord blood samples and matching maternal blood 
samples were taken at delivery. The data were collected in two different studies: P1026 
(US) and PANNA (Europe). Pharmacokinetic parameters were calculated.
Results: Eighteen women were included in the analysis. Most women received 150mg 
maraviroc twice daily with a protease inhibitor (12; 67%), two (11%) received 300mg 
maraviroc twice daily without protease inhibitor, and four (22%) had an alternative 
regimen. Geometric mean ratios (90% confidence interval) of third trimester versus 
postpartum maraviroc were 0.72 (0.60-0.88) for AUCtau and 0.70 (0.58-0.85) for 
maraviroc Cmax. Only one patient showed Ctrough concentrations below the suggested 
target of 50ng/mL, both during pregnancy and postpartum. The median (range) ratio 
of maraviroc cord blood/maternal blood was 0.33 (0.03-0.56). Viral load close to 
delivery was less than 50 copies/mL in 13 participants (76%). All children were tested 
HIV negative at testing.
Conclusions: Overall maraviroc exposure during pregnancy was decreased, with a 
reduction in AUC and Cmax of around 30%. Ctrough was reduced by 15% but exceeded 
the minimum Ctrough target concentration. Therefore, the standard adult dose seems to be 
sufficient in pregnancy.
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Introduction
It is estimated that worldwide 16 million women were living with HIV in 2013, with 
around 1.3 million of them giving birth.[1,2] HIV infected pregnant women may receive 
antiretrovirals both to protect their own health and to reduce the risk of mother to child 
transmission (MTCT) of HIV.[3] Combination antiretroviral therapy (cART) has been shown 
to be a highly effective strategy for prevention of MTCT of HIV, reducing the risk from 
15-40% to less than 2%.[3] 
Maraviroc is an antagonist to C-C chemokine receptor type 5 (CCR5), which plays an 
important role in blocking HIV-1 entry into susceptible cells.[4] It is effective for treatment 
of CCR5-tropic HIV-1 as part of cART therapy. The standard recommended dose for 
maraviroc therapy in adults or adolescents is 300mg twice daily (BID), unless co-admin-
istered with a boosted protease inhibitor, in which case the dose is reduced to 150mg 
BID.[5] There are no data available describing maraviroc pharmacokinetics and safety 
when used during pregnancy, and the U.S. Department of Health and Human Services 
(DHHS) perinatal guidelines include no recommendations regarding maraviroc therapy 
or dosing regimens during pregnancy.[6] 
Pregnancy is associated with a myriad of physical changes that affect the pharmacoki-
netics of drugs,[7,8] mostly resulting in a reduction in drug exposure during pregnancy.[9] 
Decreased antiretroviral concentrations may lead to inadequate viral suppression and/
or development of antiretroviral resistance, and may increase the risk of MTCT in HIV-in-
fected pregnant women.[3, 10] Data describing maraviroc pharmacokinetics in pregnancy 
have not been published.
Specific safety issues of maraviroc during pregnancy include the influence of maraviroc 
on pregnancy duration and fetal development. Maraviroc is assigned to the FDA 
Pregnancy Category B, as animal reproduction studies failed to demonstrate a risk to 
the fetus and there are no adequate and well-controlled studies in pregnant women. 
Reports of safety of maraviroc during human pregnancy are limited. The most recent 
Antiretroviral Pregnancy Registry interim report (through 31 July 2014) includes only a few 
patients who received maraviroc, who did not exhibit any birth defects with exposure 
to maraviroc in the first trimester (n=16) or second and third trimesters (n=6).[11] No data 
about the influence of maraviroc on pregnancy duration are available.
Current available data on transfer of maraviroc across the human placenta are limited to 
one case report and data from an ex vivo placenta perfusion study both indicating minor 
placental transfer.[12,13] Fetal antiretroviral exposure via placental transfer may provide 
pre-exposure prophylaxis of the fetus and newborn against HIV infection, possibly con-
tributing to prevention of perinatal transmission of HIV, but also may result in drug related 
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fetal teratogenicity and/or toxicity.[6]
Overall, available data are too limited to make grounded recommendations regarding 
maraviroc use and dosing regimens during pregnancy, highlighting the exclusion of 
pregnant women from clinical trials during the development of new drugs, mainly due 
to concerns of potential risks to the fetus.[14] As a result, HIV-infected pregnant women 
are currently receiving maraviroc as part of clinical care in the absence of pregnancy 
specific safety and pharmacokinetic data. Two protocols, the ‘International Maternal 
Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network’ P1026s protocol and 
the ‘Study on pharmacokinetics of newly developed antiretroviral agents in HIV-infected 
pregnant women (PANNA) Network’, have been developed to study the safety and 
pharmacokinetics during pregnancy of antiretroviral drugs used for clinical care that 
lack safety and pharmacokinetic data obtained during pregnancy. In this report, these 
networks have collaborated to describe the pharmacokinetics, transplacental transfer, 
and safety of maraviroc in pregnant HIV-infected women.
Methods
The data presented in this study were collected in two studies. Both were non-random-
ized, open-label, parallel-group, multi-center phase-IV studies in HIV-infected pregnant 
women. PANNA recruited patients from HIV treatment centers in Europe. IMPAACT 
recruited patients from sites in the Americas. Here, we report data of pregnant HIV-
infected patients treated with maraviroc as part of their cART. 
The studies were conducted in compliance with the principles of the “Declaration of 
Helsinki”. Informed consent was obtained from each participant before entering the 
studies. The studies were approved by the medical ethical committee from each indi-
vidual centre involved and by the national authorities if applicable. The studies were reg-
istered at ClinicalTrials.gov under the numbers NCT00825929 and NCT00042289.
Patient eligibility
Patient eligibility included being HIV-infected, pregnant, at least 18 years of age at 
screening and treated with a cART regimen containing maraviroc as prescribed for 
clinical care for at least 2 weeks before the day of first pharmacokinetic evaluation. 
Subjects continued to take their prescribed medications throughout pregnancy. Women 
continued on study until the completion of postpartum pharmacokinetic sampling. 
Patients were excluded if they had a past medical history or current condition that might 
interfere with drug absorption, distribution, metabolism or excretion (such as renal failure 
or hepatic failure) or presented with grade III/IV anaemia (i.e. Hb <4.6 mmol/L or <7.4 
g/dL) at screening (PANNA specific) or multiple pregnancy (IMPAACT specific).
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Safety assessments and viral load
Inclusion screening consisted of: medical history, physical examination, serum biochem-
istry and hematology, HIV-1 RNA load determination and CD4+ T cell count. Analyses 
for safety assessments were performed by local laboratories. Blood samples for safety 
assessments were further taken at the visits for pharmacokinetic blood sampling and at 
delivery.  Patients were asked for adverse events at each visit and serum biochemistry, 
hematology, HIV-1 RNA load and CD4+ T cell count.  The HIV-status of the infants was 
assessed.
Pharmacokinetic blood sampling
The 12 or 24 hour intensive pharmacokinetics were performed in the third trimester 
between 30 and 36 weeks of gestation. At least 2 weeks postpartum (preferably 4-6 
weeks postpartum) pharmacokinetic sampling was repeated. At delivery (if possible) 
a cord blood and a maternal blood sample were taken. Evaluation at visits included 
sampling pre-dose and at 1, 2, 4, 6, 8 and 12 hours post medication intake at all 
pharmacokinetic study days. Subjects in the PANNA study also had samples collected 
0.5 and 3 hours after dosing, and subjects receiving once a day dosing had samples 
collected 24 hours post dosing. Plasma was separated and stored at < -18°C until 
shipment on dry ice to the central laboratory for analysis. Information collected included 
the time of the two prior doses of maraviroc and maternal weight.
Analytical methods
Concentrations of maraviroc in plasma were analyzed by two centers.
The PANNA samples were analyzed at the Ottawa Hospital Research Institute, Ottawa, 
Ontario, Canada and IMPAACT samples were analyzed at the Pediatric Clinical Phar-
macology Laboratory at the University of California, San Diego. Both laboratories 
used a validated liquid chromatography mass spectrometry/mass spectrometry (LC/
MS/MS) method. The lower limits of quantification were 5 ng/mL (PANNA) and 3.9 
ng/mL (IMPAACT). The linear calibration ranges in plasma were from 5 to 1000 ng/mL 
(PANNA) and 3.9 to 2000 ng/mL (IMPAACT). Both pharmacology laboratories par-
ticipate in the AIDS Clinical Trial Group (ACTG), United States, pharmacology quality 
control (precision testing) program, which performs standardized interlaboratory testing 
twice a year.[15]
Pharmacokinetic assessments
Pharmacokinetic parameters were determined using a non-compartmental model in 
WinNonlin version 6.3 (Pharsight Corporation, CA, USA). Area under the curve (AUC0-tau) 
using the trapezoidal rule, the trough concentration (Clast) defined as the sample taken 
at time point 12hr or 24hr, average plasma concentration (Cavg), maximum concentra-
tion (Cmax), elimination half life (Thalf), time of maximum concentration (Tmax), apparent 
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clearance (CL/F, being the dose/AUC0-tau) and apparent volume of distribution (Vd/F, 
being (CL/F)/kel) were determined per individual curve. 
Statistical analysis data handling
Patients with evaluable pharmacokinetic data during pregnancy were included in de-
mographic, safety analyses and descriptive statistics of the pharmacokinetic parameters. 
pharmacokinetic parameters are reported as geometric means with 95% intervals for the 
150mg maraviroc BID dose with a protease inhibitor. The pharmacokinetic parameters 
for the other dosing regimens were reported for each individual, because the data 
were too limited to be described statistically. Geometric mean ratios (GMR) with 90% 
confidence intervals for individual third trimester to postpartum parameters were deter-
mined for all pharmacokinetic parameters by combining data from all dosing regimens, 
provided that the same maraviroc dose was used during and after pregnancy. A paired 
t-test on the ln-transformed pharmacokinetic parameters was performed to compare third 
trimester data with postpartum.
The Mann-Whitney U test was used to compare AUC0-tau ratios between studies (PANNA 
versus IMPAACT) to test for between-study differences. Cord blood/maternal blood con-
centration ratios were determined and described.
Results
Eighteen HIV-infected pregnant women (IMPAACT 11; PANNA 7) completed third-tri-
mester sampling between 31 and 38 weeks of gestation, and 14 completed sampling 
between 4 and 15 weeks postpartum. Four subjects withdrew from the study and did 
not have postpartum sampling performed.
The characteristics of the women and their pregnancy outcomes are depicted in Table 
1. Twelve women (67%) were on 150mg maraviroc BID with a protease inhibitor, 
two (11%) were on 300mg maraviroc BID without a protease inhibitor, two were on 
300mg maraviroc once daily (QD) with a protease inhibitor, two were on 300mg 
maraviroc BID with a protease inhibitor. The protease inhibitors used were darunavir/
ritonavir (14 women), lopinavir/ritonavir (1 woman) and atazanavir/ritonavir (1 woman). 
Ten patients also received raltegravir. Eleven women started maraviroc treatment before 
pregnancy, six patients started during pregnancy (two in the first trimester, four in the 
second trimester), and the start date was not known for one patient. None of the women 
used other medication possibly interacting with maraviroc.
Pharmacokinetics
The mean plasma concentration-time profiles of maraviroc for the 150mg BID with a 
protease inhibitor regimen in the third trimester and postpartum are presented in Figure 1; 
summary statistics for the pharmacokinetic parameters for the 150mg maraviroc BID 
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Table 1. Subject characteristics
 median (range) or n (%)
Number of patients included 18 (IMPAACT 11/PANNA 7)
Age at delivery (years) 25 (20-41)
Race/ethnicity  
Black, non-hispanic (n (%)) 9 (50%)
Hispanic (n (%)) 6 (33%)
White (n (%)) 2 (11%)
Other, more than one race (n (%)) 1 (6%)
Smoking (n (%)) 7 (21%)
Alcohol use (N (%)) 4 (12%)
Maraviroc regimen
150mg maraviroc BID + PI 12 (67%)
300mg maraviroc BID – PI 2 (11%)
300mg maraviroc  QD + PI 2 (11%)
300mg maraviroc BID + PI 2 (11%)
NRTIs used Combivir® (4, 22%); Truvada® (3; 17%); tenofovir DF alone (2, 
11%); lamivudine alone (1, 6%); abacavir alone (1, 6%); zidovudine 
alone (1, 6%); NRTI-free regimen (6, 33%)
Other ARVs used Raltegravir (10, 56%); etravirine (1, 6%)+PI; enfuvirtide (1, 6%)
Start MVC during pregnancy n(%) 6/17 (35%), 1 unknown
First trimester
Second trimester
2 (12%
4 (24%)
Third trimester (n=18)  
Gestational age (weeks) 34 (31-38)
Weight (kg) 75 (48-128)
HIV-RNA undetectable <50 (n (%)) 13 (72%)
HIV-RNA <400 (n (%)) 15 (83%)
CD-4 count (cells/mm3) 481 (66-1030)
Post partum (n=14)  
Time after delivery (weeks) 7 (4-15)
Weight (kg) 73 (56-121)
HIV-RNA undetectable <50 (n (%)) 11 (73%) 3 missing
HIV-RNA <400 (n (%)) 14 (93%), 3 missing
CD-4 count (cells/ mm3) 521 (66-1465)
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with protease inhibitor dosing regimen are listed in Table 2. Individual pharmacokinetic 
parameters for the other maraviroc treatment regimens can also be found in Table 
2. Figure 2 presents the individual AUC0-tau ratios (third trimester/postpartum) for the 
different maraviroc treatment regimens. Individual ratios did not indicate obvious differ-
ences between these regimens. When the ratio between pregnancy and postpartum 
pharmacokinetic parameters for all subjects (separate regimens were pooled together) 
were compared, significant reductions in AUC0-tau (28%; p=0.008) and  Cmax (30%; 
p=0.007) were observed (Table 3). Clast was reduced by 15% (p=0.096) and thalf was 
marginally increased (4%, p=0.407). AUC0-tau ratios did not show significant differences 
Table 1. - continued Subject characteristics
 median (range) or n (%)
Pregnancy outcomes (n=18)  
Gestational age (weeks) 39 (37-41)
Caesarian section 12 (67%), 1 unknown
Maternal HIV-RNA undetectable <50 (n (%)) 13 (76%), 1 missing
Maternal HIV-RNA undetectable <400 (n (%)) 14 (82%), 1 missing
Birth weight (grams) 3215 (2350-3750)
Infant uninfected (n (%)) 18 (100%)
PI: Protease inhibitor
Figure 1. Maraviroc (150mg BID + PI) mean concentration-time profiles in pregnancy and postpartum
Mean +- SD maraviroc concentrations at steady state measured in the third trimester of pregnancy (square) and postpar-
tum (filled circle), reference concentrations (dotted line) from Kakuda et al.[17]
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  3rd trimester, n=12 postpartum, n = 10
150 mg BID + PI
  GM 95%CI lower 95%CI upper GM 95%CI low 95%CI upper
AUCtau  (ng⋅mL/h) 2717 2038 3622 3645 2429 5469
Cmax  (ng/mL) 448 318 632 647 408 1025
Tmax  (h) 3.09 1 6 2.03 0.98 4
T1/2  (h) 5.7 4.2 7.7 5.5 4.1 7.5
Clast  (ng/mL) 108 81 145 128 89 184
Cl/Fss  (L/h) 55 41 74 44 28 69
Vd/Fss  (L) 456 293 711 352 181 683
Cavg  (ng/mL) 226 170 302 304 202 456
300 mg BID no PI
  indiv 1 indiv 2 indiv 1  Indiv 2
AUCtau  (ng⋅mL/h) 911 1601 995  NA
Cmax  (ng/mL) 339 349 368 NA
Tmax  (h) 1.92 6.03 0.83 NA
T1/2  (h) 8.3 3.3 12.0 NA
Clast  (ng/mL) 30 91 33 NA
Cl/Fss  (L/h) 329 187 301 NA
Vd/Fss  (L) 3934 890 5227 NA
Cavg  (ng/mL) 76 133 83 NA
300 mg QD + PI
  indiv 3 indiv 4 indiv 3 indiv 4
AUCtau  (ng⋅mL/h) 5548 10289 7368 12990
Cmax  (ng/mL) 906 1173 835 1796
Tmax  (h) 3.00 2.05 2.08 3.00
T1/2  (h) 7.9 7.2 7.9 5.1
Clast  (ng/mL) 56 115 74 90
Cl/Fss  (L/h) 54 29 41 23
Vd/Fss  (L) 620 303 466 170
Cavg  (ng/mL) 231 429 307 541
Table 2. Pharmacokinetic parameters maraviroc during pregnancy and postpartum
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Figure 2. Individual maraviroc AUC and Clast ratios (3
rd trimester of pregnancy/postpartum) per dosing regimen
Individual maraviroc AUC and Clast ratios in the third trimester of pregnancy/postpartum for each dosing regimen used. 
For the 150mg twice daily dose in combination with a protease inhibitor the median was reported (line). MVC = maravi-
roc; BID = twice daily; PI = protease inhibitor; QD = once daily
* Tmax: median + range; GM: geometric mean; CI: confidence interval; BID: twice daily; QD: once daily; PI: protease 
inhibitor; NA: not available; AUC, area under the curve; Cmax, maximum concentration; Tmax, time of maximum concentra-
tion; Clast, concentration at last time point (12h or 24h post dosing); T1/2, half-life; CL, apparent clearance; Vd, apparent 
volume of distribution
Table 2. - continued Pharmacokinetic parameters maraviroc during pregnancy and postpartum
  3rd trimester, n=12 postpartum, n = 10
300 mg BID + PI
  indiv 5 indiv 6 indiv 5 indiv 6
AUCtau  (ng⋅mL/h) 8400 5784 15447 NA
Cmax  (ng/mL) 1143 1246 2161 NA
Tmax  (h) 4.00 2.08 4.00 NA
T1/2  (h) 5.1 4.0 3.7 NA
Clast  (ng/mL) 314 136 482 NA
Cl/Fss  (L/h) 36 26 19 NA
Vd/Fss  (L) 264 148 104 NA
Cavg  (ng/mL) 700 482 1287 NA
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between women from the PANNA study and the IMPAACT studies (p=0.755), indicat-
ing no between-study differences, although statistical power to exclude a difference 
between the cohorts was limited.
All women but one had maraviroc concentrations both during pregnancy and postpar-
tum above the suggested minimum target trough concentrations for ART-experienced 
patients with resistant HIV-1 strains of 50 ng/mL.[5] Furthermore, all patients had a Cavg 
above the suggested threshold of 75 ng/mL.[16] The patient with the sub-therapeutic 
Ctrough showed a Cavg just above the threshold (76 and 83 ng/mL).  The woman whose 
trough concentration did not exceed the target Ctrough received maraviroc 300mg BID 
without a protease inhibitor. Her third trimester C12h concentration was 29.7ng/mL and 
postpartum 33.4ng/mL. Predose concentrations were 24.6 ng/mL (third trimester) and 
24.2ng/mL (postpartum) respectively.
Ten umbilical cord blood (CB) samples were collected with matching maternal blood 
samples. The median time between the reported last dose and delivery was 10h (range 
2-16h); the median time between CB sample and maternal sample was 2.5 minutes 
(0-79 min). The median (range) of the concentrations found in the maternal and CB 
samples were 222 (26-597) ng/mL and 52 (4-209) ng/mL, respectively. The median 
(range) ratio of CB/maternal blood was 0.33 (0.03-0.56).
Pregnancy outcome and safety
The median gestational age at delivery was 39 (range: 37-41) weeks and median birth 
weight was 3215 (range: 2350-3750) grams. One baby was low birth weight, weighing 
2350 grams after delivery at 37.9 weeks GA. All children were tested negative for HIV. 
Two congenital abnormalities were reported: congenital pulmonary airway malforma-
P-value from paired samples t-test on ln-transformed parameters.
CI, confidence interval; AUC, area under the curve; Cmax, maximum concentration; T1/2, half-life; CL, apparent clearance; 
Vd, apparent volume of distribution;
Parameter Ratio (%) 90% CI Low  90% CI Upper P-value
AUCtau 72 60 - 88 0.008
Cmax 70 58 - 85 0.007
T1/2 104 86 - 127 0.407
Clast 85 72 - 101 0.096
CLss/F 131 105 - 164 0.043
Vd/F 139 95 - 204 0.116
Cavg 72 60 88 0.008
Table 3. Geometric mean ratios for maraviroc pharmacokinetics: 3rd trimester versus postpartum (n=14)
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tion (or cystic adenomatoid malformation), for which the relationship to maternal ARV 
use could not be judged; sacral dimple, assessed as not related to maternal ARV use. 
Two mothers developed a serious adverse event (SAE). One had a three day hospital 
admission due to haemoptysis at 38 weeks gestation, and was diagnosed with a respi-
ratory tract infection.  Another mother was admitted to a psychiatric hospital. These SAEs 
were assessed as not related to maraviroc administration. Two grade 3 or 4 laboratory 
events were reported: abnormal glucose and abnormal potassium level 3. HIV viral 
loads were detectable (>50 copies/mL) for four patients around delivery: 55, 2106, 
3547 and 5110 copies/mL. These patients used maraviroc 150mg BID with a protease 
inhibitor (darunavir/r) and etravirine (n=2) and/or raltegravir (n=3), enfuvirtide (n=1) and 
an NRTI backbone (n=3). Three out of these four patients had relatively low maraviroc 
exposure (AUC0-tau) and Clast in the third trimester of pregnancy. However, three patients 
with an even lower AUC0-tau and Clast did not show a detectable viral load.
Discussion
We describe the pharmacokinetics of maraviroc in 18 pregnant HIV-infected patients 
during the third trimester of pregnancy and after delivery. The data were collected by 
two networks: PANNA (Europe) and IMPAACT (US and Argentina). Overall, maraviroc 
concentrations were reduced in the third trimester of pregnancy, with reductions in 
AUCtau (28%), Cmax (30%) and Clast (15%). Transplacental passage of maraviroc was low, 
with a median cord blood to maternal delivery ratio of 0.33.
In our population of mainly cART-experienced women, 76% had undetectable HIV RNA 
levels at delivery and none of the children tested HIV positive. Maraviroc was well 
tolerated during pregnancy and infant outcomes were good. The median gestational 
age at delivery was 39 weeks, with no preterm births.
The maraviroc postpartum pharmacokinetic profiles with 150mg maraviroc BID with a 
protease inhibitor observed in this study were similar to those reported in the literature for 
non-pregnant adults (mixed sex).[17] The postpartum curves for the other dosing regimens: 
300mg BID without a protease inhibitor, or 300mg QD with a protease inhibitor 
were also consistent with the non-pregnant reference pharmacokinetic profiles.[18] Most 
patients used 150mg maraviroc BID with a protease inhibitor and the individual ratios of 
the patients using other regimens fell within the range of ratios reported for this regimen. 
Consistent with previous assessments of antiretroviral pharmacokinetics in pregnancy 
there was substantial inter patient variability. Because the number of patients using alter-
native regimes was low, we could not directly compare the effect of pregnancy on the 
different regimens.
Only one subject showed maraviroc trough concentrations below the suggested minimum 
target concentration for ART-experienced patients with resistant HIV-1 strains of 50 ng/
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mL, both during pregnancy and postpartum.[5] She was using the 300mg BID regimen 
without a protease inhibitor, but with tenofovir and raltegravir. Plasma concentrations of 
tenofovir were also very low on both occasions, whereas raltegravir exposure was not 
abnormal (data not shown). She reported to have been adherent for at least the week 
prior to pharmacokinetic assessment and she did not use other medication concomi-
tantly. The below target trough concentrations of maraviroc in this subject during both 
pregnancy and postpartum suggests that the low troughs were patient specific and not 
caused by pregnancy. Despite these low levels she had an undetectable viral load in 
the third trimester and postpartum, which is in line with a recent study in which no sig-
nificant relationship between maraviroc exposure and antiviral response was found.[19]
Four subjects had a detectable viral load around delivery, the maraviroc exposure was 
relatively low in the third trimester in three of these patients, but three other patients 
showed even lower exposure. Therefore, a relationship between exposure and having 
a detectable viral load could not be demonstrated. The four subjects with a detectable 
viral load were patients with a complicated treatment regimen (including at least three 
classes of antiretrovirals) and long treatment histories, indicating that these patients were 
difficult to treat.
Maraviroc is a CYP450 3A4 substrate and exposure is increased when taken together 
with the strong CYP3A4 inhibitor ritonavir, leading to the recommendation that maraviroc 
doses should be decreased when administered along with a boosted protease inhibitor 
regimen. A limitation of our study is the heterogeneous population and different doses 
and antiretroviral regimens used, a consequence of the opportunistic design of both 
studies. The population studied by PANNA and IMPAACT mainly received the recom-
mended adult dose of 150mg maraviroc BID with a protease inhibitor (67%) or 300mg 
maraviroc BID without a protease inhibitor (11%)  However, our subjects received other 
doses as well, including 300mg maraviroc once daily with a protease inhibitor (11%) 
and 300mg maraviroc twice daily with a protease inhibitor (11%).
We observed a decrease of around 30% in AUC, average and peak concentration in 
the third trimester of pregnancy. No other data on the influence of human pregnancy 
on maraviroc pharmacokinetics have been published or presented. A study in rhesus 
macaques reported unchanged maraviroc pharmacokinetics of a single dose intrapar-
tum compared to non-pregnant animals.[20] However, this study is of limited value as it is 
difficult to compare data from non-human primates with human data and to extrapolate 
exposure with a single dose to chronic exposure.
The decrease in exposure to maraviroc observed in our subjects during pregnancy 
is of similar magnitude to the decrease seen with the protease inhibitors atazanavir, 
darunavir and lopinavir.[21-23] Several metabolism related mechanisms could explain the 
lower maraviroc exposure in pregnancy: increased CYP450 3A4 activity in the gut and 
liver leading to decreased gastro-intestinal absorption due to increased gut metabolism 
and increased hepatic clearance, and/or to less boosting by ritonavir associated with 
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lower ritonavir exposure in pregnancy. Unfortunately, paired third trimester and post-
partum data are available for only a single woman not using a protease inhibitor. The 
ratio of the maraviroc AUCtau third trimester/postpartum was 0.92 for this patient, while 
the ratios of the maraviroc AUCtau third trimester/postpartum for patients concomitantly 
using a protease inhibitor ranged from 0.35-1.46. Therefore, we cannot conclude that 
less boosting in pregnancy is the major cause of the lower maraviroc exposure. Other 
mechanisms may also explain the lower exposure, including reduced intestinal motility, 
a larger plasma volume and increased hepatic blood flow.
Placenta passage of maraviroc is limited, with a median cord blood to maternal blood 
ratio of 0.33. This is consistent with the previously ratio of 0.37 in a single case report[12] 
and higher than that reported in an ex vivo placenta perfusion model. ABC efflux 
transporters may possibly play a role resulting in limiting maraviroc transfer across the 
placenta to the fetus.[13]
In conclusion, although overall maraviroc exposure is 28-30% lower during pregnancy, 
Ctrough was reduced to a lesser extent. All except one of the subjects met the target 
trough concentration during pregnancy for antiretroviral resistant HIV-1, suggesting that 
the standard adult dose seems to be sufficient in pregnancy.
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Abstract
Pregnant women are usually excluded from clinical trials. Physiologically-based-phar-
macokinetic (PBPK) modelling may provide a method to predict pharmacokinetics in 
pregnant women, without having to perform extensive in vivo clinical trials. Here, we 
used mechanistic modelling to delineate the potential impact of drug transporters on 
darunavir pharmacokinetics and identify current knowledge gaps that limit the accurate 
PBPK modelling of darunavir/ritonavir (darunavir/r) exposure in pregnancy. Simcyp 
(v13.2) was used for PBPK modelling, using physicochemical and in vitro pharmacoki-
netic parameters of darunavir and ritonavir from literature. Km and Vmax for CYP3A4-me-
diated darunavir biotransformation and inhibition by ritonavir were determined experi-
mentally. Sensitivity analyses were used to assess the contribution of hepatocyte influx 
and efflux transporters. Simulations were compared to previously published clinical phar-
macokinetic data. We found that the well-stirred-liver-model overestimated darunavir 
exposure substantially. A permeability-limited-hepatic-model, including hepatic-uptake 
and -efflux transporters and efficient enterohepatic circulation, resulted in an acceptable 
description of darunavir/r exposure. For the 600/100mg darunavir/r twice-daily dose 
and the 800/100mg once-daily dose, peak and total exposure at steady state were 
estimated within 2-fold range of reported data. The model predicted a decrease in AUC 
of 27% and 41%, which is in the range of the observed decrease during pregnancy 
of 17-22% and 33% for the twice-daily and the once-daily dose, respectively. In con-
clusion: our data support a clinically relevant role of hepatic transporters in darunavir 
pharmacokinetics. The described model successfully approximated ritonavir-boosting 
and the decrease in darunavir exposure during pregnancy. Future in vitro experiments 
should generate quantitative kinetic data of passive and transporter-mediated darunavir 
handling by hepatocytes and intestinal epithelium.
161PBPK modelling of darunavir/r pharmacokinetics in pregnancy
Introduction 
Pregnant women are generally excluded from clinical trials during the development 
phase of new drugs, for ethical and safety reasons.[1-3] However, medication use during 
pregnancy is not uncommon.[4] Most information regarding safety, pharmacokinetics 
and placental transfer is collected after drugs are available on the market. This impli-
cates that pregnant women often use medication, while the treating physicians have no 
knowledge of the systemic drug exposure, nor placental transfer of the drug and hence 
the safety for the unborn child. Vice versa, medication in pregnant women may be 
withheld by physicians because they lack this critical information, and clinical benefit is 
missed. It would be a tremendous advantage to use in silico modelling for the prediction 
of maternal and foetal exposure of (new) drugs possibly being used during pregnancy. 
Such models may be particularly relevant in the treatment of HIV. To prevent mother-
to-child transmission, pregnant HIV-infected women should use combination antiretro-
viral treatment (cART).[5,6] Pregnancy-induced reductions in maternal exposure to these 
drugs may lead to sub-therapeutic levels, eventually leading to virological failure and/
or resistance, thus requiring dose adjustment.[7] Moreover, clinical drug-drug interaction 
trials are not performed in this patient population, leaving physicians unaware of the 
possible impact of concomitantly administered interacting drugs in the pregnant patient 
population.
Physiologically based pharmacokinetic (PBPK) modelling is a mechanistic approach to 
predict absorption, distribution, metabolism and excretion (ADME) of drugs, based on 
anatomy and physiology of the human body, physicochemical properties of the drug 
as well as in vitro pharmacokinetic data on the transport and biotransformation of the 
drug. In this way, the handling of a drug by the body can be simulated, taking molecular 
processes as a starting point. This contrasts with population or compartmental pharma-
cokinetic methods, which are based on empirical models that take clinical pharmaco-
kinetic data as a starting point. As such, PBPK modelling provides a potentially relevant 
approach to predict the effect of pregnancy itself on drug pharmacokinetics. During 
pregnancy, numerous changes in physiology are known to occur, which affect pharma-
cokinetic parameters like volume of distribution, plasma protein binding and metabolic 
clearance of drugs.[8-10] In addition, PBPK modelling would in principle allow quantitative 
assessment of the potential impact of concomitantly prescribed interacting drugs on 
drug exposure. This is particularly useful in HIV-infected pregnant women, who typically 
use a cocktail of drugs. In fact, in these patients drug-drug interactions are intentionally 
employed to optimize treatment. For example, ritonavir, a strong cytochrome P450 3A4 
(CYP3A4) inhibitor, is used to boost (increase the exposure) of antiretroviral drugs that 
are metabolized by CYP3A4. Finally, PBPK modelling provides an effective manner to 
integrate the currently available mechanistic drug disposition data and obtain a better 
understanding of the pharmacokinetic behaviour of a compound. 
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Recently, Simcyp has developed a PBPK modelling platform that includes physiological 
changes in relation to duration of pregnancy (p-PBPK model).[11,12] Exposure to drugs 
during pregnancy at any gestational age may be predicted, permitted that in vitro 
pharmacokinetic data of all relevant processes to drug disposition are available.[11] To 
study the feasibility of such a p-PBPK modelling approach for adequate prediction of 
maternal drug pharmacokinetics during pregnancy, we now focused on the antiretroviral 
compound darunavir. Darunavir is an HIV-protease inhibitor (PI), always co-administered 
with ritonavir to boost darunavir plasma concentrations.
We developed and evaluated a mechanistic model to predict darunavir exposure of the 
common treatment regimens used in pregnancy, namely 600/100mg darunavir/r twice 
daily and 800/100mg darunavir/r once daily. These efforts also aimed to elucidate 
whether the required mechanistic in vitro pharmacokinetic parameters to incorporate in 
such a model are currently available and identify current knowledge gaps that limit the 
accurate PBPK modelling of darunavir/r exposure, thereby generating new hypotheses 
and hence directions for future studies.
Methods
PBPK modelling platform
For this study we used the Simcyp Population-based Pharmacokinetic Simulator version 
13 release 2 (Simcyp Limited, a Certara company, Sheffield, UK) as PBPK platform. 
Details on the algorithms to calculate in vivo pharmacokinetic parameters, a description 
of the Simcyp in vitro–in vivo extrapolation (IVIVE) methods, the structure of the physio-
logical model and a description of the differential equations used, have been published 
before.[13-16] Simulations were performed using the Simcyp virtual populations of healthy 
volunteers and pregnant women. For each simulation, number of patients, gender, age 
range and gestational age of the virtual population were matched with clinical data 
sets used for validation.
Physicochemical and in vitro pharmacokinetic parameters of darunavir
Physicochemical properties (molecular weight, log P) and blood and protein binding 
properties of darunavir were obtained from literature (see Table 1). Holmstock et al.[17] 
studied the permeability of darunavir using Caco-2 monolayers in absence and presence 
of ritonavir. In presence of ritonavir the intestinal permeability of darunavir in mice was 
reported to be 2.7-fold increased, as a result of the strong P-glycoprotein inhibitory effect 
of ritonavir.[17] This was in line with studies reporting similar increases in darunavir per-
meabilities in Caco-2 monolayers in the presence of P-glycoprotein (P-gp) inhibitors.[18] 
Therefore, when modelling the pharmacokinetics of darunavir alone, we used a reported 
in vitro Caco-2 permeability of 7 ⋅ 10-6 cm s-1 for darunavir alone and 18.6 ⋅ 10-6 cm s-1 
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when simulating combined darunavir/r administration. Darunavir is mainly eliminated by 
hepatic metabolism, almost exclusively by CYP3A4, without a significant contribution of 
renal elimination.[19] We therefore did not include a renal clearance component for the 
unchanged drug in our simulations. To determine Km and Vmax for CYP3A4-mediated 
darunavir metabolism, we performed in vitro tests using human liver microsomes (HLM) 
and baculosomes overexpressing human recombinant CYP3A4. See the corresponding 
paragraph below for a more detailed description of these studies. 
For darunavir simulations the Simcyp full PBPK distribution model was applied, which 
makes use of a number of time-based differential equations in order to simulate the con-
centrations in various organ compartments: the blood (plasma), adipose, bone, brain, 
gut, heart, kidney, liver, lung, muscle, pancreas, skin and spleen, with addition of the 
fetoplacental compartment during pregnancy. Inter-individual variability is introduced 
through tissue volume prediction, based on known relations between these and easy-
to-measure parameters such as age, sex, weight and height. Initially, we used a well-
stirred liver model without hepatic basolateral uptake, canalicular excretion or intestinal 
re-absorption of darunavir. In subsequent steps, modelling with a permeability-limited 
liver model was performed, exploring various degrees of hepatic uptake and efflux 
clearance, while also addressing the impact of various efficiencies of intestinal re-uptake 
of drug that was excreted unchanged into bile. Modelling results were validated against 
literature, as indicated in the PBPK workflow section below, as well as in the results 
section.
Physicochemical, in vitro and clinical pharmacokinetic parameters of ritonavir
The ritonavir model used to simulate boosting was a semi-mechanistic pharmacokinetic 
model, based on both in vitro as well as clinical pharmacokinetic data and phys-
icochemical parameters. Absorption was based on first-order kinetics (ka=0.24/h 
and fa=1) and Vss=0.41 L/kg, in line with data that has been derived from clinical 
studies, and as included in the existing Simcyp compound library.[20] Oral ritonavir 
clearance of the 100mg boosting dose has been reported in healthy volunteers to be 
16 L/h.[21] For the pregnant situation we increased the oral clearance to 20 L/h, as 
derived from clinical observations.[22,23] The interaction potential of ritonavir with other 
drugs was based on competitive inhibition of CYP2C9, CYP2D6 and CYP3A4 (see 
Table 2), of which CYP3A4 competitive inhibition potential is particularly important to 
simulate darunavir boosting. We performed in vitro tests in HLM to corroborate and if 
necessary update the IC50 of ritonavir on CYP3A4-mediated darunavir biotransforma-
tion (see below). In addition to competitive inhibition, Fahmi et al.[24] and Kaspera et 
al.[25] described that ritonavir also displays mechanism-based inhibition of CYP3A4. In 
addition to a competitive inhibition, we also included mechanism-based inhibition in 
the model. Kaspera et al. reported a Kapp (concentration of mechanism-based inhibitor 
associated with half maximal inactivation rate) of 0.1 µM and a Kinact (rate of enzyme 
inactivation) of 0.32/h, respectively.[25] Inductive properties of ritonavir on CYP3A4 
164 Chapter 10
have also been described and were added to the model based on Kirby et al..[26] As 
we also explored a potential role of hepatic uptake and efflux transport in the pharma-
cokinetics of darunavir, we included reported in vitro inhibitory potencies of ritonavir on 
the following relevant transport proteins: P-gp (hepatic canalicular efflux), Organic Anion 
Transporting Polypeptide 1B1 (OATP1B1, SLCO1B1) and OATP1B3 (SLCO1B3), which 
are both hepatic basolateral influx transporters.[27,28]
In vitro testing
Enzyme kinetics
A range of darunavir concentrations (1-25 µM) was incubated with HLM in presence 
and absence of NADPH. To avoid depletion of NADPH during the incubations a re-
generating system was employed. Each incubation mixture (250 µL) contained HLM 
(0.25 mg/mL), components of the NADPH-regenerating system (1 mM NADP, 3 mM 
MgCl2, 1 IU/L glucose-6-phosphate dehydrogenase, 10 mM glucose-6-phosphate) and 
darunavir (1-25 µM) in phosphate buffer (pH=7.4). After 10 minutes pre-incubation of 
buffer containing HLM and darunavir at 37 °C, the reaction was started by adding the 
NADPH-regenerating system. The mixture was subsequently incubated for 30 min at 37 
°C, a time interval over which darunavir biotransformation was linear (data not shown). 
Parallel incubations were performed in the absence of NADPH to correct for loss of 
darunavir (substrate), unrelated to CYP3A4-mediated biotransformation. The reaction 
was stopped by adding 500 µL of ice-cold methanol, after which the samples were 
homogenized and left on ice for at least 10 minutes. The samples were then centrifuged 
at 10,000 rpm for 2 minutes. Darunavir biotransformation was assessed by measuring 
disappearance of the substrate from the incubation buffer (also see paragraph on 
kinetic analysis). An aliquot of 500 µL of the supernatant was used for determination 
of darunavir concentrations by HPLC, a method adapted from the protocol described 
by Droste et al.[29] (LLOQ of 50nM or 0.027 mg/L). The same protocol was used to 
analyse the results obtained from the incubations with baculosomes over-expressing 
human recombinant CYP450 3A4 (20 pmol/mL), over a darunavir concentration range 
of 1-10 µM.
Michaelis-Menten kinetic analysis 
The rate of darunavir conversion by HLM and baculosome incubations was calculat-
ed by subtracting the amount of darunavir remaining in the preparation at the end of 
the incubation period in the presence of NADPH from the amount of darunavir that 
remained after the incubation in the absence of NADPH. Data were expressed as 
pmol.min-1.mg-1 microsomal protein (HLM) or pmol.min-1.pmol-1 CYP3A4 (baculosomes) 
and plotted against measured initial darunavir concentrations (µM). Data were analysed 
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by nonlimear regression analysis according to the Michaelis–Menten equation using 
Graphpad Prism 5 (version 5.02, GraphPad Software Inc) according to:
V = (Vmax⋅[darunavir])/(Km + [darunavir])
where Vmax is the maximum bioconversion rate of the enzyme and Km (µM) is the 
Michaelis constant, defined as the reaction concentration required to reach half of Vmax.
Inhibitory effect of ritonavir on darunavir biotransformation
Incubations with HLM were performed as described above, in the presence of 1 µM 
darunavir (substrate) and ritonavir (inhibitor) at concentrations ranging from 0.01-0.3 
µM. The concentration of ritonavir causing half maximal inhibition of CYP3A4-mediated 
darunavir biotransformation (IC50) was obtained by plotting the normalized darunavir 
bioconversion rates (% of control) against log [ritonavir] (M). The IC50 was estimated 
by fitting a one binding site inhibition model with a variable slope to the data, using 
Graphpad. Derived IC50 values from three separate experiments each performed in 
duplicate were subsequently converted to a Ki value (binding affinity of the inhibitor) 
using the Cheng-Prusoff equation (IC50/ ((1+ [darunavir] /Km, darunavir)).
PBPK workflow and statistical analysis
We first simulated darunavir kinetics in healthy volunteers, when administered as a 
single dose without ritonavir. We then verified the interactions of darunavir with ritonavir, 
first for a single dose of darunavir, after Sekar et al. and Rittweger et al.[19,30] and 
then for the steady-state situation for the clinical dosing regimens 600/100mg daruna-
vir/r twice-daily[31,32] and 800/100mg once-daily.[33,34] Before applying the ritonavir 
semi-mechanistic model in the darunavir PBPK modelling approach, ritonavir model 
performance was validated against data available from interaction studies between 
ritonavir and midazolam (a probe substrate for CYP3A4).[26,35] Acceptance criteria 
were defined as follows: both geometric mean Cmax and AUC should not deviate more 
than 2-fold from the observed pharmacokinetic parameters, as is commonly applied in 
assessing PBPK-model performance. After modelling of darunavir/r exposure in healthy 
volunteers in single as well as multiple dose regimens, we proceeded to modelling 
darunavir/r pharmacokinetics during pregnancy. Simulations of twice daily 600/100 
and once daily 800/100 darunavir/r were performed during the second and third 
trimester (the same gestational age as reported in published clinical sudies). For the 
non-pregnant situation, simulations were performed using the healthy volunteer pop-
ulation (100% females, matched for age where reported). An independent samples 
t-test (SPSS 20) was performed on the log-transformed AUCs comparing the pregnant 
situation with the non-pregnant situation (per gestational age), resulting in geometric mean 
ratios (pregnant:non-pregnant) and 90% confidence intervals. Finally, we performed 
simulations with higher darunavir/r dosages: 900/100mg darunavir/r once daily, 
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as well as 800/100mg and 900/100mg darunavir/r twice daily during pregnancy 
(third trimester), to predict which dose would compensate for the observed decrease in 
exposure. These dosages were chosen because darunavir is available as 300, 400, 
600 or 800mg film-coated tablets for oral use.
Comparison of physiological parameters of the Simcyp pregnant population with a 
real-life HIV-infected pregnant population
Within a clinical study coordinated by our institution (PANNA study; www.pannastudy.com), 
several physiological parameters (haematocrit, serum creatinine, 1-acid glycoprotein 
and albumin concentrations) were collected during pregnancy and after delivery, next 
to the primary aim of the study to collect pharmacokinetic parameters of antiretroviral 
drugs. We compared these physiological parameters within the real-life HIV-infected 
pregnant population collected in PANNA, with those used to define the Simcyp virtual 
healthy pregnant population as describe by Abduljalil et al.[10] Mean ± SD values for the 
respective physiological parameters were calculated (99 HIV-infected pregnant patients) 
at the different gestational ages, ± 2 weeks of the gestational ages reported by Ab-
duljalil et al.[10] Data were compared with the mean values summarized by Abduljalil 
to investigate if there were any differences between HIV-infected and non-HIV infected 
pregnant women. An independent samples t-test was used to analyse the data (SPSS 
20).
Results
In vitro metabolic clearance of darunavir
Literature search yielded values for a substantial number of mechanistic pharmacokinet-
ic parameters related to absorption and distribution of darunavir (Table 1). However, 
quantitative data on in vitro darunavir metabolic clearance by CYP enzymes (Km and 
Vmax values) were not available in peer-reviewed literature (we found only a conference 
abstract). As it is known from literature that darunavir is a CYP3A4 substrate, we deter-
mined the in vitro metabolic Km and Vmax using HLM.
The rate of conversion of darunavir in HLMs was found to be linear up to 30 min (data 
not shown). Enzyme kinetics was therefore determined at a protein concentration of 
0.25 mg/mL over a 30 minute time period. We found that darunavir bioconversion 
was saturable with increasing concentrations (Figure 1), characterized by a Km (95% CI) 
of 1.1 (0.3-1.8) µM and Vmax (95% CI) of 180 (150-210) pmol.min
-1.mg-1 protein. The Km 
value derived from the experiments performed in baculosome CYP3A4-overexpression 
system was 0.80 (0.17-1.43) µM (CLint, met [intrinsic metabolic clearance] of 2.25 µl min
-
1pmol-1 CYP3A4) which, with respect to Km, is in line with results obtained with the HLM.
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Parameter Value References
Physicochemical Molecular weight 548 g/mol Pubchem[52] ; http://www.
antimicrobe.org/d94.asp 
(Feb 2015)[53] ; http://
www.drugbank.ca/drugs/
db01264 (Feb 2015)[54]
Log Po:w 1.8
Compound type Weak Base
pKa (strongest basic)
pKa (strongest acidic)
2.39
13.59
http://www.drugbank.
ca/drugs/db01264 (Feb 
2015)[54]
Physiological charge 0
Blood to plasma ratio 0.64 EMA scientific discussion[19,55]
Fraction unbound in plasma 0.06 EMA scientific discussion[19,55]
Main plasma binding protein 1-acid glycoprotein (AGP) EMA scientific discussion[19,55]
Absorption Absorption model Advanced Absorption and Dissolution 
Model (ADAM)
Permeability predicted via Caco-2
Apical pH : Basolateral pH 6.5 : 7.4
Activity Passive & Active
Papp Caco-2 (10E-06 cm/s) 7 (absence of ritonavir)
18.9 (presence of ritonavir)
Holmstock et al. 2012[17]
Holmstock et al. 2012[17]
Scalar 1
Dosage form Immediate release, dissolution over 2 
hour period (fed condition)
Available for reabsorption 
after biliary excretion
Sensitivity analysis 0-100%, 80% 
was optimal
Distribution Distribution Model Full PBPK Model
Predicted Vss (L/h) 1.23 Prediction method by 
Rodgers et al.[56]
Kp scalar 6 Empirically determined[19,55]
Table 1. Physico-chemical and in vitro pharmacokinetic parameters of darunavir
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Simulation of darunavir pharmacokinetics without ritonavir 
We simulated the concentration-time curve of a single oral 600mg dose of darunavir 
in plasma with the well-stirred liver model, hence assuming passive partitioning of drug 
from plasma into liver tissue, instantaneous homogeneous distribution across liver mass, 
and CYP3A4-mediated metabolic clearance as the only relevant clearance mechanism. 
As can be seen in Figure 2, the simulations overestimated the total exposure of darunavir 
when compared with the clinical data presented by Sekar et al. and Rittweger et al..
[19, 30]
Inclusion of hepatic influx and efflux transport via sensitivity analyses
According to the general workflow of PBPK modelling and simulation described by Ke 
et al.,[12] we refined the model by taking clues from in vitro pharmacological studies 
as a starting point. Visual inspection of the curves indicated that the simulated absorp-
tion phase was in line with the observed data. Therefore, we explored whether other 
clearance mechanisms may contribute to darunavir plasma clearance. It is known that 
darunavir interacts with basolateral OATP1B1, 2B1, 1B3 and canalicular P-gp hepato-
cyte membrane transporters.[18,28,36] Therefore, we investigated whether inclusion of a 
Table 1. - continued Physico-chemical and in vitro pharmacokinetic parameters of darunavir
* Prediction method 2 = after Rodgers et al.[56]
Vmax: maximum rate of metabolite formation (pmol/min/mg microsomal protein)
Km: Michaelis-Menten constant (substrate concentration at ½ Vmax) µM
CLint, T: In vitro transporter-mediated intrinsic clearance 
Fumic: fraction of unbound drug in the in vitro microsomal incubation (calculated)
Parameter Value References
Metabolism/
elimination
Clearance Type Enzyme Kinetics
Test system HLM
Enzyme kinetics CYP3A4 Vmax = 181 pmol/min/mg microso-
mal protein
Km = 1.1 µM
Protein concentration = 0.25 mg/mL
Fu, mic = 0.96 (pH 7.4)
Determined
Determined
Determined
Calculated
Transport Passive difussion clearance 0.1 µL/min/million cells Simcyp default value
Basolateral hepatocyte 
uptake, CLint,T 
Sensitivity analysis 0-500 µL/min/
million cells; 100 µL/min/million 
cells used in final model
Canalicular hepatocyte efflux 
(P-gp) CLint,T
Sensitivity analysis 0-500 µL/min/
million cells; 100 µL/min/million 
cells used in final model
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Parameter Value References
Physicochemical Molecular weight 720.95 g/mol Pubchem[57]
Log Po:w 4.3 Simcyp compound library
Compound type Monoprotic Base
pKa 2 Simcyp compound library
Blood to plasma ratio 0.587 Simcyp compound library
Fraction unbound in plasma 0.02 http://www.drugbank.ca/
drugs/DB00503 [58]
Main plasma binding protein 1-acid glycoprotein (AGP)
Absorption Absorption model First-order absorption
Fraction absorbed 1 Simcyp compound library
Ka (1/h) 0.24 Simcyp compound library
Distribution Distribution Model Minimal PBPK Model
Vss (L/kg) 0.41 Simcyp compound library
Metabolism/elimi-
nation
Clearance Type In vivo clearance
CLpo (L/h) 16, non pregnant; 20 pregnant Product characteristics 
Norvir,[21] Colbers et al.[22]
CLr (L/h) 0.32
Interaction CYP CYP2C9 Ki (µM) 4 (fumic 0.29)
CYP2D6 Ki (µM) 10 (fumic 0.29)
CYP3A4 Ki (µM) 0.03 (fumic 0.976) determined
CYP3A4 Kapp (µM) 0.1 (fumic 0.91) Kaspera et al. 2014[25]
CYP3A4 Kinact (1/h) 0.32 (fumic 0.91) Kaspera et al. 2014[25]
Interaction transp ABCB1 (P-gp) Ki (µM) 0.2 (fuinc 0.233) Drewe 1999[27]
Pooled basoleteral uptake Ki (µM) 2.5 (fuinc 1) Annaert 2010[28]
Table 2. Physico-chemical and in vitro pharmacokinetic parameters of ritonavir
* Prediction method 2 = after Rodgers et al.[56]
Ki: concentration of inhibitor that supports half maximal inhibition
Fumic: fraction of unbound drug in the in vitro microsomal incubation (calculated)
Kapp: concentration of mechanism-based inhibitor associated with half maximal inactivation rate
Kinact: inactivation rate of the enzyme
Fuinc: fraction of unbound drug in the in vitro hepatocyte incubation
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Figure 1. Rate of darunavir disappearance from human 
liver microsomal incubations at increasing substrate 
concentrations. Data represent a typical experiment 
performed in duplicate, mean ± range (min/max) are 
presented. A Michaelis-Menten equation was fitted to 
the data as described in the materials and methods 
section. Calculated Km and Vmax are 1.1 µM and
180 pmol.min-1.mg-1 microsomal protein.
Figure 2. Simulation of darunavir plasma concentrations after a single oral dose of 600mg, using the well-stirred liver 
model on linear (A) and semi-logarithmic (B) scale. The closed circles represent the observed concentrations,[19] the 
dashed line represents the simulated mean concentrations, and the dotted lines represent the associated 95% confidence 
intervals of the simulated concentrations. Simulated plasma concentration data were derived from 8 healthy subjects (3 
female, 5 male), aged 27-37 years, matching the subjects in the reported trial as much as possible. 
Figure 3. Darunavir single dose (600mg oral), 
simulation of increasing CLint, T uptake values using the 
permeability-limited liver model. The closed circles 
represent the observed concentrations,[19] the solid line 
reflects the data obtained with the well-stirred liver 
model while the dashed lines represent simulated mean 
concentrations applying the permeability-limited liver 
model with varying CLint,T uptake values: 100, 200, 
300, 400 and 500 µL/min/million hepatocytes.
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Figure 4. Darunavir single dose (600mg oral) simula-
tion results when assuming combined influx and efflux 
processes taking place using the permeability-limited 
liver model (PMBL). The closed circles represent the 
observed concentrations,[19] the solid line reflects the 
data obtained with the well-stirred liver model (WSLM), 
while the dashed lines represent simulated mean con-
centrations applying the permeability-limited liver model 
with different CLint,T uptake/CLint,T efflux values, as indicated 
in the graph. 
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Figure 5. Inhibition of darunavir metabolism in human 
liver microsomal preparations by ritonavir. Data repre-
sent the mean ± SEM of three separate experiments, 
each performed in duplicate. A one-site binding model 
with variable slope was fitted to the data in order to 
estimate ritonavir IC50. The calculated IC50 was 0.06 µM. 
Figure 6. Scatter plot representing the AUC ratio 
(AUCwith inhibitor/AUCwithout) of simulated and clinical drug-
interaction studies between midazolam and different 
ritonavir doses, as reported by Katzenmaier et al., Kirby 
et al. and Mathias et al..[26, 35, 37] Dashed lines represent 
a two-fold difference from the observed values. AUC: 
area under the plasma concentration-time curve,  RTV:  
ritonavir
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basolateral influx and a canalicular efflux component in the model could improve simu-
lations. In Figure 3, the effect was examined of an increased intrinsic uptake clearance 
on model fit. In Figure 4, it can be seen that inclusion of a hepatocyte cannalicular 
efflux component next to a basolateral uptake step, allows for better model fits at lower 
intrinsic transport clearance values (CLint,T, µL.min
-1⋅million cells-1).
In vitro transport parameters (Km, Vmax or CLint,T) for darunavir in human hepatocytes or 
recombinant overexpression systems of drug transporters were not available in literature. 
We therefore compared the estimated CLint,T values derived from our simulations with 
measured values of other hepatocyte uptake and efflux transporter substrates. In Table 
3, it can be seen that the required CLint,T values are of pharmacological relevance, when 
combined hepatocellular influx and efflux processes take place.
Inhibitory effect of ritonavir on CYP3A4
Darunavir is, however, always administered together with ritonavir. Ritonavir inhibits 
CYP3A4-mediated darunavir metabolism, hence boosting its plasma exposure. In order 
to simulate this effect on a mechanistic level, the ritonavir IC50 for CYP3A4-mediated 
darunavir metabolism is required. As can be seen in Figure 5, ritonavir completely 
Compound
CLint uptake transport
(µL min-1 million cells-1)
CLint efflux transport
(µL min-1 million cells-1) Reference
Bosentan 17.9 Ménochet et al.
9.1 7.4 Jones et al.
Cerivastatin 9.6 (2.7) 6.2 (1.8) Jones et al.
Fluvastatin 45 (21) 17 Jones et al.
Pitavastatin 40.7 Ménochet et al.
Pravastatin 2.77 Ménochet et al.
1.8 1.2 Jones et al.
Repaglinide 79.0 Ménochet et al.
30 (16) 0 Jones et al.
Rosuvastatin 9.21 Ménochet et al.
9.3 (2.6) 1.5 (0.088) Jones et al.
Telmisartan 95.2 Ménochet et al.
Valsartan 2.88 Ménochet et al.
2.1 (0.48) 96 Jones et al.
Table 3. CLint,T influx and efflux values reported in literature
Jones et al.[43] presented in vitro parameters estimated from sandwich culture human hepatocyte parameters at a single 
substrate concentration, mean from multiple replicates of one to two donors. Ménochet et al.[44] performed uptake 
kinetics in cryopreserved human hepatocytes at seven concentrations, the uptake parameters were estimated using a 
mechanistic two-compartment model. In bold: parameters reported close to simulation estimates.
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inhibited darunavir bioconversion, with an IC50 of 0.06 (0.04-0.10) µM, which was 
equivalent to a mean Ki value of 0.03 µM. The Ki value was included in the ritonavir 
model, together with other parameters listed in Table 2. Performance of the ritonavir 
PBPK model was then validated in simulations with midazolam, a probe substrate 
for CYP3A4. We simulated the interaction between several doses of ritonavir and 
midazolam, as described by Katzenmaier et al.[37], Kirby et al.[26] and Mathias et al.[35] 
In Figure 6 the results of these simulations are presented, demonstrating that the model 
could predict the increase in midazolam exposure within a 2-fold difference of reported 
clinical Cmax and AUC ratio’s.
Simulation of combined darunavir/r administration
Next, simulations of the interaction of darunavir with ritonavir were performed. First, the 
influence of ritonavir multiple doses (start 2 days prior to darunavir administration until 
day 4) on a single dose darunavir (600mg, given on day 3) was simulated and the 
data were compared with those reported by Rittweger et al.[19] As can be seen in Figure 
7, a strong boosting effect could be simulated when combining darunavir with ritonavir. 
However, this was only the case if it was assumed that unchanged drug excreted via the 
bile was readily available for enteric reabsorption. Reducing the percentage available 
for re-absorption to 0% abolished enterohepatic cycling and the boosting effect of 
ritonavir was lost. In contrast, it followed from our simulations that enterohepatic recir-
culation does not appear to be a major player in determining exposure of single dose 
darunavir without ritonavir, as inclusion of reabsorption of biliary excreted darunavir was 
not necessary to describe these clinical data (Figure 7).
We also assessed whether the model predicted the steady-state pharmacokinetics 
of relevant clinical dosage regimens of 600/100mg darunavir/r twice daily and 
800/100mg darunavir/r once daily. Simulations were compared with two studies for 
each regimen.[32-34,38] For this situation, darunavir/r pharmacokinetics could also be 
simulated succesfully with indicated CLint,T uptake of 100 µL/min/million cells, CLint,T efflux 
of 100 µL/min/million cells and efficient enteric reuptake (80%) values in place. The 
simulated geometric mean darunavir AUCs and Cmax values were within a factor 2 from 
the observed parameters (Figure 8).
Simulation of darunavir and ritonavir in pregnancy
With the same model, simulations were performed in pregnancy, for both regimens 
at steady-state, during the second and third trimester, which could be compared with 
available literature data. The results are depicted in Figures 9 and 10. It can be seen that 
that the prediction of the shape of the curves for both the non-pregnant as the pregnant 
situation was good. For the 800/100mg darunavir/r once-daily dosing regimen the 
exposure, however, was somewhat underestimated. In Table 4 the simulated pharma-
cokinetic parameters are compared with the observed parameters from several studies.
[22,39] Pharmacokinetic parameter values as well as their decrease during pregnancy 
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Figure 7. Linear (A) and semi-logarithmic (B) plasma concentration-time curves for a single oral dose of darunavir 
(600mg) either after 2 days pre-treatment and in combination with 100 mg ritonavir twice daily (black), or as a single 
oral dose of 600 mg darunavir alone (grey). A permeability-limited liver model was simulated, with combined influx and 
efflux processes taking place, both at a clearance rate of 100 µl/min/million cells. For the SD darunavir/r simulations, 
response of the model to varying percentages of biliary excreted unchanged drug available for enteric re-absorption are in-
dicated (reflecting a maximum degree of enteric hepatic recirculation possible). The closed circles represent the observed 
concentrations.[19]
Figure 8. Scatter plot representing the AUC and Cmax from 
simulated and clinical darunavir/r trials at steady-state. 
For the 600/100mg darunavir/r twice-daily dose two 
studies by Sekar et al.[31, 32] were used  and for the 
800/100mg darunavir/r once-daily dose results reported 
by Boffito et al.[33] and Kakuda et al.[34] were used. 
Dashed lines represent a two-fold difference from the ob-
served values. AUC: area under the plasma concentration-
time curve, Cmax: maximum concentration, DRV: darunavir.
Figure 9. Simulation of darunavir plasma concentrations at steady-state (14 days of treatment) after BID 600/100mg 
darunavir/r in (A) the third trimester of pregnancy (gestational week 36, n=11, age 20-35 years) and (B) postpartum/
non-pregnant (n=11, age 20-35 years). The closed circles represent the observed concentrations,[39] the solid line 
represents the simulated mean concentrations, the dashed lines represent the 95% confidence interval of the simulated 
concentrations.
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Reference 2nd trimester 3rd trimester postpartum
GM ratio 2nd/pp 
(90%CI)
GM ratio 3rd/pp 
(90%CI)
600/100mg darunavir/ritonavir BID
AUC (mg⋅h/L)
Zorrilla[39] 39 (SD 10) 44 (SD 16) 55 (SD 27) 0.76 (0.63-0.90) 0.83 (0.72-0.97)
Colbers[22]  41 (27-62) 53 (38-73)  0.78 (0.60-1.00)
simulation 34 (25-46) 34 (26-45) 47 (36-61) 0.73 (0.51-1.02) 0.73 (0.53-1.02)
Cmax (mg/L)
Zorrilla[39] 4.6 (SD 1.1) 5.1 (SD 0.5) 6.5 (SD 2.4) 0.72 (0.61-0.86) 0.81 (0.69-0.96)
Colbers[22]  5.0 (3.2-7.8) 6.5 (4.4-9.7)  0.76 (0.53-1.11)
simulation 4.7 (3.7-6.1) 4.6 (3.7-5.8) 6.6 (5.3-8.3) 0.71 (0.53-0.96) 0.70 (0.53-0.93)
800/100mg darunavir/ritonavir QD
AUC (mg⋅h/L)
Colbers[22]  53 (44-63) 76 (65-90)  0.67 (0.56-0.82)
simulation  29 (23-37) 49 (37-65)  0.59 (0.42-0.83)
Cmax (mg/L)
Colbers[22]  5.3 (4.5-6.2) 6.8 (5.9-7.8)  0.78 (0.65-0.95)
simulation  3.8 (3.3-4.5) 5.9 (4.7-7.5)  0.65 (0.51-0.82)
Simulations increased doses, third trimester of pregnancy
dosing 
regimen AUC simulation
nonpregnant 
AUC BID
nonpregnant 
AUC QD
GM ratio 3rd/non-
pregn BID (90%CI)
GM ratio 3rd/non-
pregn QD (90%CI)
800/100mg 
BID
44 (33-58) 47 (36-61)  0.93 (0.67-1.29)  
900/100mg 
BID
50 (38-66) 47 (36-61)  1.05 (0.76-1.47)  
600/100mg 
BID*2
69 (53-90)  49 (37-65)  1.41 (1.00-1.98)
900/100mg 
QD
39 (30-51)  49 (37-65)  0.80 (0.57-1.12)
Table 4. Darunavir pharmacokinetic parameters in pregnancy: simulated versus observed
600/100mg AUC0-12h*2 to compare the AUC to an AUC0-24h. GM, geometric mean; 2nd, second trimester of pregnancy; 3rd, 
third trimester of pregnancy; pp, postpartum; CI, confidence interval; BID, twice daily; AUC, area under the curve; Cmax, 
maximum concentration; SD, standard deviation; QD, once daily.
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Figure 10. Simulation of darunavir plasma concentrations at steady-state, after 14 days of treatment with QD 
800/100mg darunavir/r in (A) the third trimester of pregnancy (gestational week 34, n=16, age 20-44 years) and 
(B) postpartum/non-pregnant (n=8, age 20-44 years). The closed circles represent the observed concentrations,[22] the 
solid line represents the simulated mean concentrations, the dashed lines represent the 95% confidence interval of the 
simulated concentrations.
Figure 11. Physiological parameters compared for healthy (non HIV) and HIV-infected pregnant women (HIV+). Data 
represent mean ± SD per week of gestation for healthy women as reported[10] and HIV-infected women (from the PANNA 
network). *indicate a significant difference between HIV-infected and not infected women (unrelated samples t-test).
0 10 20 30 40 50
0.25
0.30
0.35
0.40
0.45
0.50
hematocrit non HIV
hematocrit HIV+
* * *
*
* *
Weeks of gestation
He
ma
toc
rit 
(L
/L
)
A B
0 10 20 30 40 50
0
20
40
60
80
100
creatinine non HIV
creatinine HIV+
*
**
Weeks of gestation
se
rum
 cr
ea
tin
ine
 (m
icr
om
ol/
L)
C
0 10 20 30 40 50
20
30
40
50
60
albumin non HIV
albumin HIV+
*
* * *
Weeks of gestation
Alb
um
in 
(g
/L
)
D
0 10 20 30 40 50
0.0
0.2
0.4
0.6
0.8
1.0
AAG non HIV
AAG HIV+
Weeks of gestation
AA
G 
(g
/L
800/100mg DRV/r QD third trimester
0 4 8 12 16 20 24
0
2
4
6
8
10
12
Time (h)
Da
run
av
ir p
las
ma
 co
nc
. (
mg
/L
)
A
800/100mg DRV/r QD postpartum
0 4 8 12 16 20 25
0
2
4
6
8
10
12
Time (h)
Da
run
av
ir p
las
ma
 co
nc
. (
mg
/L
)
B
177PBPK modelling of darunavir/r pharmacokinetics in pregnancy
were predicted well for both dosing regimens, and remain within a factor two from 
the observed values. The decrease of AUC in the second and third trimester for the 
600/100mg darunavir/r twice- daily dose was predicted to be 27% (ratio of 0.73) 
versus 24% (ratio 0.76) observed in the second trimester and 27% (ratios of 0.73) 
predicted versus 17-22% observed in the third trimester. For the 800/100mg daruna-
vir/r once-daily dose, a decrease in AUC of 41% was predicted, versus an observed 
decrease of 33% in the third trimester. 
Also the simulations with increased dosages are described in this table. The 600/100mg 
darunavir/r twice-daily dose in the third trimester of pregnancy is expected to result 
in a total daily exposure compensating (even overcompensating) for the decrease 
in exposure during pregnancy with the 800/100mg once-daily dose. A dose of 
900/100mg darunavir/r once daily did not compensate for the decrease in exposure 
of the 800/100mg darunavir/r once-daily dose, as still a 20% lower exposure was 
observed compared with the non-pregnant situation (Table 4). A dose of 800/100mg 
darunavir/r twice daily was predicted to compensate for the decreased exposure during 
pregnancy for the twice daily regimen, and a dose of 900/100mg darunavir/r twice 
daily was expected to overcompensate the decreased exposure (see Table 4).
Physiological parameters in the Simcyp virtual population library versus a real-life 
HIV-infected pregnant population
In Figure 11 the data on hematocrit, serum creatinine, albumin and alpha-1-acid glyco-
protein concentrations were compared between HIV-infected pregnant women included 
in the PANNA study and the summary of Abduljalil that describes the parameters 
used for the Simcyp p-PBPK model.[10] Hematocrit was 15% lower in weeks 36-39 of 
gestation in healthy pregnant women and decreased with 11% in HIV-infected pregnant 
women. Albumin concentrations decreased with 18% for both populations. Serum creat-
inine concentrations were approximately 18% lower at the end of pregnancy in healthy 
pregnant women, and for the HIV-infected pregnant population the serum creatinine 
concentration was 40% lower at the end of pregnancy compared with the postpartum 
period. However, alpha-1-acid glycoprotein levels, the main darunavir binding protein 
in plasma, did not differ between the two populations. Updating the Simcyp model 
with indicated parameters did also not significantly alter simulation outcomes (data not 
shown).
Discussion
In this study, we developed and evaluated a mechanistic model to predict darunavir 
exposure, both in non-pregnant as well as pregnant women. Particularly, these efforts 
also focussed on elucidating the availability of crucial mechanistic in vitro pharmaco-
kinetic parameters that need to be incorporated in such a model. Recently, Siccardi et 
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al. published a paper on the simulation of the pharmacokinetics of several antiretrovirals 
with anti-depressant drugs.[40] The pharmacokinetics of darunavir/r were also briefly 
described in terms of a PBPK model, which only included CYP3A4-mediated metabo-
lism as a clearance mechanism. Interestingly, a literature search (Table 1) revealed that 
darunavir pharmacokinetics are likely to be also subject to P-gp mediated transport. 
Various in vitro studies demonstrated an altered disposition of darunavir during co-ad-
ministration or co-incubation with P-gp inhibitors, one of which is ritonavir, the drug 
commonly used to boost darunavir exposure in vivo.[17] Moreover, there is also a possible 
involvement of active hepatocellular uptake in the disposition of darunavir. At least in 
the rat, high concentrations of darunavir were found in the liver.[41] This would be in line 
with active hepatic uptake, while also from in vitro studies it is known that darunavir can 
interact with OATPs.[28] Therefore, we argued that an accurate PBPK model describing 
darunavir/r should at least take into account these active transport processes. 
An accurate determination of metabolic clearance forms the basis of our conclusion that 
uptake and efflux transporters are indeed crucial to describe darunavir pharmacokinetic 
mechanistically. Therefore, we first conducted extensive studies on in vitro metabolic 
darunavir clearance. The values we found were in the same order of magnitude as the 
data described by Mamidi et al.,[42] viz. a Km and Vmax of 3.1 µM and 458 pmol.mg
-1.
min-1, respectively. Our in vitro studies yielded similar metabolic intrinsic in vitro clear-
ances, i.e. 164 versus 147 µl.mg-1.min-1 by Mamidi et al. Using the baculosomal data 
for exposure simulation with the well-stirred liver model indeed led to similar results as 
obtained with our HLM data and the preliminary HLM data described by Mamidi et al..
[42] The consistent overestimation of exposure further underlined the need to include drug 
transporters. That Siccardi et al. were able to describe darunavir kinetics with only a 
metabolic clearance step, may be partly explained by the higher CYP3A4 CLint, met  they 
used of 3.25 µl.min-1.pmol-1 vs 2.25 µl.min-1.pmol-1 in our study.
Initial (well-stirred liver) model performance could indeed be improved when uptake 
and efflux transport mechanisms were included against the background of a perme-
ability-limited liver model. Quantitative transport kinetic data for darunavir is missing, 
but what is crucial in our findings is that simulation outcome improved with CLint,T values 
in the range of what is found to be pharmacologically feasible for other transport sub-
strates.[43, 44] Nevertheless, our findings now urge for more detailed, quantitative studies 
on darunavir transport kinetics in cultures of hepatocytes or overexpression systems, in 
order to validate whether CLint,T, uptake and CLint,T ,efflux values are in line with the values 
that we propose in our simulations.  These studies should also include measurements on 
membrane transporter abundance to allow accurate in vitro–in vivo extrapolations (IVIVE) 
of this aspect. As in vivo abundance of several hepatic transporters have already been 
reported in literature,[45] it is of particular relevance that new studies on the transporter 
kinetics of darunavir should also include quantification of absolute transporter expression 
in the in vitro incubation systems.
Figure 7 depicts the simulation of exposure following a single dose of darunavir alone 
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or single dose of darunavir combined with ritonavir. The boosting effect of ritonavir 
could be adequately simulated if efficient enterohepatic recycling was assumed, i.e. 
when 80-100% of the darunavir that was excreted unchanged via the bile was set to 
be available for enteric re-absorption. Enterohepatic circulation of darunavir has been 
suggested previously[46] but to our knowledge we are the first to capture this in a mech-
anistic model.  However, for the unboosted darunavir dose, it was not necessary to 
include an efficient enterohepatic cycling step to adequately simulate exposure. In fact, 
upon including this process, this resulted in a slightly over-predicted exposure. This raises 
a mechanistic question, as it seems likely that the majority of unchanged darunavir 
excreted into bile should in principle be readily available for reabsorption. Indeed, 
biliary excreted darunavir enters the intestine in an already solubilised, highly micellar 
state, irrespective of ritonavir co-administration.
An alternative explanation may be that this discrepancy results from non-linearity in in-
testinal absorption of darunavir. At high concentrations, e.g. after ingestion of a tablet, 
efflux at the level of the intestine may be less likely to occur as a result of P-gp satura-
tion, resulting in a higher intestinal permeability. At the relatively low concentrations of 
darunavir that reach the intestine via the bile, only a limited amount may permeate the 
intestinal epithelium as it could be actively excreted back into the intestinal lumen by P-gp 
again. This would explain why modelling with an inefficient enterohepatic cycling step 
provides a better fit to the clinical data obtained for administration of darunavir alone. In 
the presence of ritonavir, however, P-gp efflux is inhibited, and therefore efficient entero-
hepatic cycling takes place. Hence, it seems likely that linearity holds over a wider con-
centration range enabling an efficient enterohepatic circulation. We took into account 
the effect of ritonavir on absorption (see Table 1, Caco-2 absorption data). However, to 
our knowledge permeability data for darunavir in absence of ritonavir were assessed 
only at high concentrations, which did not allow us to correct for possible concentration 
dependency of absorption. Inclusion of transporters on a mechanistic level and addi-
tional measurements in Caco-2 cells covering a wider concentration range may reveal 
whether this effect indeed takes place.
A limitation of the ritonavir model is that physiological changes in pregnancy did not 
affect the ritonavir concentrations in the current model, whereas in real-life this is the case.
[22, 39] We compensated for this in our simulations by adjusting the oral ritonavir clearance 
used for simulations in non-pregnant individuals to reported values during pregnancy. In 
general a 50% decrease in ritonavir exposure is described in pregnancy, which could 
lead to less boosting of the co-administered protease inhibitor.[22,47] However, clinical 
studies demonstrated that also a 50mg ritonavir dose boosted darunavir almost as pow-
erfully as the 100mg dose.[48] Therefore, we found this aspect not crucial for our current 
simulation study and did not write a full mechanistic ritonavir PBPK model based on in 
vitro metabolic clearance parameters. Future studies may address this in more detail.
As can be seen in Figures 10 and 11, particularly for 800/100mg darunavir/r once 
daily, the model over-predicted the elimination rate. We hypothesize that a possible 
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explanation for discrepancies between the observed and simulated data is that the 
Simcyp pregnancy PBPK model is based on physiological changes described for 
‘healthy’ pregnant women, whereas the pregnancy pharmacokinetic curves we used 
were taken from HIV-infected pregnant women. To determine whether these populations 
are different, we compared physiological parameters (hematocrit, albumin, serum creati-
nine and AAG) included in the Simcyp model with parameters collected in the PANNA 
study. Although the hematocrit and albumin concentrations were lower in the HIV-infected 
women, the effect of pregnancy was similar for both physiological parameters. Slightly, 
but significantly lower hematocrit, albumin and creatinine concentrations were observed 
for HIV-infected women, both in pregnancy and in non-pregnant state (postpartum for 
the PANNA study). Anaemia, with decreased hematocrit, is common in HIV-infected 
patients, as a result of the disease, or possibly caused by certain antiretroviral agents.[49] 
Albumin concentrations are known to be lower in HIV-infected patients, but also known 
to increase again after initiation of antiretroviral treatment (32mg/L pretreatment, increas-
ing to 37.7mg/L)[50], which is in line with the serum albumin concentrations we found in 
the women on antiretroviral treatment. Decreased serum creatinine concentration at the 
end of pregnancy, pointing to possible increased GFR, is relevant for renally excreted 
drugs. However, for darunavir/r we do not expect an effect, as renal clearance is very 
low. Renal impairment is not expected to influence darunavir clearance.[41] Nevertheless, 
our findings are important for mechanistic pharmacokinetic modelling on other drugs, 
which are excreted renally, have high albumin binding, or exhibit high distribution into 
red blood cells.
Finally, we used the pregnancy PBPK model to predict which alternative dose levels 
may compensate for the decreased exposure observed in pregnancy. It is, however, 
questionable whether it is necessary to increase the dose during pregnancy. As lower 
exposure could not be correlated to virological failure in the PANNA study, the conclu-
sion was that antiretroviral naive pregnant patients, who are adherent, take darunavir 
with food and are not using concomitant medication reducing darunavir concentrations, 
the darunavir/r 800/100mg once daily is adequate. For all other patients, darunavir/r 
600/100mg twice daily is recommended during pregnancy.[22] However, in certain 
cases, our prediction using the PBPK model will be helpful in choosing the most optimal 
dose. We expect a twice-daily 900/100mg darunavir/r dose to generate higher 
exposure. Both alternative dosages (800/100mg twice daily and 900/100mg twice 
daily) are being tested in a P1026 protocol by the IMPAACT group.[51]
Conclusion
A PBPK model that takes hepatic transporter action and entero-hepatic circulation into 
account could adequately simulate darunavir/r pharmacokinetics for several dosage 
regimens and patient populations. To improve the mechanistic basis of the model, we 
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propose that future studies address hepatic, but also intestinal transporter-mediated 
darunavir disposition in more detail. The current model predicted decreased exposure 
during pregnancy to be compensated by the 600/100mg darunavir/r twice daily 
dosing for a woman who initially took the 800/100mg darunavir/r once-daily dose. 
For the 600/100mg twice-daily dose (used in treatment-experienced patients) the 
reduction in exposure can be compensated by a 800/100mg darunavir/r twice-daily 
dosing regimen.
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General discussion
HIV-infected women should use antiretrovirals during pregnancy to prevent the trans-
mission of the virus from the mother to the child. The knowledge of pharmacokinetic 
behaviour of antiretrovirals in pregnancy is very limited. With the results described in this 
thesis, mainly generated by the PANNA network, we have enlarged the knowledge 
about the pharmacokinetic alterations in pregnancy for a selection of antiretrovirals. This 
is important information when selecting the optimal treatment and dosing regimen for 
pregnant HIV-infected women. The results of the PANNA study, reported in the public 
domain, have been incorporated in two clinical guidelines for the treatment of HIV-in-
fected pregnant women: perinatal guidelines of the Department of Health and Human 
Services (DHHS) and the British HIV Association.[1,2] This confirms the importance of 
these pharmacokinetic data coming available for treating physicians.
The impact of pharmacokinetic changes in pregnancy and the clinical consequences
In the PANNA study an approximate 25% decrease in exposure (AUC) was observed 
in the third trimester of pregnancy for most antiretrovirals studied: tenofovir DF (23%), 
emtricitabine (25%), atazanavir (34%), darunavir (22-33%), saquinavir (14%), maraviroc 
(28%) and rilpivirine (30-40%, two cases only). For the booster ritonavir an even more 
dramatic decrease of 50% was observed, independent of the protease inhibitor used 
concomitantly: approximately 43% decrease in AUC with saquinavir; 55% decrease 
with atazanavir and a 26% and 41% decrease for the twice-daily regimen and the 
once-daily darunavir regimen respectively. For raltegravir lower exposure in pregnancy 
was observed but this was less clear, due to the substantial inter- and intra-person 
variation of raltegravir pharmacokinetic parameters.
Table 1a and 1b show an overview of geometric mean ratios of the pharmacokinetic 
parameters and the 90% confidence interval comparing the third trimester’s situation with 
the postpartum situation, extracted from studies from the PANNA network and presented 
in this thesis. If a minimal therapeutic concentration is defined, the number of patients (%) 
with concentrations below this target is reported. Additionally the conclusions drawn in 
the separate papers are summarised in this table.
Lower AUCtau and Cmax were observed for all compounds during pregnancy, with 90% 
confidence intervals of the geometric mean ratio not including 1 for most compounds. 
This indicates that most women have a lower exposure during pregnancy, compared 
with the postpartum (control) situation. For most antiretrovirals described here the half-life 
was not affected by pregnancy: the geometric mean ratio was approximately 1. For 
atazanavir/ritonavir 300/100mg once daily and darunavir/ritonavir 800/100mg 
once daily and rilpivirine the half-life was shorter in the pregnant situation by 13-41%.
The minimum plasma concentration (Ctrough, or Clast), the parameter mostly used for 
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Table 1a. Overview of pharmacokinetic changes of antiretrovirals in pregnancy (summary of data presented in this 
thesis) 
Parameter chapter GMR (90%CI) Study conclusion
third trimester/postpartum
Nucleoside/Nucleotide reverse transcriptase inhibitors
Emtricitabine 200mg QD 6 n=24
AUC0-tau 0.75 (0.68-0.82) Although pharmacokinetic exposure of 
the NRTIs TDF and FTC during pregnancy 
is approximately 25% lower, this was 
not associated with virological failure in 
this study and did not result in MTCT.
No dose adaptation recommended.
Cmax 0.87 (0.77-0.99)
Cpredose 0.57 (0.44-0.73)
Ctrough 0.77 (0.52-1.12)
Thalf 1.05 (0.91-1.21)
CLss/F 1.34 (1.22-1.47)
Vd/F 1.40 (1.28-1.53)
n (%)<ther. threshold NA
Tenofovir 245mg QD 6 n=27
AUC0-tau 0.77 (0.71-0.83)
Cmax 0.81 (0.74-0.89)
Cpredose 0.81 (0.68-0.96)
Ctrough 0.79 (0.70-0.90)
Thalf 1.00 (0.87-1.15)
CLss/F 1.3 (1.20-1.40)
Vd/F 1.30 (1.12-1.51)
n (%)<ther. threshold NA
Protease Inhibitors
Saquinavir/r 1000/100mg 
BID
3 n=9 (paired data) The standard dose of 1000/100mg BID 
tablet regimen can be recommended 
in pregnancy. This treatment generates 
adequate levels throughout pregnan-
cyand has a solid safety and efficacy 
profile.
AUC0-tau 0.86 (0.50-1.48)
Cmax 0.81 (0.48-1.35)
Ctrough 1.64 (0.56-1.97)
Thalf 1.05 (0.80-1.39)
CLss/F 1.13 (0.65-1.95)
n (%)<ther. threshold 0.1 
mg/L
none
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Table 1a. - continued Overview of pharmacokinetic changes of antiretrovirals in pregnancy (summary of data presented 
in this thesis) 
Parameter chapter GMR (90%CI) Study conclusion
third trimester/postpartum
Atazanavir/r 300/100mg QD 4 n=26 (incl 1 patient 
400/100mg QD)
Despite 34% lower atazanavir exposure 
during pregnancy, atazanavir/ritonavir 
300/100mg once daily generates 
effective concentrations for PI-naive 
patients, even if co-administered with 
TDF. For treatment experienced patients 
(with relevant PI resistance mutations) 
TDM of atazanavir should be considered 
to adapt the atazanavir/ritonavir dose 
on an individual basis.
AUC0-24h 0.66 (0.57-0.75)
Cmax 0.70 (0.61-0.80)
C24h 0.59 (0.48-0.72)
Thalf 0.87 (0.76-1.00)
CLss/F 1.53 (1.34-1.75)
Vd/F 1.15 (0.85-1.56)
n (%)<ther. threshold 0.15 
mg/L
none
Darunavir/r 600/100mg BID 5 n=5 For antiretroviral-naive patients, who are 
adherent, take darunavir with food and 
are not using concomitant medication 
reducing darunavir concentrations, 
800/100 mg of darunavir/ritonavir 
once daily is adequate in pregnancy. 
For all other patiënt 600/100 mg of 
darunavir/ritonavir twice daily is recom-
mended during pregnancy.
AUC0-12h 0.78 (0.60-1.00)
Cmax 0.76 (0.53-1.11)
Cpredose 0.82 (0.70-0.96)
C12h 0.89 (0.58-1.36)
Thalf 1.12 (0.79-1.59)
CLss/F 1.28 (1.00-1.66)
Vd/F 1.43 (1.11-1.84)
n (%)<ther. threshold 0.55 
mg/L
none
Darunavir/r 800/100mg QD 5 n=9 (including 1 patient using 
600/100mg QD)
AUC0-24h 0.67 (0.56-0.82)
Cmax 0.78 (0.65-0.95)
Cpredose 0.77 (0.54-1.10)
C24h 0.58 (0.44-0.78)
thalf  0.59 (0.40-0.87)
CLss/F 1.50 (1.24-1.81)
Vd/F 0.76 (0.47-1.23)
n (%)<ther. threshold 0.55 
mg/L resistant virus
1 (8%) in third trimester
n (%)<ther. threshold 0.055 
mg/L wild type
none
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Parameter chapter GMR (90%CI) Study conclusion
third trimester/postpartum
Integrase inhibitor
Raltegravir 400mg BID 7 n=17 The pharmacokinetics of raltegravir sho-
wed extensive variability. The observed 
mean decrease in exposure toraltegravir 
during third trimester compared to 
postpartum is not considered to be of 
clinical importance. Raltegravir can be 
used in standard dosages in HIV-infected 
pregnant women.
AUC0-12h 0.71 (0.53-0.96)
Cmax 0.82 (0.55-1.23)
C12h 0.64 (0.34-1.22)
Thalf 1.04 (0.73-1.47)
CLss/F 1.41 (1.04-1.90)
V/F 1.24 (0.67-2.27)
n (%)<ther. threshold of 
0.020 mg/L 
1 (5%) in third trimester
Entry inhibitor
Maraviroc 8 n=15 While overall maraviroc exposure is 
28-30% lower during pregnancy, Ctrough 
was reduced to a lesser extent. All but 
one of our patients met the target 
trough concentration during pregnancy 
and virologic responses were good, 
suggesting that the standard adult dose 
seems to be sufficient in pregnancy.
AUCtau 0.72 (0.60-0.88)
Cmax 0.70 (0.58-0.85)
Clast 0.85 (0.72-1.01)
Thalf 1.04 (0.86-1.27)
CLss/F 1.31 (1.05-1.64)
V/F 1.39 (0.95-2.04)
n (%)<ther. threshold of 50 
ng/mL
1 in third trimester and post-
partum (300mg BID regimen 
without PI)
Non-Nucleoside reverse transcriptase inhibitors
Rilpivirine case 1 case 2 More data regarding rilpvirine pharma-
cokinetics in pregnancy are needed. But, 
due to the large decrease in exposure 
in these two cases, TDM of rilpivirine in 
pregnancy is recommended.
AUCtau 0.70 0.57
Cmax 0.64 0.93
Clast 0.57 0.44
Thalf 0.70 0.69
n (%)<ther. threshold of 
0.040 mg/L
both cases
Table 1a. - continued Overview of pharmacokinetic changes of antiretrovirals in pregnancy (summary of data presented 
in this thesis) 
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TDM purposes (the lowest concentration during the dose interval, just before the next 
medication intake) was decreased in pregnancy for all compounds described, except 
for saquinavir. For saquinavir and atazanavir no Ctrough concentrations were observed 
below the advised therapeutic threshold. For darunavir one patient on the 800/100mg 
once-daily regimen showed a Ctrough below the threshold for treatment experienced 
patients, however the concentration was above the threshold for treatment-naive patients. 
The 800/100mg once daily dose is not recommended in patients with relevant protease 
inhibitor mutations. In that case the 600/100mg twice-daily dose should be given and 
in this group neither we, nor another group[3]  found values below this limit. One patient 
had a Ctrough below the target for raltegravir in the third trimester of pregnancy, at this visit 
she had a viral load of 74 copies/mL, which declined to undetectable at delivery. For 
maraviroc one patient had Ctrough concentrations below the target during pregnancy and 
Parameter chapter GMR (90%CI)
third trimester/postpartum
Ritonavir + saquinavir: twice daily 100mg 3 n=9
AUC0-tau 0.57 (0.39-0.82)
Cmax 0.61 (0.41-0.89)
Ctrough 0.88 (0.52-1.47)
CLss/F 1.64 (1.18-2.42)
Ritonavir + atazanavir: once daily 100mg 4 n=26
AUC0-tau 0.45 (0.37-0.53)
Cmax 0.42 (0.42-0.51)
Ctrough 0.47 (0.36-0.62)
Thalf 0.90 (0.78-1.04)
CLss/F 2.24 (1.88-2.68)
Ritonavir + darunavir: twice daily 100mg 5 n=5
AUC0-tau 0.74 (0.65-0.84)
Cmax 0.63 (0.53-0.76)
Ctrough 0.72 (0.56-0.92)
Thalf 1.17 (0.95-1.43)
CLss/F 1.35 (1.18-1.55)
Ritonavir + darunavir: twice daily 100mg 5 n=9
AUC0-tau 0.59 (0.42-0.83)
Cmax 0.59 (0.42-0.82)
Ctrough 0.72 (0.47-1.10)
Thalf 1.00 (0.75-1.33)
CLss/F 1.70 (1.20-2.41)
Table 1b. Overview of pharmacokinetic changes of ritonavir in pregnancy (summary of data presented in this thesis) 
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postpartum. She used the 300mg twice-daily dose without protease inhibitor, which 
in her case might result in sub-therapeutic exposure. Both women using rilpivirine in 
pregnancy showed Ctrough levels below the target, although we only described two 
cases, we would suggest that TDM should be performed during pregnancy for this 
compound.
Special attention should be given to the important decrease of ritonavir exposure during 
pregnancy (Table 1b). Ritonavir is used to increase the plasma concentrations of other 
protease inhibitors by its strong inhibition of Cytochrome P450 3A4. This decrease could 
result in a diminished boosting effect on the protease inhibitors and contribute to the 
lower exposure to these agents in pregnancy.
Taken together, these data suggest an overall trend of lower drug concentrations occurring 
during pregnancy, with a proportion of women having sub-therapeutic plasma con-
centrations, which occasionally was associated with suboptimal virological response. 
Fortunately, no MTCT was observed in the population studied. Another consequence 
of sub-therapeutic levels of antiretroviral agents in presence of the virus is development 
of resistance. The PANNA network was not designed to detect resistance in the period 
after delivery, this should be studied in larger groups of patients.
Possible mechanisms behind the pharmacokinetic alterations in pregnancy
The pregnancy induced physiological changes causing the lower exposure to antiretro-
virals seem most likely to be the increased plasma volume, decreased absorption, and 
increased hepatic clearance due to enzyme induction, or increased liver blood flow.
The increased blood volume (increases by 40–50% up till week 32 of pregnancy)[4] can 
result in lower Ctrough and Cmax, and a lower AUC, and higher volume of distribution.[5] 
This is in line with the Vd/F changes observed for most compounds, see Table 1. Also 
reduced absorption can lead to lower Cmax and AUC; we cannot confirm or rule out this 
mechanism. Further, we did not observe a shorter half-life for most compounds during 
pregnancy. The only compounds showing faster elimination were darunavir with the 
once-daily dosing regimen and rilpivirine (only 2 cases studied). The mechanism behind 
this faster metabolism/excretion can be by increased activity of CYP3A4. It is thought 
that this increased activity is regulated by progesterone activation of the pregnane X 
receptor (PXR) receptor, leading to upregulation of the CYP3A4 hepatic enzyme.[5] A 
reason for not being able to detect a difference in half-life for the other compounds is the 
fact that we cannot accurately determine the elimination half-life because of the limited 
sampling time after dosing. Within PANNA we collect information over a dosing interval 
only in the steady-state situation.
For the protease inhibitors, less boosting by ritonavir can also be considered as a con-
tributing factor. Ritonavir exposure dramatically decreases during pregnancy: the AUC is 
approximately 50% lower (see Table 1b). However, for the protease inhibitors described 
in this thesis a 50mg ritonavir dose boosts almost as powerfully as the 100mg dose. 
This was observed for darunavir,[6] 1,500/50mg versus 1,500/100mg saquinavir/r in 
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Thai individuals,[7] and 300/50mg atazanavir/r in healthy volunteers.[8]
Within PANNA two renally excreted drugs were studied: tenofovir and emtricitabine. 
Because it is known that renal clearance is increased during pregnancy,[4,5] this was 
explored in our study (chapter 6). The estimated creatinine clearance was increased 
during pregnancy by around 40%. Although possibly influencing the decreased 
exposure during pregnancy found in this study, this was not translated into shorter half-life 
of tenofovir and emtricitabine. The reason could also be the limited sampling period, 
due to which the terminal elimination half-life cannot be assessed accurately.
Another mechanism possibly changing pharmacokinetics is decreased protein binding 
in pregnancy. In the PANNA study albumin concentrations and alpha-1-acid glycopro-
tein (AAG) concentrations (if possible) were determined during pregnancy and postpar-
tum. In chapter 10 we summarize these findings. A decrease of approximately 18% for 
albumin concentrations was observed in pregnancy and a decrease of approximately 
32% for AAG (only limited number of observations). However, this did not result in higher 
free fraction of darunavir in pregnancy. The measured free fraction was 10% postpartum 
and 12% in the third trimester.
Role of therapeutic drug monitoring
It is recognized that a general dose of medication can result in variable levels of exposure 
in individual patients: some patients can experience toxicity because of high drug levels 
and for others the general dosage might be sub-therapeutic. By determining individual 
exposure in clinical practice (usually by collecting a blood sample just before the next 
dose of medication is taken), we are able to individualize treatment. This approach 
is called therapeutic drug monitoring (TDM). TDM can also play a role in assessing 
adherence to medication, when treatment fails. TDM is not recommended in all cases 
and for all drugs. Requirements for TDM to be useful are: listed in Table 2.[9]
Most antiretrovirals meet more than two of these criteria: 1, 2, 3, 5 and 7. In the 
management of HIV, TDM of antiretrovirals can, together with viral load measurement, 
Table 2. Requirements for therapeutic drug monitoring
Good relationship between concentration and clinical response
Good relationship between concentration and toxicity
Narrow therapeutic index
Poor relationship between dose and concentration
Significant pharmacokinetic variability
Difficulty in monitoring therapeutic effect
Available drug assay
196 Chapter 11
CD4 T-cell counts and genotyping for resistance, improve therapy. The advantage of 
combining TDM with clinical parameters is the possibility to adjust dosing, and hence 
exposure, early in treatment which may prevent or delay resistance development. Using 
viral load alone as marker for effective therapy has the disadvantage that drug resis-
tance may already have developed by the time HIV replication is observed.[10] For NRTIs 
TDM is not a useful tool, because the NRTIs are pro-drugs and the plasma concentra-
tions have not (yet) been correlated successfully to viral outcome. For protease inhibitors 
and NNRTIs this relation has been established, which results in minimal effective trough 
levels, as stated in treatment guidelines for adults.[11] These minimal concentrations are 
based on in vitro (IC50/IC95 adjusted for protein binding) and in vivo (EC50/EC95) 
literature data.
There is consensus that TDM should not be used for all patients on antiretroviral treatment. 
But it is indicated for some circumstances or patient groups with changes or variability in 
drug levels: when possibly pharmacokinetic interacting drugs are used; renal or hepatic 
insufficiency; gastrointestinal disturbances; less than recommended food intake; children; 
or pregnancy.
Pregnancy induces many physiological changes, influencing the absorption, distribu-
tion, metabolism and excretion of drugs, mostly leading to lower exposure to drugs 
in pregnancy.[4] These changes generate a great variability of pharmacokinetics 
in pregnant women, making prediction of individual alterations in pregnant patients 
difficult, which supports the use of TDM to avoid underdosing and subtherapeutic drug 
concentrations during pregnancy. A concern to address as well, is the fact that the phys-
iological changes evolve over gestation, so, changes in exposure, and dose adjustment 
requirements, could be different for the first, second or third trimester.
The use of TDM in pregnancy has been evaluated by several groups. Weinberg et al.[12] 
found that 44% of the patients in the study showed protease inhibitor concentrations 
below the target in the third trimester of pregnancy (mainly nelfinavir and lopinavir) and 
44% of the women had a viral load >50 copies/mL at delivery. However, there was 
no correlation between low virologic response and protease inhibitor concentrations 
below the target. Roustit et al. (antiretroviral treatment specific)[13] and Matsui (general)[9] 
reviewed the use and impact of the TDM in pregnancy. According to Matsui it is ques-
tionable whether the target concentrations derived from “non-pregnant” adults can be 
extrapolated to the pregnant population. For antiretroviral medication we believe that 
the target concentration is probably the same, as the concentrations required to inhibit 
viral enzymes/processes are not changed in the pregnant situation. A factor to take 
into account is the correction for protein binding applied to define the target concen-
tration. Because protein binding decreases in pregnancy, the target could possibly be 
lower. Roustit et al. conclude that despite the uncertainty of the clinical consequences of 
the lower exposure to several antiretrovirals, TDM for nevirapine, nelfinavir, saquinavir, 
indinavir and lopinavir is advisable. For atazanavir, TDM seems not to be necessary 
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and for the (in that period of time) newer antiretrovirals they conclude that more data 
are needed.[13] For two protease inhibitors: boosted lopinavir and boosted atazanavir 
dedicated papers were published where TDM in pregnancy has been investigated. 
Else et al.[14] showed that during pregnancy the number of patients with atazanavir 
levels below the target (0.15 mg/L, 6-8%) was similar to the number postpartum (7%). 
In this study 21% of the patients had a viral load >50 copies/mL in the third trimester 
of pregnancy. Low atazanavir exposure during pregnancy did not appear to be detri-
mental to virological control. They advise careful monitoring  during pregnancy, and to 
increase the dose from 300 to 400mg once daily if necessary.[14]
Lambert et al.[15] reported lopinavir TDM in 43 patients during pregnancy. Six (13%) 
patients had lopinavir concentrations below 1.0 mg/L, of which only one had a detect-
able viral load (209 copies/mL) during the third trimester of pregnancy. In total 39% of 
the patients showed a detectable viral load during pregnancy. Therefore, a correlation 
between subtherapeutic exposure and detectable viral load could not be concluded. A 
retrospective study performed in the UK on TDM of lopinavir in pregnancy in 73 women 
showed that as a result of TDM the dose was adjusted in 10% of the patients and 11% 
of the patients (with low lopinavir levels) had adherence reviews. However, also in this 
study, TDM was not associated with virological outcome. They conclude that TDM can 
play an important role in the clinical management of HIV-positive pregnant women.[16]
We have also performed a retrospective analysis on lopinavir TDM in pregnancy using 
the Athena cohort (The Netherlands)(unpublished data). Patients taking lopinavir for 
>4 weeks during pregnancy were selected from the Athena cohort (2004-2011). 243 
pregnant patients using lopinavir were included, 76% started lopinavir during pregnancy. 
153/243 (63%) had TDM during pregnancy (increasing from 26% in 2004 to approx-
imately 69% from 2006 onwards); a total of 300 evaluable lopinavir TDM samples 
were collected from 131 patients using lopinavir 400/100mg twice daily. The majority 
(71%) of samples was taken in the third trimester. 11/131 (8%) of the patients showed 
at least one sample below the target concentration for naive patients (1 mg/L), in 8 of 
these patients TDM was repeated resulting in therapeutic levels in 7/8 patients. In 1 of 
the 3 patients without repeat sample the lopinavir concentration was below detection 
limit, an indication for non-adherence. 47/243 (19%) of all patients had an HIV viral 
load >50 copies/mL at delivery. 2/11 (18%) of the patients with at least one sample 
below the target concentration for naive patients had a detectable viral load at delivery 
vs. 17/120 (14%) of patients with concentrations above the target (p=0.718), which is 
in line with the virological response reported by other groups. 
These data indicate that treating physicians in The Netherlands are aware of the 
possible effect of pregnancy on pharmacokinetics of protease inhibitors, because in 
63% of the cases TDM was performed. These data were not published, because we 
were confronted with possible errors in the data when we investigated the actions taken 
in case of sub-therapeutic levels in a pregnant woman. We found that in most cases the 
lopinavir dose had not been increased, which was not consistent with the information 
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the treating physician had on file. This shows that it is important to be cautious using 
cohort data when the number of patients to draw conclusions from is very low. In this 
case it concerned 11 patients, with important consequences when one or two entries 
in the database are not correct, without judging the quality of the entire database. The 
reason for the discrepancy is usually not clear: lack of clarity of patient notes or error in 
data entry in the database.
Instead of performing TDM on an individual basis, which is not readily available for 
every hospital, another option would be to increase the dose for all patients during 
pregnancy for certain compounds. Increased doses in pregnancy have been explored 
for lopinavir/r (500/133 mg twice daily and 600/150 mg twice daily[17-20] and ataza-
navir/r (also because it is frequently given with tenofovir, possibly reducing atazana-
vir exposure).[21] An increased dose of 600/150 mg lopinavir/r compensates for the 
lower exposure during pregnancy.[18,20] A randomized trial studied safety and efficacy of 
lopinavir/r 600/150 mg twice daily compared with 400/100 mg twice daily.[19] No 
difference in virological response (viral load at delivery) for women with a baseline viral 
load<50 copies/mL was observed, but the viral suppression of the increased dose was 
better in patients with a higher baseline viral load. Maternal adverse effects were not 
more prominent in the higher dose, nor preterm births or lower birth weight.
The high dose atazanavir/ritonavir of 400/100 mg once daily compensated for the 
exposure loss during pregnancy in the third trimester and should be considered during 
the second trimester, especially if given in combination with tenofovir.[21]
The number of studies (and the number of patients in the studies) is low. In addition, it 
is prudent to avoid higher doses than necessary as foetal drug exposure is related to 
maternal concentration. Therefore, if TDM is available, TDM during pregnancy seems a 
better option in case of doubt.
TDM can be a tool to optimize the dose for an individual pregnant patient; however, 
for most antiretroviral agents it seems not necessary to perform standard TDM during 
pregnancy. For the compounds investigated in this thesis we suggest that TDM during 
pregnancy can help to optimize treatment of HIV-infected women during pregnancy 
for atazanavir (for treatment-experienced patients) and rilpivirine (because we do not 
know much about this compound and the first results were consistent and made us alert). 
Another antiretroviral agent for which TDM adds to the treatment of pregnant HIV-infect-
ed women is lopinavir, because during pregnancy 13-44% of the women experience 
subtherapeutic levels. Although this has not been correlated to virologic failure or mother-
to-child transmission of the virus, it seems safe to perform TDM in the second and third 
trimester of pregnancy and increase the dose if necessary.
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Detectable viral load and exposure to antiretrovirals
The decrease in exposure to antiretrovirals observed in our studies was not very large 
and, more importantly, could not be linked to virological failure in our study. Most patients 
had therapeutic levels during pregnancy except for four patients: one on darunavir, one 
on maraviroc and two on rilpivirine. Despite the overall achievement of therapeutic drug 
concentrations, a considerable percentage of the women had a detectable viral load 
at, or around delivery (in the PANNA study approximately 20-25%), see Table 3 for a 
summary.
The percentage of women with detectable viral load (>50 copies/mL) at or around 
delivery despite cART use is in line with what has been reported by other groups.[22-26]
A large American cohort study reported 13% of cART naive women at conception 
(pregnancy start) to have a detectable viral load (>400 copies/mL) at delivery. They 
found the following factors to be related: timing of cART initiation and consistent use 
during pregnancy. Approximately 24% of the women starting cART in the third trimester 
had a detectable viral load at delivery. Also social factors, as ethnicity and education, 
Table 3. Viral load around delivery
VL detectable around 
delivery
Viral load Median GA Relation with ARV exposure
Saquinavir
1000/100 mg BID
1/30 (3%) 189 copies/mL Around 
delivery
SQV Cmin: 0.781 mg/L at 
33 weeks
Atazanavir 6/31 (19%) 68, 100, 120, 162, 
290 and 402
34 weeks 
(median)
No stat significant difference
Tenofovir DF/
emtricitabine
7 (21%) /<200: 1 (3%) 72-272 copies/mL 34 weeks 
(median)
Comparable tenofovir and 
emtricitabine exposure as 
patients with undet VL
Darunavir 7/21 (29%) 3/6 BID: 242, 272 
and 1610 copies/
mL; 4/18 on QD 74, 
121, 144 and 28711 
copies/mL
35 weeks 
(median)
2 non-adherent patients; for 
QD regimen no relation/BID 
maybe lower
Raltegravir 3/22 (14%) 144, 242, 290 
copies/mL
35 weeks 
(median)
All had adequate C12h levels 
in third trimester
Rilpivirine 1/2 (50%) VL 77 copies/mL 36 weeks and 
5 days
C0h at 32 weeks 0.04 mg/L
Maraviroc 4/17 (24%) <400: 2 (18%)
These entries may contain the same patients, as these are data from the PANNA study and patients could use more 
than one compound of the described ARVs.
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were associated with a detectable viral load at delivery.[25] Read et al.[27] found a 
detectable viral load (>50 copies/mL) around delivery in 23% of the women, who 
were treatment naive at pregnancy start. Starting treatment early was associated with 
successful treatment especially when pre-treatment RNA viral load was above 10,000 
copies/mL.
A cohort study of the UK and Ireland showed that 20% of the cART treated pregnant 
women had a detectable viral load at delivery (>50 copies/mL) in the period 2007-2011.
[23] They found a mother-to-child transmission rate of 0.1% for women with viral loads of 
less than 50 copies/mL around delivery, whereas the rate was 1.2% among women with 
viral loads between 51 and 999 copies/mL. This stresses the importance of achieving 
an undetectable viral load around delivery. Furthermore they found a steep decrease 
in mother-to-child transmission probability with each additional week of cART, up till 15 
weeks of cART use during pregnancy. This decrease was more marked for patients with 
a higher baseline viral load > 30,000 copies/mL.
In 2008 a French group published the results from their cohort. They found an overall 
MTCT rate of 1.3% for women on cART during pregnancy. The rate was 0.4% in term 
births and when maternal HIV RNA was below 50 copies/mL at delivery. The rate 
of mother-to-child transmission increased with viral load, short duration of antiretroviral 
therapy, female gender and severe premature delivery. The type of antiretroviral therapy 
was not associated with transmission.[26] An Italian cohort showed results in line with 
these data: 25% of the pregnant patients on cART had a detectable viral load (>50 
copies/mL) in the period 2010–2013, in this cohort no MTCT took place (n=169 preg-
nancies).[24]
The Monitoring Report 2013 of the HIV monitoring in The Netherlands reported a 
percentage of women with a detectable viral load around delivery between 14 and 
24 (between 2005 and 2011). They indicate that factors associated with a detectable 
viral load at delivery are: low CD4 T-cell counts and high HIV RNA levels at baseline. 
Women starting cART during pregnancy are more likely to have a detectable viral load 
around delivery than women who started cART before they became pregnant.[22]
Overall, the percentage of women with a detectable viral load around delivery is above 
10%, for patients in cART, which is suggested to be the aim of WHO target for 2020 
(90–90–90 - An ambitious treatment target to help end the AIDS epidemic, issued in 
2014).
The underlying mechanism for the relatively high percentage of women with a detect-
able viral load around delivery is still unclear. In the individual studies described in this 
thesis we could not relate lower exposure to the individual antiretrovirals to increased 
viral load. The number of patients in each article are low, but this number increases 
when we analyse the complete data-set within the PANNA study (n=125 now). It would 
also be possible to take into account whether patient were treatment-naive at start of 
pregnancy, or treatment-experienced, as well as initial viral load for the first group of 
patients.
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We plan to analyse the full PANNA dataset, possibly determining factors related to 
sub-optimal virologic response.
Placenta passage
The ability of the compounds to pass the placenta barrier was explored, this transport 
was quantified by relating the cord blood concentrations at delivery to the maternal 
plasma concentrations at the same time point. Cord blood/maternal ratios were 1.63 
for emtricitabine, 1.21 for raltegravir, 0.82 for tenofovir, 0.33 for maraviroc, 0.20 for 
atazanavir, and 0.15 for darunavir. This is in line with what has been reported in the 
recent review of Else et al.[28] For rilpivirine a ratio of 0.74 was observed, which was 
the first human in vivo information on placenta passage published in the public domain. 
See Figure 1 for an overview.
FTC 1.63
(0.46 − 1.82)
n=10
RAL 1.21
(1.13 − 4.53)
n=9
TDF 0.82
(0.64 − 1.10)
n=14
ATV 0.20 
(0.06 − 3.05)
n=12
DRV 0.13 
(0.08 − 0.35)
n=8
CORD BLOOD:MATERNAL BLOOD RATIO AT DELIVERY
Ratio = 1
Ratio = 0
Ratio = 1.75
RPV 0.74 
n=1
RTV < 0.05 
n=26
MVC 0.33 
(0.03 − 0.56)
n=10
Figure 1. Cord blood-maternal blood ratios
FTC = emtricitabine; RAL = raltegravir; TDF=tenofovir; RPV=rilpivirine; MVC=maraviroc; ATV=atazanavir; 
DRV=darunavir; RTV=ritonavir
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Ritonavir is the only compound investigated in this thesis which was not detectable in 
most cord blood samples. A total of 26 cord blood samples only 1 had a detectable 
ritonavir concentration, with a cord blood/maternal ratio of 0.05 (0.05mg/L in cord 
blood and 1.06mg/L in maternal blood). Twelve samples had ritonavir concentrations 
below the lower limit of quantification (LLOQ) with detectable maternal concentrations 
(ranging from 0.058-0.416mg/L) at the same time point. For the remaining 13 samples 
both cord blood and maternal samples were below LLOQ. Ritonavir seems hardly to 
reach the foetus during pregnancy. Overall, ritonavir is administered in a low dose 
(100mg) as a pharmacological booster. During pregnancy ritonavir exposure reduced 
2-fold; therefore, concentrations in the maternal circulation are low. From our data a 
ratio (CB/maternal blood) of 0.05 is suggested.[28] This very low placenta passage 
could be due to affinity to transporters such as P-gp, which transport compounds from 
the syncytiotrophoblast into the maternal circulation.[29] This finding is also in line with a 
human placental perfusion model, indicating that the clearance index of ritonavir was 
very low, with little accumulation in the foetal compartment and no accumulation in 
placental tissue.[30] Other groups also found transplacental passage of ritonavir (n=6) 
to be minimal.[31] On the other hand, in a study of plasma and hair drug concentration 
in 51 mother-infant pairs in Uganda receiving ritonavir-boosted-lopinavir-based therapy 
during pregnancy and breastfeeding, infant plasma levels at delivery and hair levels 
at age 12 weeks suggested in utero transfer of ritonavir: 2% of infants had detectable 
plasma ritonavir concentrations at birth and the mean infant-to-maternal-hair ritonavir 
concentration at 12 weeks postpartum was 0.47. However, transfer during breastfeed-
ing was not observed, with no infant having detectable ritonavir plasma levels at 12 
weeks.[32]
Knowledge of placenta transfer properties of antiretroviral drugs is important to be able 
to predict whether a drug will reach the foetus during pregnancy and possibly cause 
teratogenic effects. Then again, treatment guidelines recommend a cART regimen with at 
least one antiretroviral drug which passes the placenta, in order to protect the baby from 
infection with HIV. The highest chance of vertical transmission of the virus occurs during 
labour. When a child has antiretrovirals ‘on board’ at that time point, this minimizes the 
chance of infection. This approach has been translated to ‘adult’ pre-exposure prophy-
laxis (PrEP): HIV infection can be prevented in people who do not have HIV, but who are 
at substantial risk of infection, by taking tenofovir DF and emtricitabine combined in a pill 
every day. These medicines can work to keep the virus from establishing a permanent 
infection when someone is exposed to HIV through sex or injection drug use.
Because until now information regarding human placenta passage of drugs only comes 
available after the drug has reached the market, it would be convenient to be able to 
predict whether a new compound will possibly pass the placenta barrier. There are 
several possibilities, amongst which the placenta perfusion model. This model is currently 
being used by the department of pharmacology and toxicology of the Radboud uni-
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versity medical center in cooperation with our research group. The placenta transfer of 
antiretroviral compounds studied in PANNA is being tested. The results can be verified 
with the human in vivo results from PANNA. Because many aspects of the placenta 
barrier have to be taken into account, for example transporter abundance, activity and 
changes of activity over time of gestation, this is a field to be explored to support the 
development of an in silico model for the prediction of placental passage of drugs and 
foetal exposure.
The choice of an antiretroviral regimen in pregnancy, product 
information and guidelines
Factors to be considered when choosing a regimen for a pregnant HIV-infected woman 
include co-morbidities, convenience, adverse effects, drug interactions, resistance testing 
results, pharmacokinetics, and knowledge of safety for the mother and the child and 
experience with use in pregnancy.
Product characteristics of antiretrovirals are very conservative in most cases. In Table 
4 an overview is given of the recommendations on use in pregnancy of the different 
compounds. Only lamivudine, zidovudine and lopinavir are allowed to be used during 
pregnancy, tenofovir DF and atazanavir use may be considered and for nevirapine 
the recommendation is left for the treating doctor. For most compounds the product 
characteristics state that the medication should be used during pregnancy only if the 
potential benefit justifies the potential risk to the foetus. Furthermore, information con-
cerning pharmacokinetic changes in pregnancy is only mentioned for lamivudine (no 
change), zidovudine (no change), lopinavir (lower exposure, but not leading to adap-
tation of the dose), atazanavir (lower exposure, with dose increase for specific groups). 
Data extracted from the product information as published on the European Medicines 
Agency website.[33]
More information on treatment and dosing recommendations can be found in specific 
guidelines: WHO, EACS and DHHS.[1,34,35] The recommendations in these guidelines, 
however, differ.
The WHO guideline focuses on the low- and middle income settings. The guideline from 
2013 in which they recommend to test all pregnant women for HIV at the first antenatal 
visit included in the routine package, but also to repeat this test in the third trimester 
of pregnancy. The WHO guideline recommends that all pregnant and breastfeeding 
women with HIV should initiate triple ARVs (ART), which should be maintained at least 
for the duration of mother-to-child transmission risk. Women meeting treatment eligibility 
criteria (amongst others CD4 T cell count <500 cells/mm3) should continue lifelong ART. 
The first line regimen contains tenofovir DF/emtricitabine (or lamivudine) and efavirenz, 
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Table 4. SPC text recommendations for use in pregnancy
PK information Recommendation for use in pregnancy
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTI)
Abacavir No PK information Not recommended for use during pregnancy.
Didanosine No PK information Not recommended for use during pregnancy.
Emtricitabine No PK information Not usually used unless absolutely necessary.
Lamivudine PK in late pregnancy were similar 
to non-pregnant women
Benefit of PMTCT is greater than the risk of having side 
effects. Talk to your doctor about the risks and benefits.
Stavudine No PK information Not recommended for use during pregnancy.
Tenofovir No PK information The use of tenofovir disoproxil fumarate may be conside-
red during pregnancy, if necessary.
Zidovudine PK in late pregnancy were similar 
to non-pregnant women
Benefit of PMTCT is greater than the risk of having side 
effects. Talk to your doctor about the risks and benefits.
Non-nucleoside reverse transcriptase inhibitors (NNRTI)
Nevirapine No PK information Currently available data on pregnant women indicate no 
malformative or foeto/ neonatal toxicity.
Efavirenz No PK information Women should not get pregnant during treatment with 
Stocrin and for 12 weeks thereafter.
Etravirine No PK information Not recommended for use during pregnancy, unless 
specifically directed by the doctor.
Rilpivirine No PK information Not recommended for use during pregnancy, unless 
specifically directed by the doctor.
Protease inhibitors
Atazanavir Extensive PK information leading 
to dose recommendations
May be considered during pregnancy only if the potential 
benefit justifies the potential risk.
Fosamprenavir No PK information Not recommended for use during pregnancy.
Indinavir No PK information Not recommended in HIV-infected pregnant patients.
Darunavir No PK information PREZISTA co-administered with cobicistat or low dose rito-
navir should be used during pregnancy only if the potential 
benefit justifies the potential risk.
Lopinavir Extensive PK information, leading 
to dose recommendations
Lopinavir can be used during pregnancy if clinically 
needed. No dose adjustment is required, once daily dosing 
not recommended.
Saquinavir No PK information Only if the potential benefit justifies the potential risk to 
the foetus.
Tipranavir No PK information Only if the potential benefit justifies the potential risk to 
the foetus.
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also for pregnant women in the first trimester of pregnancy and women of childbearing 
age, the same regimen as for non-pregnant adults. There are some safety concerns about 
efavirenz: reproduction toxicology studies in primates suggested increased number of 
birth defects. Next to that, case reports and retrospective clinical data reported neural 
tube defects among humans,[36] which led to a concern about efavirenz use in the first 
trimester of pregnancy (or even in non-pregnant women of childbearing potential). The 
WHO issued a “technical update on treatment optimization concerning the use of 
efavirenz during pregnancy: a public health perspective”[37] comparing safety, toler-
ability, efficacy and costs of efavirenz treatment with nevirapine in pregnancy. In this 
document they conclude that efavirenz exposure in early pregnancy has not resulted 
in increased birth defects; new evidence suggests that efavirenz is clinically superior to 
nevirapine in terms of long-term viral suppression; the costs of efavirenz decreased and 
has as advantage that it is available in a once-daily fixed-dose combination tablet.[37] 
A recent systematic review and a meta-analysis (with data of 2026 pregnancies on 
efavirenz) did not find an increase in overall birth defects and no elevated birth defects 
for efavirenz compared with other ARV exposure in pregnancy[38] and a prevalence 
for neural tube defect of 0.05%, which is comparable to estimates of 0.02-0.2% in 
the general population in the USA. A study in Ugandan HIV-infected pregnant women 
Table 4. - continued SPC text recommendations for use in pregnancy
PK information Recommendation for use in pregnancy
Boosters, CYP3A4 inhibitors
Ritonavir No PK information Only if the potential benefit justifies the potential risk to 
the foetus.
Cobicistat No PK information Should not be used during pregnancy unless the clinical 
condition of the woman requires treatment with cobicistat 
co-administered with atazanavir or darunavir.
Integrase inhibitors
Dolutegravir No PK information Should be used during pregnancy only if the expected 
benefit justifies the potential risk to the foetus
Elvitegravir No PK information Should not be used during pregnancy unless the clinical 
condition of the woman requires treatment with elvite-
gravir.
Raltegravir No PK information Should not be used during pregnancy.
Entry inhibitors (CCR5 binding)
Maraviroc No PK information Should be used during pregnancy only if the potential 
benefit justifies the potential risk to the foetus.
Fusion inhibitors
Enfuvirtide No PK information Should be used during pregnancy only if the potential 
benefit justifies the potential risk to the foetus.
PK: pharmacokinetic
206 Chapter 11
compared lopinavir/r with efavirenz based cART.[39] They found that virologic suppres-
sion (HIV-1 RNA <400 copies/mL) at delivery was higher for efavirenz (98% versus 86%) 
and the women on efavirenz experienced less diarrhoea and nausea.[39]
Furthermore, neural tube defects are induced in the first 5-6 weeks of pregnancy and 
in most cases; the woman is unaware of her pregnancy at that timepoint. Although the 
WHO Guidelines Development Group emphasized that better data on birth defects are 
needed, it felt confident that this potential low risk should be balanced against the pro-
grammatic advantages and the clinical benefit of efavirenz in preventing HIV infection 
in infants and for the mother’s health. The need for monitoring of safety of efavirenz, 
emtricitabine and tenofovir in pregnancy, as these compounds are more widely used 
after implementation of the new WHO guidelines is stressed by experts in the field.[40] 
Pregnancy does not seem to change efavirenz exposure.[41]
EACS and DHHS guidelines still recommend avoidance of efavirenz use during con-
ception and early pregnancy. The EACS guideline recommends to start cART early in 
the second trimester with cART in the same regimen as non-pregnant patients for treat-
ment-naive HIV-infected pregnant women, but avoiding efavirenz in the first 8 weeks and 
not starting nevirapine (NVP) in pregnancy (continuation is possible). Preferred protease 
inhibitors are: lopinavir/r, atazanavir/r, saquinavir/r with an option to add raltegravir 
to the triple therapy if the viral load is not undetectable in the third trimester.[35] The 
DHHS guideline recommends 2 NRTIs and a boosted protease inhibitor or an NNRTI. 
They indicate preferable ARVs in all classes. Preferred NRTIs are: abacavir/lamivudine, 
tenofovir DF/emtricitabine or lamivudine, zidovudine/lamivudine; preferred protease 
inhibitor: atazanavir/r, lopinavir/r; preferred NNRTI: efavirenz, if started after week 8 
of gestation. Alternative ARVs are darunavir/r, saquinavir/r, nevirapine and raltegravir. 
The DHHS guidelines identify the alteration in pharmacokinetics as a factor to be con-
sidered when choosing a treatment regimen in pregnancy. They state that pharmacoki-
netic changes in pregnancy may lead to lower plasma levels of drugs and necessitate 
increased dosages, more frequent dosing, or boosting, especially of protease inhibitors.
[1]
For atazanavir and lopinavir, pharmacokinetic changes during pregnancy and the 
consequences thereof have been reported in the SPC text as well. For atazanavir 
these recommendations are in line with the recommendations given in the guidelines: 
unboosted atazanavir is not recommended during pregnancy.[1] Use of an increased 
dose (400/100mg atazanavir/r once daily with food) from the second trimester 
onwards results in plasma concentrations equivalent to those in non-pregnant adults 
on standard dosing. Although some experts recommend increased atazanavir dosing 
in all women during the second and third trimesters, the package insert recommends 
increased atazanavir dosing only for ARV-experienced pregnant women in the second 
and third trimesters also receiving either tenofovir DF or an H2-receptor antagonist. For 
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lopinavir, however, the label information states that pregnant women without docu-
mented lopinavir associated resistance mutations can use the 400/100mg lopinavir/r 
twice-daily dose during pregnancy and in the postpartum period. The DHHS guideline, 
in contrast, suggests to increase the dose to 600/150mg lopinavir/r twice daily from 
the second trimester onwards.[1]
Protease inhibitor based regimens were most frequently used during pregnancy from 
1996 onwards in the US.[42] Townsend et al.[23] reported 72% of the treatments during 
pregnancy to contain protease inhibitors, 23% to contain NNRTIs and 4% a combi-
nation of a protease inhibitor and an NNRTI, the remaining patients were on a triple 
NRTI regime. These data were collected between 2007 and 2011 in the UK and 
Ireland. D’Armnio Monforte et al. reported the actual ARVs used during pregnancy from 
1997-2013 in an Italian cohort. Lopinavir was the most popular protease inhibitor (28%), 
atazanavir the second with 16%. The most frequently used NNRTI was nevirapine 
(16%). Lamivudine and zidovudine were the most frequently used NRTIs (69% and 63% 
respectively), with tenofovir DF and emtricitabine as second combination (32 and 25%).
[24] Griner et al. reported that in 2009 boosted lopinavir was also the most frequently 
used protease inhibitor during pregnancy in the US.[42]
In summary: the treatment guidelines are not in line with each other concerning the 
preferred treatment of HIV-infected pregnant women. With respect to efavirenz use, 
they even contradict each other: WHO guidelines recommend this compound as first 
line; the guidelines used in the developed world recommend not to use efavirenz during 
conception and early pregnancy. Because of the possible teratogenicity and possible 
effects on brain development, which can only be detected on the long term in children 
exposed in utero, efavirenz does not seem to be the best choice for treatment during 
pregnancy when other options are available.
The DHHS and EACS guidelines are in line recommending boosted protease inhibitors, 
with the exception of saquinavir/r, which is not used very frequently. Applying dose 
increases for lopinavir and atazanavir is suggested by the DHHS guidelines, however, 
it remains questionable whether this should be done in every pregnancy, considering 
also the wide inter-subject variability and potential for an increase in maternal adverse 
events with some dose increases. If TDM is available, it is preferable to dose increase 
on an individual basis. The option of EACS to add raltegravir in late pregnancy in case 
of suboptimal virologic suppression seems a good idea, because in the prevention of 
mother-to-child transmission suppression of the virus in the mother is essential.
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Is there a need for regulatory guidelines for trials in pregnant 
women?
During the development process of a new drug generally pregnant women, and even 
women of childbearing potential, are excluded from clinical trials. The reasons for 
exclusion of pregnant women from clinical trials are primarily the safety concerns for both 
the mother and the foetus (possible teratogenicity). Institutional review boards are reticent 
to approve trials in pregnant women, for ethical reasons mentioned above. Other reasons 
mentioned include a lack of financial incentives for investigation in pregnant women and 
the absence of a mandate for such studies to be conducted prior to approval by the 
regulatory authorities.[43] Therefore, when a drug reaches the market, no information on 
safety or pharmacokinetics in pregnant women is available, nor whether the compound 
passes the placental barrier and reaches the foetus during pregnancy. It is regarded 
not to be ethical to expose pregnant women (and the unborn child) to new medication, 
as the consequences may be dramatic. However, when a drug reaches the market 
pregnant women might be exposed to the drug, without knowing the consequences. 
For this reason regulatory authorities require pharmaceutical industry to set up a registry 
collecting safety data of exposure to the drug during pregnancy.[44,45] Pharmacokinetic 
data in pregnancy are generally not collected by the pharmaceutical industry. Most post 
marketing studies investigating pharmacokinetic changes of drugs during pregnancy are 
set up by independent, academic groups. Two examples are the IMPAACT group and 
the PANNA network, on which data this thesis is based. An advantage for independent 
groups to study pharmacokinetics of for example antiretrovirals is that these groups can 
include “all” compounds in their study. The pharmaceutical industry is only interested 
in the compound they market, therefore, performing a study like this is (relatively) much 
more expensive for industry.
Voices rise for development of a regulatory guidance to perform pharmacokinetic 
and safety studies in pregnancy for compounds very probably going to be used in 
pregnancy.[43] The timing of such a study would be after completion of the reproductive 
toxicity studies, which could be planned earlier in the development of the drug. Another 
option to study the behaviour of the compound in pregnancy is to not exclude pregnant 
women from clinical studies. For example: if a woman becomes pregnant participating 
in a clinical trial with a new drug, at this moment they will drop-out immediately from 
the study and study drug is discontinued as soon as possible. The pregnancy and 
outcome will be followed-up for safety reasons. If a pharmaceutical company has a 
study protocol in place for collection of information in pregnancy (pharmacokinetics, 
efficacy, and safety) a woman could enter this study when she becomes pregnant. 
The ethical feasibility of this approach depends on the alternative medication available 
for the disease in question. But, if there is no alternative, this would be an option. 
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When deciding if performing studies in pregnant women is ethical, one should consider 
whether it is ethical NOT to perform studies in pregnant women when a drug will be 
used during pregnancy when it reaches the market.
Alternative options for extensive in vivo studies
Post marketing studies as described above are expensive to perform. It would be conve-
nient to be able to predict alterations in pharmacokinetics in pregnancy in a computer 
model.
Population pharmacokinetic models can help to predict exposure of pregnant women to 
antiretrovirals. Population pharmacokinetics identifies factors which can explain (correlate 
to) the variability in drug concentrations in the various individuals within the treated popu-
lation. Examples of the factors possibly correlated to the drug concentrations are: body 
weight, metabolic functions, plasma protein concentrations, disease, co-medication use 
or, in our case: pregnancy. To build such models, real life data are necessary, although 
the models can be developed using only sparse samples. The results from the PANNA 
study can be used to develop population pharmacokinetic models for different antiretro-
virals. The first model has been developed based on the data from PANNA and more 
models will be developed in the future. 
Figure 2. Pregnancy PBPK model (Simcyp)[46]
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An in silico model which does not necessarily need input from clinical studies is the 
physiologically-based-pharmacokinetic (PBPK) model. PBPK modelling is a mathematical 
technique to predict absorption, distribution, metabolism and excretion (ADME) of for 
example medication, based on physicochemical properties and in vitro biotransforma-
tion. The model consists of different compartments corresponding to the different organs 
and tissues, connected by blood or lymph flows. Recently, a PBPK model including 
physiological changes in relation to duration of pregnancy (pregnancy PBPK model) has 
been developed by Simcyp, see Figure 2.
The pregnancy PBPK model can be used to predict exposure to drugs during pregnancy 
at any gestational age, and eventually predict exposure of increased doses of medica-
tion, and indicate the gestational age at which a dose increase should be suggested. 
The foetoplacental unit (combination of foetus, placenta, amniotic fluid, membranes and 
umbilical cord) is included as a perfusion-limited compartment running in parallel with 
the other maternal compartments.
In chapter 10 we describe a first exploration of the pregnancy PBPK model (p-PBPK) 
with an antiretroviral drug, in this case darunavir/r. This model predicts the maternal 
exposure at steady state (including the interaction with ritonavir) fairly well. Both the 
AUC and Cmax in pregnancy and postpartum are comparable with the observed data 
and the decrease of exposure during pregnancy is predicted acceptably well. A major 
shortcoming of the available p-PBPK model is that the exposure of the foetus cannot 
be assessed. Furthermore, for the development of a valid model for a drug to be 
able to predict human exposure requires much in vitro data, often not published in the 
public domain, or published without some essential information needed for the model 
(protein concentrations in the matrix for example). Using a PBPK model can on the other 
hand help to determine gaps in the knowledge concerning the exact behaviour of a 
compound in the body.
We plan to develop PBPK models for other compounds for which data are available 
from the PANNA network and predict the exposure in pregnancy using the p-PBPK 
model. According to our knowledge the p-PBPK model has not yet (or not extensively) 
been validated for renally excreted compounds, or UGT substrates. Furthermore, we 
plan to expand the model with a valid placenta-foetal compartment, see the “placenta 
passage” section of this discussion.
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Conclusion, a personal perspective for treatment recommenda-
tions during pregnancy
The aim of this thesis was to describe pharmacokinetic alterations of antiretrovirals during 
pregnancy, and indicate efficacy, safety and cord blood/maternal ratios.
In the patients described in this thesis, despite some of them having sub-therapeutic 
drug concentrations, this, fortunately, did result in mother-to-child transmission of the virus. 
There are several factors to consider when a relationship between drug exposure and 
mother-to-child transmission is being made: women are treated with combination antiret-
roviral therapy, consisting of at least three compounds. This means that the compound 
measured in this study is not the only active antiretroviral drug used. Furthermore, in >50% 
of the cases delivery was done by caesarean section, which is known to decrease the 
chance of mother-to-child transmission.[47,48]
For most antiretrovirals reported in this thesis the exposure is approximately 25% lower 
during pregnancy. Only 4 patients showed Ctrough levels below the target for efficacy. 
The pregnancy induced physiological changes causing the lower exposure to antiretro-
virals seem most likely to be the increased plasma volume, decreased absorption, and 
increased hepatic clearance due to enzyme induction, or increased liver blood flow.
For tenofovir DF, emtricitabine, saquinavir, darunavir, raltegravir and maraviroc we 
concluded that the dose does not have to be adapted during pregnancy. For ataza-
navir (for treatment-experienced patients) and rilpivirine we suggest that TDM during 
pregnancy can help to optimize treatment of HIV-infected women during pregnancy.
Twenty percent of the patients had a detectable viral load (>50 copies/mL) around 
delivery, which did not lead to mother-to-child transmission. The viral loads around 
delivery were mostly below 500 copies/mL (84%) and maximally 28 711 copies/mL. In 
most cases the mode of delivery was caesarean section, further reducing the chance of 
mother-to-child transmission. One congenital abnormality was reported in the PANNA 
study, a relationship with ARV use could not be ruled out, but because the patient also 
used methadone during pregnancy, and no ARVs during the first weeks after conception 
were used, the relationship to ARV use is questionable.
The underlying mechanism for the relatively high percentage of women with a detect-
able viral load around delivery is still unclear. Lower exposure to antiretrovirals could not 
be related to increased viral load.
Placenta passage for emtricitabine and raltegravir is good, with a cord blood/maternal 
blood ratio >1; moderate for tenofovir DF and rilpivirine (ratio between 0.5 and 1) and 
not very good for maraviroc, atazanavir and darunavir and almost non-existent  for 
ritonavir.
We were able to predict maternal darunavir concentrations in the second and third 
trimester using a pregnancy PBPK model. This tool can be applied to predict the maternal 
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exposure for new drugs prior to coming to the market. Further development of the foetal 
unit is needed to also predict placenta transfer of new drugs.
What is the optimal choice of antiretroviral treatment during pregnancy? This was not a 
research question of the PANNA network, but here I will pose my opinion below.
From our work we can confirm that emtricitabine and tenofovir tenofovir DF pass the 
placenta well, seem to be generally safe and can be a good choice as back-bone of 
the treatment during pregnancy. The child will be protected also by these agents in case 
of blood-blood contact during partum.
When a choice for a protease inhibitor is being made, atazanavir/r once daily, or 
saquinavir/r or darunavir/r twice daily seem to be the most robust choice, more robust 
from a pharmacokinetic perspective than lopinavir/r (twice daily).
Raltegravir or maraviroc are also an acceptable option, but safety data during pregnancy 
are scarce. Adding raltegravir to a triple regimen when the viral load is still high at the 
end of pregnancy seems a good choice, also protecting the baby during delivery. For 
rilpivirine we have not yet collected enough data to draw conclusions.
My personal opinion is that efavirenz should be avoided in the first trimester of pregnancy 
for safety reasons and because other options are available in the Western world.
Data generated by the PANNA network help to decide on the optimal treatment for 
pregnant HIV infected women, and make treating physicians aware of the influence of 
pregnancy on drug exposure. It is important to continue this network and add new an-
tiretroviral agents to the list of medication to be investigated in pregnancy. This approach 
can also be used for other agents used in pregnancy.
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Summary
HIV (human immunodeficiency virus) is the virus that causes AIDS. The blood, semen, 
vaginal fluid and breast milk of HIV-infected persons contains the virus. If these infected 
body fluids come into contact with the blood stream (for example wounds) or mucous 
membranes, the infection can be transmitted. The virus binds to specific immune cells 
(CD4 T lymphocytes, CD4-cells). It is through these cells that the virus replicates and 
even destroys the cells over time. The immune system weakens; the body has problems 
fighting other infections and eventually the lethal disease AIDS can develop.
In 2013 a total of 35 million people were infected with HIV worldwide, 3.2 million of 
them were children. The majority of the HIV infected people live in Sub-Saharan Africa 
(70%) and 50% of the patients is female. Approximately 17,750 people were infected 
with HIV in 2014 in The Netherlands; most of the patients in The Netherlands (80%) 
are male.
HIV cannot (yet) be cured, and no vaccine is available. Medication can suppress the 
replication of the virus. These medicines affect the different steps of the life cycle of the 
virus. HIV patients need to take at least three of these medicines daily. By the use of 
these medicines, the amount if HIV in the body is reduced, and the immune system is 
strengthened.
This thesis describes the use of HIV medication by HIV infected pregnant women. HIV 
can be transmitted from mother to child, especially during delivery, when blood-blood 
contact can take place. To prevent infection of the child, the mother needs to use HIV 
medication during pregnancy. The amount of virus particles in blood and other body 
fluids is reduced by the treatment, which decreases the chance of infection during 
blood-blood contact dramatically. Without treatment 25-40% of the children would be 
infected during pregnancy or delivery; treatment reduces this percentage to <2%. HIV 
medication can reach the unborn child during pregnancy and could be harmful for the 
health and development of the child. On the other hand, a positive aspect is that the 
child already has medication in the body at the moment of possible contact with the HIV 
virus of the mother. This additionally protects against infection. 
I investigate the concentrations of HIV medication during pregnancy in the blood of the 
mother; we call this exposure to HIV medication. The human body removes possible 
toxic compounds during pregnancy, to protect the child. The body recognizes HIV med-
ication as possibly dangerous compounds and often eliminates the medication faster. 
Apart from that, the weight of pregnant women increases and the total body volume 
is higher, as a result of which concentrations of the medication can be lower during 
pregnancy. For efficacy of HIV medication it is important that sufficient medication is 
present in the body. When the concentrations are too low, this may lead to therapeutic 
failure and resistance against the HIV medication.
To perform this study, investigating the exposure to HIV medication (antiretroviral med-
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222 Appendix
ication) in pregnancy, we have set up a network of hospitals in Europe, because the 
number of HIV-infected pregnant women in The Netherlands was too low to perform 
such a study. This so called PANNA network – both the network and the study carry this 
name – includes 21 hospitals in the Netherlands, United Kingdom, Germany, Belgium, 
Spain, Italy and Ireland.
In cooperation with the PANNA investigators, I have composed a list of antiretrovirals for 
which, according to our opinion, none or insufficient knowledge was available of the 
effect of pregnancy on exposure (blood concentrations) to these medicines. To study this, 
we have included pregnant women, using antiretrovirals, and recorded a pharmacoki-
netic curve in the third trimester of pregnancy. The pharmacokinetic curve consisted of 
collection of blood samples at 10 time points after medication intake. Four to six weeks 
after delivery, the women returned to the study site to have another pharmacokinetic 
curve recorded. This curve served as control (non-pregnant) situation. We compared 
the exposure during pregnancy with the “non-pregnant” exposure, a within-subject com-
parison. Besides that, we also explored whether effective blood concentrations were 
reached.
We also wanted to know whether the compounds passed the placenta barrier, and 
hence reached the unborn child. For this purpose we collected a cord blood sample 
during delivery and determined the concentration of the medication in this sample.
The objective of the study, as described in my thesis, was to describe pharmacokinetic 
alterations of specified antiretroviral agents during pregnancy, and to indicate efficacy, 
safety and cord blood/maternal ratios.
Chapter 2 of the thesis is a review of the studies investigating the pharmacology of 
antiretrovirals in pregnancy, published in 2012. Both, studies with intensive sampling (col-
lection of a pharmacokinetic curve), as well as (random) sparse sampling studies, were 
reported. Furthermore, for some antiretrovirals, placenta passage was described. Most 
of the agents investigated in 2012 showed a decrease in exposure during pregnancy. 
In spite of that, the need for dose increase during pregnancy remains ambiguous. 
In the subsequent seven chapters the effect of pregnancy is described on pharmacoki-
netics of three protease inhibitors; two NRTIS; one NNRTI; one integrase inhibitor and 
one entry inhibitor.
The first agent, saquinavir, is discussed in chapter 3. The study was performed prior to 
initiation of the PANNA-network. However, the design of the study was approximately 
identical. In the saquinavir study, a curve was taken in the second trimester – if this was 
possible – in addition to the third trimester curve. Pharmacokinetic curves were collected 
from 37 women using 1000/100mg saquinavir/ritonavir twice daily during pregnancy 
(16 in the second trimester, 31 in the third trimester and 9 postpartum). No significant 
difference was found in saquinavir exposure during pregnancy compared with postpar-
tum. The variance in results was very large in this study. No sub-therapeutic saquina-
vir concentrations (<0.1 mg/L) were observed during pregnancy or postpartum. This 
led to the conclusion that saquinavir exposure in the new tablet formulation generates 
223
adequate saquinavir concentrations throughout the course of pregnancy and is safe to 
use; therefore, no dose adjustment during pregnancy is needed.
The following chapters describe antiretroviral agents investigated in the PANNA protocol.
Atazanavir/r results of 31 patients are depicted in chapter 4. Apart from the effect of 
pregnancy on the exposure to atazanavir, we also investigated whether concomitant use 
of tenofovir DF had an additional effect because tenofovir DF possibly reduces atazana-
vir concentrations. Twenty one out of 31 patients used tenofovir DF as NRTI. Atazanavir 
exposure was 34% lower during the third trimester, Cmax was 30% lower and C24h was 
41% lower, compared with postpartum. No statistical difference in pharmacokinetic 
parameters was found between patients using tenofovir versus no tenofovir. None of 
the patients showed atazanavir concentrations <0.15 mg/L (target for treatment-naive 
patients). Atazanavir showed a moderate placenta passage. The cord blood/mother 
blood-ratio was 0.20 (n=12). The children were born after a median (range) gestational 
age of 39 weeks (36-42). Approaching delivery 81% (25 patients) had an HIV viral 
load <50 copies/mL, all <1,000 copies/mL. One baby had a congenital abnormality, 
which was not likely to be related to atazanavir/ritonavir use. None of the children 
were HIV-infected. Our conclusion was: atazanavir/ritonavir 300/100mg once daily 
generates effective concentrations for protease inhibitor (PI)-naive patients, even if co-ad-
ministered with tenofovir. For treatment-experienced patients (with relevant PI resistance 
mutations) therapeutic drug monitoring of atazanavir should be considered to adapt the 
atazanavir/ritonavir dose on an individual basis.
Concerning darunavir/r results of 24 patients (600/100mg twice daily (n=6); 
800/100mg once daily (n=17); and 600/100mg once daily (n=1)) are described 
in chapter 5. Darunavir exposure was 22% decreased in pregnant patients using 
darunavir/r 600/100mg twice daily and 33% decreased in patients using darunavir/r 
800/100mg once daily. We also analysed free darunavir concentrations in a subset 
of plasma samples, both of the third trimester as well as the postpartum curve. The 
unbound fraction of darunavir was not different during pregnancy (12%) compared 
with postpartum (10%). The median (range) ratio of darunavir cord blood/maternal 
blood was 0.13 (0.08-0.35). The children were born after a median (range) gestational 
age of 38 weeks (36-41). Close to delivery 67% of the patients showed a viral load 
<50 copies/mL and 88% had <300 copies/mL. All children were tested HIV-negative 
and no congenital abnormalities were reported. We concluded that darunavir AUC 
and Cmax are substantially decreased in pregnancy for both darunavir/r regimens. This 
decrease in exposure did not result in mother-to-child transmission. For antiretroviral-naive 
patients, who are adherent, take darunavir with food and are not using concomitant 
medication reducing darunavir concentrations, 800/100mg darunavir/r once daily is 
adequate in pregnancy. For all other patients 600/100mg of darunavir/r twice daily is 
recommended during pregnancy.
In chapter 6 we describe the effect of pregnancy on the NRTIs tenofovir DF and 
emtricitabine. We included 34 pregnant women in the analysis. The majority used the 
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combination tablet Truvada® (n=31, 91%). Tenofovir exposure (AUC) was 23% lower 
and emtricitabine exposure was 25% lower during pregnancy. Both agents pass the 
placenta well. The cord blood/maternal blood ratio was 1.63 for emtricitabine and 
0.82 for tenofovir. Most patients (97%) had a viral load less than 200 copies/ml around 
delivery, 83% had less than 50 copies/mL. The median (range) gestational age was 38 
(36-41) weeks at delivery. All children were tested HIV-negative and no congenital ab-
normalities were reported. Tenofovir DF and emtricitabine can be used in the standard 
dose during pregnancy.
Raltegravir exposure in pregnancy is described in chapter 7. Twenty-two patients were 
included of which 68% started raltegravir during pregnancy. Overall AUC and C12h 
plasma concentrations in third trimester were on average 29% and 36% lower compared 
with postpartum. Raltegravir readily crosses the placenta, with a median (IQR) ratio of 
raltegravir cord/maternal blood of 1.21 (1.02-2.17; n=9) and was well tolerated during 
pregnancy. Approaching delivery 86% of the patients had an undetectable viral load 
(<50 copies/mL). None of the children were HIV-infected. Exposure to raltegravir was 
highly variable. The observed mean decrease in exposure to raltegravir during third 
trimester compared to postpartum is not considered to be of clinical importance. Ralte-
gravir can be used in standard dosages in HIV-infected pregnant women.
Chapter 8 is a description of two cases of rilpivirine use during pregnancy. Because 
nothing had been published on the effect pregnancy on rilpivirine pharmacokinetics 
or placenta passage, we reported the first two patients using rilpivirine in the PANNA 
study. Rilpivirine crosses the placenta moderately (cord blood/maternal blood ratio of 
0.74). Rilpivirine exposure during pregnancy was decreased by approximately 30-43%. 
Both patients showed low trough concentrations, even lower than the target concen-
tration of 0.040 mg/L. We strongly recommended therapeutic drug monitoring for 
rilpivirine during pregnancy.
Chapter 9 on the effect of pregnancy on maraviroc exposure is written in collabora-
tion with IMPAACT. IMPAACT is an American research group, performing studies like 
the PANNA study in the United States of America, South America and Thailand. We 
combined the results regarding maraviroc to be able to report data from a substan-
tial amount of patients. In total 18 patients were included in the analysis (IMPAACT 
11; PANNA 7). Most women received 150mg maraviroc twice daily with a protease 
inhibitor (12; 67%), two (11%) received 300mg maraviroc twice daily without protease 
inhibitor, and four (22%) had an alternative regimen. Maraviroc exposure was 28% 
lower during pregnancy, with a 30% decreased Cmax. Only one patient showed Ctrough 
concentrations below the suggested target of 50 ng/mL, both during pregnancy and 
postpartum. Maraviroc passes the placenta moderately: the median (range) ratio of 
maraviroc cord blood/maternal blood was 0.33 (0.03-0.56).
The median (range) gestational age ate delivery was 39 (37-41) weeks. Viral load close 
to delivery was less than 50 copies/mL in 13 participants (76%). All children were tested 
HIV-negative. Despite a reduction in exposure, the standard dose of maraviroc can be 
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used during pregnancy.
Figure 1 and 2 summarize the effect of pregnancy on AUC (exposure) and Ctrough (trough 
concentration) on several agents, depicted as geometric mean ratio and the 90% con-
fidence interval.
The development of a physiologically-based-pharmacokinetic (PBPK) model of darunavir 
is described in chapter 10. A PBPK-model is a computer model, which can be used to 
simulate exposure of an agent in blood and also exposure in several organs, based on 
physicochemical properties of the drug and the physiology of the human body. Physio-
logical changes, appearing in pregnancy, can be included in the model. This makes it 
Figure 1. Geometric mean ratio of AUC (pregnancy/postpartum) and 90% confidence interval
Figure 2. Geometric mean ratio of Ctrough (pregnancy/postpartum) and 90% confidence interval
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possible to predict exposure to drugs during pregnancy, without performing extensive in 
vivo studies in pregnancy. This is a major advantage of such a computer model.
We built a model that describes the exposure of both standard doses of darunavir/r 
(600/100mg twice daily and 800/100mg once daily) well for both healthy subjects 
as in pregnancy. The model was built using Simcyp (v13.2), a PBPK model platform.
The physicochemical and in vitro pharmacokinetic parameters of darunavir and ritonavir 
were derived from literature. Km and Vmax for CYP3A4-mediated darunavir biotransforma-
tion and inhibition by ritonavir were determined experimentally. We discovered that it 
was not possible to generate an acceptable model for darunavir without inclusion of a 
role for transporters. Sensitivity analyses were used to assess the contribution of hepato-
cyte uptake and efflux transporters. 
For darunavir alone and also for the darunavir-ritonavir interaction, peak and total 
exposure at steady state were estimated within 2-fold range of reported data. The 
model predicted a decrease in AUC of 27% and 41%, which is in the range of the 
observed (literature and PANNA data) decrease during pregnancy of 17-22% and 
33% for the twice-daily and the once-daily dose, respectively. In conclusion: our data 
support a clinically relevant role of hepatic transporters in darunavir pharmacokinetics. 
The described model successfully approximated ritonavir-boosting and the decrease 
in darunavir exposure during pregnancy. Future in vitro experiments should generate 
quantitative kinetic data of passive and transporter-mediated darunavir handling by 
hepatocytes and intestinal epithelium.
In the General Discussion (Chapter 11) I place the previous chapters in a broader 
perspective and I summarize the results and compare the results with each other. First I 
treat the impact of pharmacokinetic alterations in pregnancy, the possible mechanisms 
behind this and the clinical consequences.
During pregnancy, the exposure was decreased by approximately 25% for most antiret-
rovirals described in this thesis. In total only four patients showed trough concentrations 
below the target concentration for effectivity. Possible mechanisms behind lower plasma 
concentrations in pregnancy are: increased plasma volume, decreased absorption and 
increased hepatic clearance due to induction of liver enzymes and/or increased liver 
blood flow.
In the patients described in this thesis, despite some of them having sub-therapeutic drug 
concentrations this, fortunately, did result in mother-to-child transmission of the virus. There 
are several factors to consider when a relationship between drug exposure and mother-
to-child transmission is being made: women are treated with combination antiretroviral 
therapy, consisting of at least three compounds. This means that the compound measured 
in this study is not the only active antiretroviral drug used. Furthermore, in >50% of the 
cases delivery was done by caesarean section, which is known to decrease the chance 
of mother-to-child transmission.
For tenofovir DF, emtricitabine, saquinavir, darunavir, raltegravir and maraviroc we 
concluded that the dose does not have to be adapted during pregnancy, provided that 
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other factors, possibly decreasing exposure are absent. For atazanavir (for treatment-ex-
perienced patients) and rilpivirine we suggest that TDM during pregnancy can help to 
optimize treatment of HIV-infected women during pregnancy.
Subsequently, we described the effectiveness of treatments, by providing an overview 
of the viral load of the pregnant women close to delivery. Twenty percent of the patients 
had a detectable viral load (>50 copies/mL) around delivery, which did not lead to 
mother-to-child transmission. The viral loads around delivery were mostly below 500 
copies/mL (84%) and maximally 28711 copies/mL. The underlying mechanism for the 
relatively high percentage of women with a detectable viral load around delivery is still 
unclear. Lower exposure to antiretrovirals could not be related to increased viral load in 
our studies.
Placenta passage of the antiretrovirals is summarized in Figure 1 of the General Discus-
sion.  Placenta passage for emtricitabine and raltegravir is good, with a cord blood/
maternal blood ratio >1; moderate for tenofovir DF and rilpivirine (ratio between 0.5 
and 1) and not very good for maraviroc, atazanavir and darunavir and almost non-ex-
istent for ritonavir. 
We were able to predict maternal darunavir concentrations in the second and third 
trimester using a pregnancy PBPK model. This tool can be applied to predict the maternal 
exposure for new drugs prior to coming to the market. Further development of the foetal 
unit is needed to also predict placenta transfer of new drugs. It would be enrichment 
if placenta passage could reliably be predicted with a computer model. We showed 
that the effect of pregnancy on maternal exposure can be simulated, but to assess 
the exposure of the unborn child during pregnancy needs extension of the model. An 
acceptable computer model for assessment of placenta passage is not yet available.
Further, I discuss the lack of clinical trials in pregnant females and the exclusion of 
pregnant women from clinical trials in general. It is regarded not to be ethical to use 
new (not yet registered) medication during pregnancy, because of possible terato-
genicity. When a woman becomes pregnant during a clinical trial with a new agent, 
the treatment is stopped immediately and the woman is excluded from the trial. If the 
pregnancy is pursued, the woman is followed-up and the outcome of the pregnancy 
is reported. When agents are registered and marketed, these will (possibly) be used 
during pregnancy, under uncontrolled circumstances. Pharmacovigilance guidelines from 
regulatory agencies (EMA and FDA) require pharmaceutical industry to set up a registry 
collecting safety data of exposure to the drug during pregnancy.
In the General Discussion I suggest to include pregnant women in clinical trials in an 
earlier stage for agents which will, almost certainly, be used in pregnancy, like antiret-
rovirals. Besides that, I propose not to exclude women who become pregnant during a 
clinical trial immediately, but to give them the opportunity to continue with the trial medi-
cation in a sub-study to investigate safety and pharmacokinetics. This can only be done 
when the reproductive toxicity studies are completed. Next to that, a computer model, 
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like a PBPK-model, could predict the pharmacokinetics during pregnancy.
Although it was not a research question of the PANNA network, I discuss the optimal 
choice of antiretroviral treatment during pregnancy. From our work we can confirm that 
emtricitabine and tenofovir DF pass the placenta well, seem to be generally safe and 
can be a good choice as back-bone of the treatment during pregnancy. The child 
will be protected also by these agents in case of blood-blood contact during partum. 
When a choice for a protease inhibitor is being made, atazanavir/r once daily, or 
saquinavir/r or darunavir/r twice daily seem to be the most robust options. Raltegravir 
or maraviroc are also an acceptable option, but safety data during pregnancy are 
scarce. Adding raltegravir to a triple regimen when the viral load is still high at the end of 
pregnancy seems a good choice, also protecting the baby during delivery. For rilpivirine 
we have not yet collected enough data to draw conclusions, the same is true for the new 
agents that became recently available. My personal opinion is that efavirenz should be 
avoided in the first trimester of pregnancy for safety reasons and because other options 
are available in the Western world.
I can conclude that data generated by the PANNA network can help to decide on the 
optimal treatment for pregnant HIV infected women, as is confirmed by incorporation of 
the results of the study in international guidlines, and make treating physicians aware of 
the influence of pregnancy on drug exposure. It is important to continue this network and 
add new antiretroviral agents to the list of medication to be investigated in pregnancy.
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Samenvatting
Hiv (humaan immunodeficiëntie virus) is het virus dat AIDS veroorzaakt. Het virus is 
bij hiv-besmette personen aanwezig in onder andere bloed, sperma, vaginaal vocht 
en moedermelk. Als deze besmette lichaamsvloeistoffen in aanraking komen met de 
bloedbaan (bijvoorbeeld wondjes) of slijmvliezen kan de infectie worden overgedra-
gen. Het virus bindt zich aan bepaalde afweercellen (CD4 T lymfocyten, CD4-cellen). 
Via deze cellen vermenigvuldigt het virus zich en het breekt deze cellen na verloop van 
tijd af. Daardoor vermindert de afweer, kan het lichaam moeilijker met andere infecties 
omgaan en kan uiteindelijk de dodelijke ziekte AIDS ontstaan.
In 2013 waren wereldwijd in totaal 35 miljoen mensen besmet met hiv, waarvan 3,2 
miljoen kinderen. Het grootste deel van deze mensen leeft in Sub-Sahara Afrika (70%) 
en 50% van de patiënten is vrouw. In Nederland waren in 2014 ca. 17.750 mensen 
besmet met hiv; het merendeel (80%) van deze patiënten in Nederland is man.
Hiv kan (nog) niet worden genezen en er is ook geen vaccin beschikbaar. Er zijn wel 
medicijnen die de vermenigvuldiging van het virus remmen. Deze medicijnen grijpen 
aan op verschillende stappen van de levenscyclus van het virus. Hiv-patiënten moeten 
dagelijks tenminste drie van deze middelen gebruiken. Door deze medicijnen neemt het 
aantal virusdeeltjes af en verbetert het immuunsysteem.
Dit proefschrift gaat over het gebruik van anti-hiv-medicijnen door zwangere hiv-geïnfec-
teerde vrouwen. Hiv kan worden overgedragen van moeder op kind, vooral tijdens de 
bevalling als er bloed-bloedcontact plaatsvindt. Om te voorkomen dat het kind besmet 
wordt, moet de moeder tijdens de zwangerschap hiv-remmers gebruiken. Het aantal 
virusdeeltjes in het bloed en andere lichaamsvloeistoffen daalt door de behandeling, 
waardoor de kans op besmetting tijdens bloed-bloedcontact drastisch wordt verlaagd. 
Zonder behandeling zou 25-40% van de kinderen besmet raken tijdens de zwanger-
schap/geboorte; met behandeling daalt dit percentage tot <2%. Deze hiv-remmers 
kunnen tijdens de zwangerschap in het ongeboren kind terechtkomen en schadelijk zijn 
voor de ontwikkeling van het kind. Een positief aspect is dat het kind al medicijnen in 
het lichaam heeft als het mogelijk in contact komt met het hiv-virus van de moeder. Dat 
geeft extra bescherming tegen besmetting.
Ik onderzoek de concentraties van de hiv-remmers tijdens de zwangerschap in het 
bloed van de moeder, zogenaamde blootstelling aan hiv-remmers. Tijdens de zwanger-
schap verwijdert het lichaam mogelijk schadelijke stoffen om het kind te beschermen. 
Het lichaam ziet de hiv-remmers ook als schadelijke stoffen en breekt ze vaak sneller af. 
Daarnaast worden  zwangere vrouwen zwaarder en het totale lichaamsvolume wordt 
groter waardoor de concentraties van de middelen gedurende de zwangerschap lager 
kunnen zijn. Voor werkzaamheid van hiv-remmers moet er wel genoeg in het lichaam 
aanwezig zijn. Te lage concentraties kunnen leiden tot falen van de therapie en tot 
resistentie tegen de hiv-remmers.
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Om dit onderzoek naar de blootstelling aan hiv-remmers in de zwangeschap uit te 
voeren, hebben we een netwerk van ziekenhuizen verspreid over Europa opgezet, 
omdat er in Nederland te weinig hiv-geïnfecteerde zwangere vrouwen zijn om een 
dergelijk onderzoek te doen. Dit zogenoemde PANNA-netwerk − zowel het onderzoek 
als het netwerk heet zo − bestaat op dit moment (juli 2015) uit 21 ziekenhuizen in 
Nederland, het Verenigd Koninkrijk, Duitsland, België, Spanje, Italië en Ierland.
Samen met de PANNA-onderzoekers heb ik een lijst van medicijnen opgesteld waarvan 
we vonden dat er nog geen, of onvoldoende, informatie beschikbaar was over het 
effect van zwangerschap op de blootstelling (concentraties in het bloed) aan die me-
dicijnen. Om dat uit te zoeken, hebben we bij zwangere vrouwen die hiv-remmers ge-
bruikten tijdens het derde trimester van de zwangerschap een farmacokinetische curve 
afgenomen door bloed te prikken op 10 tijdstippen na inname van de medicatie. Deze 
vrouwen kwamen 4-6 weken na de bevalling weer terug om nog een farmacokineti-
sche curve af te laten nemen, deze curve gebruikten we als controlesituatie. We hebben 
de blootstelling in de ‘zwangere situatie’ vergeleken met de ‘niet-zwangere situatie’, een 
vergelijking binnen personen. Daarnaast hebben we ook onderzocht of de bloedcon-
centraties hoog genoeg waren om werkzaam te zijn.
We wilden ook graag weten of de middelen de placenta kunnen passeren en dus in 
het kind terecht komen. Dat hebben we onderzocht door tijdens de bevalling navel-
strengbloed af te nemen en de geneesmiddelconcentraties daarin te bepalen.
Het onderzoek, als beschreven in mijn proefschrift, had als doel het beschrijven van 
farmacokinetische veranderingen van bepaalde antiretrovirale middelen (hiv-remmers) in 
de zwangerschap. Daarnaast onderzocht ik of de middelen veilig en effectief waren en 
of ze de placenta passeren.
Hoofdstuk 2 van het proefschrift is een samenvatting van de farmacologische onderzoe-
ken naar antiretrovirale middelen in de zwangerschap die in 2012 waren gepubliceerd. 
Er zijn zowel onderzoeken met intensieve sampling (afname van farmacokinetische 
curves) als onderzoeken waarbij zo nu en dan een bloedmonster is afgenomen (random 
sparse sampling) gerapporteerd, daarnaast was voor een aantal middelen ook de 
placentapassage beschreven. Voor de meeste stoffen die in 2012 waren onderzocht, is 
een daling van de blootstelling geobserveerd in de zwangerschap. De noodzaak van 
een dosisverhoging tijdens de zwangerschap blijft echter onduidelijk.
In de volgende zeven hoofdstukken wordt het effect van zwangerschap op de farma-
cokinetiek van drie proteaseremmers besproken: twee NRTIs, een NNRTI, een integra-
seremmer en een entryremmer.
Het eerste middel, saquinavir, wordt besproken in hoofdstuk 3. Het onderzoek ernaar 
is uitgevoerd voordat het PANNA-netwerk was opgezet, maar de opzet van het 
onderzoek was ongeveer gelijk. In het onderzoek naar de werking van saquinavir is 
naast een curve in het derde trimester ook een farmacokinetische curve afgenomen in 
het tweede trimester van de zwangerschap – indien dit mogelijk was. Van 37 vrouwen 
die tijdens de zwangerschap 1000/100mg saquinavir/ritonavir tweemaal daags ge-
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bruikten, zijn farmacokinetische curves verzameld (16 in het tweede trimester, 31 in het 
derde trimester en 9 postpartum). Geen significant is verschil gevonden in blootstelling 
aan saquinavir tijdens de zwangerschap ten opzichte van postpartum. De spreiding in 
de resultaten was wel erg groot. Er zijn geen subtherapeutische saquinavir-concentraties 
(<0,1 mg/L) gemeten tijdens de zwangerschap of postpartum. De conclusie van dit 
onderzoek was dan ook dat saquinavir-blootstelling (van de nieuwe tablet) voldoende 
hoog is tijdens de zwangerschap en dat saquinavir in de zwangerschap veilig kan 
worden gebruikt. Er is geen dosisaanpassing nodig.
De volgende hoofdstukken beschrijven antiretrovirale middelen die onderzocht zijn in 
het PANNA-protocol.
Voor atazanavir/r beschrijven we de resultaten van 31 patiënten in hoofdstuk 4. We 
onderzochten naast het effect van zwangerschap op de blootstelling van atazanavir 
ook of er een verschil was tussen patiënten die tenofovir als comedicatie gebruikten, 
omdat tenofovir atazanavir-concentraties mogelijk verlaagt. Eenentwintig van de 31 
patiënten gebruikten tenofovir als NRTI. De blootstelling aan atazanavir was 34% lager 
in het derde trimester, Cmax was 30% lager en C24h was 41% lager in vergelijking met 
postpartum. Er is geen significant verschil gevonden in farmacokinetische parameters 
tussen patiënten die wel en geen tenofovir als comedicatie gebruikten. Er zijn geen 
atazanavir-concentraties gemeten onder 0,15mg/L (de streefwaarde voor nog niet be-
handelde patiënten). Atazanavir passeert de placenta matig. De navelstrengbloed/
moederbloed-ratio was 0,20 (n=12). De kinderen werden geboren na een mediane 
(range) zwangerschapsduur van 39 weken (36-42). Rond de bevalling had 81% van 
de patiënten een viruslast <50 kopieën/mL en 100% <1.000 kopieën/mL. Er is één 
aangeboren afwijking gezien bij een van de baby's, deze was waarschijnlijk niet gere-
lateerd aan atazanavir-gebruik. Geen van de kinderen was hiv-geïnfecteerd. We con-
cludeerden dat atazanavir/r (300/100mg eenmaal daags) tijdens de zwangerschap 
voldoende blootstelling geeft, zelfs in combinatie met tenofovir. Voor patiënten die be-
handeling-naïef zijn (zonder relevante mutaties die relevant zijn voor proteaseremmers) 
hoeft de dosis in de zwangerschap niet te worden aangepast. Voor patiënten die voor-
behandeld zijn en/of relevante mutaties hebben, kan therapeutische drug monitoring 
worden overwogen en kan de dosis op individuele basis worden aangepast.
Voor darunavir/r zijn in hoofdstuk 5 de resultaten beschreven van 24 patiënten (dar-
unavir/r 600/100mg tweemaal daags (n=6); 800/100mg eenmaal daags (n=17); 
en 600/100mg eenmaal daags (n=1)). De blootstelling aan darunavir was 22% lager 
in zwangere patiënten die darunavir/r 600/100mg tweemaal daags gebruikten en 
33% lager in patiënten die darunavir/r 800/100mg eenmaal daags gebruikten. We 
hebben ook de vrije concentraties darunavir gemeten in een aantal plasmamonsters 
van zowel de derde-trimestercurve als postpartum. De ongebonden fractie was in de 
zwangerschap (12%) ongeveer gelijk aan postpartum (10%). De mediane navelstreng-
bloed/moederbloed-ratio was 0,13. De kinderen werden geboren na een mediane 
(range) zwangerschapsduur van 38 weken (36-41). Rond de bevalling had 67% van 
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de patiënten een viruslast <50 kopieën/mL en 88% <300 kopieën/mL. Er heeft geen 
overdracht van hiv op het kind plaatsgevonden en er zijn geen aangeboren afwijkin-
gen gerapporteerd. De conclusie was dat de daling van darunavir AUC en Cmax in de 
zwangerschap niet leidde tot transmissie van het hiv-virus naar het kind. De dosis van 
800/100mg eenmaal daags darunavir/r is voldoende voor patiënten die niet voorbe-
handeld zijn. Zij moeten darunavir met eten innemen en geen comedicatie gebruiken 
die de darunavir-concentraties kan verlagen. Voor alle andere patiënten wordt de 
600/100mg dosering tweemaal daags tijdens de zwangerschap aangeraden.
In hoofdstuk 6 beschrijven we het effect van zwangerschap op de NRTIs tenofovir en 
emtricitabine. In totaal waren 34 zwangere vrouwen opgenomen in de analyse. De 
meeste vrouwen gebruikten de combinatietablet Truvada® (n=31, 91%). Tenofovir-bloot-
stelling (AUC) was 23% lager en emtricitabine-blootstelling was 25% lager in de zwan-
gerschap. Beide middelen passeren de placenta goed. De navelstrengbloed/moeder-
bloed-ratio was 1,63 voor emtricitabine en 0,82 voor tenofovir. De meeste patiënten 
(97%) hadden minder dan 200 virusdeeltjes/mL rondom de bevalling, 83% had minder 
dan 50 virusdeeltjes/mL. De mediane (range) zwangerschapsduur was 38 (36-41) 
weken op het moment van bevalling. Geen van de kinderen was met hiv besmet en er 
zijn geen aangeboren afwijkingen gezien. Tenofovir en emtricitabine kunnen tijdens de 
zwangerschap in de gangbare dosering worden gebruikt.
De blootstelling aan raltegravir in de zwangerschap is beschreven in hoofdstuk 7. We 
hebben 22 patiënten geïncludeerd, waarvan 68% tijdens de zwangerschap met ral-
tegravir-gebruik startte. Blootstelling aan raltegravir was erg variabel, de blootstelling 
(AUC) en C12h waren 29% en 36% lager in het derde trimester. Raltegravir passeert de 
placenta goed met een navelstrengbloed/moederbloed-ratio van 1,21 en werd goed 
verdragen tijdens de zwangerschap. Rond de bevalling had 86% van de patiënten een 
ondetecteerbare viruslast (<50 kopieën/mL). De zwangerschapsduur was 38 (38-39) 
weken. Er heeft geen overdracht van het virus plaatsgevonden. De daling in blootstelling 
aan raltegravir tijdens de zwangerschap is als niet klinisch relevant beoordeeld. Daarom 
kan raltegravir tijdens de zwangerschap in de standaarddosering worden gebruikt.
Hoofdstuk 8 is een beschrijving van twee casussen van rilpivirine-gebruik in de zwan-
gerschap. Er was nog niets bekend over het effect van zwangerschap op rilpivirine 
farmacokinetiek of placentapassage. Daarom hebben we de eerste twee patiënten 
die geïncludeerd zijn in het PANNA-onderzoek apart beschreven. Rilpivirine passeert 
de placenta matig (navelstrengbloed/moederbloed-ratio van 0,74). De blootstelling 
was 30-43% lager in de zwangerschap. Beide patiënten hadden een lage dalspiegel 
tijdens de zwangerschap, zelfs lager dan de streefwaarde van 0,040 mg/L. We 
raadden dan ook aan om rilpivirine spiegels te meten tijdens de zwangerschap.
Hoofdstuk 9 over het effect van zwangerschap op maraviroc-blootstelling is tot stand 
gekomen in samenwerking met IMPAACT. IMPAACT is een Amerikaanse groep die een 
soortgelijk onderzoek als PANNA uitvoert maar dan in de Verenigde Staten, Zuid-Ameri-
ka en Thailand. We hebben onze data met betrekking tot maraviroc samengevoegd om 
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een substantieel aantal patiënten te kunnen rapporteren. In totaal zijn 18 patiënten geïn-
cludeerd (IMPAACT 11; PANNA 7). De meeste vrouwen gebruikten 150mg maraviroc, 
tweemaal daags, in combinatie met een proteaseremmer (12; 67%). Twee vrouwen 
(11%) gebruikten 300mg maraviroc, tweemaal daags, zonder proteaseremmer, en vier 
vrouwen hadden een ander regime. De blootstelling aan maraviroc was 28% lager in 
de zwangerschap, met een 30% lagere Cmax. De dalspiegels waren 15% lager in de 
zwangerschap, maar bijna allemaal boven de streefwaarde. Maraviroc passeert de 
placenta matig met een navelstrengbloed/moederbloed-ratio van 0,33 (0,03-0,56). De 
kinderen werden geboren na een mediane zwangerschapsduur van 39 (37-41) weken. 
De viruslast rond de bevalling was <50 kopieën/mL in 13 patiënten (76%). Alle kinderen 
waren hiv-negatief. Ondanks een afname aan blootstelling kan de standaarddosering 
voor maraviroc gehandhaafd blijven in de zwangerschap.
In figuur 1 en 2 zijn de effecten van de zwangerschap op AUC (blootstelling) en dal-
spiegel (Ctrough) van de verschillende middelen weergegeven als geometrisch gemiddel-
de ratio met het bijbehorende 90% betrouwbaarheidsinterval.
De ontwikkeling van een physiologically-based-pharmacokinetic (PBPK) model voor 
darunavir hebben we in hoofdstuk 10 beschreven. Een PBPK-model is een compu-
termodel waarmee op basis van de fysisch-chemische en kinetische eigenschappen 
van een stof en de specifieke fysiologische parameters van het menselijk lichaam de 
blootstelling in het bloed, maar ook in verschillende organen kan worden gesimuleerd. 
Ook fysiologische veranderingen die tijdens de zwangerschap optreden, kunnen in 
het model worden meegenomen waardoor de blootstelling aan medicatie tijdens de 
zwangerschap kan worden voorspeld zonder uitgebreid in vivo onderzoek als basis. 
Figuur 1. Geometrisch gemiddelde ratio’s AUC (zwangerschap/postpartum) en 90% betrouwbaarheidsinterval
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Dit is een groot voordeel van een dergelijk computermodel.
Wij hebben een model gebouwd dat de blootstelling van beide doseringen darunavir/
ritonavir (600/100mg tweemaal daags en 800/100mg eenmaal daags) goed be-
schrijft voor zowel gezonde proefpersonen als in de zwangerschap. Het model is 
gebouwd in Simcyp (v13.2), een PBPK-modelplatform. De fysisch-chemische eigen-
schappen van darunavir en ritonavir zijn aan de literatuur ontleend. De Km en Vmax voor 
CYP3A4 gemedieerd metabolisme van darunavir en de inhibitie van dit metabolisme 
door ritonavir zijn via in vitro experimenten bepaald. We hebben ontdekt dat we zonder 
het includeren van een rol voor transporters geen goed passend model konden maken 
voor darunavir. Middels sensitiviteitsanalyses hebben we de contributie van opnamen 
en efflux transporters geschat. De schattingen van de blootstelling aan darunavir alleen 
en ook van darunavir/ritonavir-interactie waren vergelijkbaar met de waardes die zijn 
gerapporteerd in de literatuur. Het model voorspelde een afname van darunavir AUC 
van 27% en 41% (tweemaal daags en eenmaal daags) in de zwangerschap, wat over-
eenkomt met de daling die geobserveerd is in de literatuur en het PANNA-onderzoek 
(17-22% en 33% voor tweemaal daags en eenmaal daags darunavir/ritonavir respectie-
velijk). We concluderen dat ons model een klinisch relevante rol van transporters voor de 
beschrijving van darunavir farmacokinetiek ondersteunt. Ons model beschrijft het effect 
van ritonavir op darunavir goed, en ook het effect van zwangerschap op de blootstel-
ling aan darunavir voor beide doseerregimes. Toekomstige experimenten moeten kwan-
titatieve gegevens genereren voor passief en actief transporter-gemedieerde verwerking 
van darunavir door hepatocyten en darmwandepitheel.
In de discussie (hoofdstuk 11) plaats ik de voorgaande hoofdstukken in een breder 
Figuur 2. Geometrisch gemiddelde ratio’s Ctrough (zwangerschap/postpartum) en 90% betrouwbaarheidsinterval
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perspectief en heb ik data samengevat en met elkaar vergeleken. Eerst behandel ik de 
impact van de farmacokinetische veranderingen in de zwangerschap, de mogelijke 
mechanismen hierachter en de klinische consequenties.
De blootstelling tijdens de zwangerschap was ongeveer 25% lager voor de meeste 
antiretrovirale middelen die in dit proefschrift zijn besproken. In totaal is bij slechts vier 
patiënten een dalwaarde gezien onder de streefwaarde voor effectiviteit. Mogelijke 
mechanismen voor de lagere plasmaconcentraties in de zwangerschap zijn: een groter 
plasmavolume, verminderde absorptie en verhoogde hepatische klaring door inductie 
van leverenzymen of verhoogde bloedflow door de lever.
Bij de patiënten die ik in dit proefschrift heb beschreven, heeft geen overdracht van 
het hiv-virus van moeder op kind plaatsgevonden, ondanks de lagere blootstelling 
aan hiv-remmers tijdens de zwangerschap en zelfs subtherapeutische concentraties 
van de antiretrovirale middelen bij een aantal patiënten. Er zijn enkele factoren die 
moeten worden meegenomen wanneer de relatie tussen blootstelling aan geneesmid-
delen en de overdracht van hiv van moeder op kind wordt onderzocht: de vrouwen 
worden behandeld met combinatie antiretrovirale-therapie die bestaat uit tenminste drie 
middelen. Dit wil zeggen dat het geneesmiddel dat gemeten is in dit onderzoek niet 
het enige antiretrovirale middel is dat gebruikt is. Daarnaast is meer dan 50% van de 
vrouwen bevallen met een keizersnee, wat de kans op overdracht van het hiv-virus 
verlaagt.
Voor tenofovir DF, emtricitabine, saquinavir, darunavir, raltegravir en maraviroc hebben 
we geconcludeerd dat het niet nodig is de dosering tijdens de zwangerschap aan te 
passen, mits er geen andere factoren zijn die de blootstelling kunnen verlagen. Voor 
atazanavir (voorbehandelde patiënten) en rilpivirine kan TDM tijdens de zwangerschap 
een rol spelen om de behandeling te optimaliseren.
Vervolgens hebben we de effectiviteit van de behandelingen beschreven door een 
overzicht te geven van de viruslast in de zwangere vrouw rondom de bevalling. Twintig 
procent van de patiënten had een detecteerbare viruslast (>50 kopieën/mL) rondom 
de bevalling, wat in geen enkel geval heeft geleid tot overdracht van het hiv-virus. 
De viruslast was meestal onder de 500 kopieën/mL (bij 84%) en maximaal 28711 
kopieën/mL. Het mechanisme voor het relatief hoge percentage vrouwen met een de-
tecteerbare viruslast rondom de bevalling, wat overeenkomt met percentages die in de 
literatuur worden gerapporteerd, is nog altijd onduidelijk. Lagere blootstelling aan de 
individuele antiretrovirale middelen kon in onze onderzoeken niet worden gerelateerd 
aan verhoogde viruslast.
De placentapassage van de verschillende middelen is samengevat in figuur 1 van 
de General Discussion. Placentapassage van emtricitabine en raltegravir is goed, met 
een navelstrengbloed/moederbloed-ratio >1; matig voor tenofovir DF en rilpivirine (ratio 
tussen 0,5 and 1) en niet zo goed voor maraviroc, atazanavir en darunavir en bijna 
nul voor ritonavir. Het zou een mooie stap voorwaarts zijn als de placentapassage 
betrouwbaar kan worden voorspeld met behulp van een computermodel. We hebben 
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laten zien dat de verandering in maternale blootstelling tijdens de zwangerschap kan 
worden gesimuleerd, maar om de blootstelling in het ongeboren kind goed te schatten, 
moet het model verder worden ontwikkeld. Een goed computermodel voor placenta-
passage is vooralsnog niet voorhanden.
Ook behandel ik het gebrek aan geneesmiddelenonderzoek in zwangere vrouwen in 
het algemeen. Het wordt niet ethisch geacht nieuwe geneesmiddelen in de zwanger-
schap te gebruiken, vanwege niet uit te sluiten teratogeniteit. Ook als vrouwen in een 
onderzoek met een nieuw middel zwanger worden, wordt de behandeling met het 
middel in de meeste gevallen meteen gestaakt en wordt de vrouw geëxcludeerd. Als de 
zwangerschap wordt voortgezet, wordt de uitkomst van de zwangerschap wel gerap-
porteerd. Als de middelen op de markt komen, worden ze echter (mogelijk) wel gebruikt 
tijdens de zwangerschap, onder niet heel goed gecontroleerde omstandigheden. Er 
zijn farmacovigilantie-richtlijnen van de EMA en FDA die de farmaceutische industrie 
verplichten post-marketing bij te houden of hun stoffen teratogeen zijn. 
In de discussie suggereer ik dat geneesmiddelenonderzoek in zwangere patiënten 
voor medicijnen die in de zwangerschap gebruikt gaan worden, zoals antiretrovirale 
middelen, eerder moet worden uitgevoerd. Daarnaast stel ik voor om vrouwen die 
tijdens een onderzoek met een nieuw geneesmiddel zwanger worden niet meteen te 
excluderen, maar hen de mogelijkheid te bieden het middel door te gebruiken en in 
een substudie de veiligheid en farmacokinetiek te bestuderen, mits er voldoende repro-
ductietoxicologisch preklinisch onderzoek is uitgevoerd. Daarnaast kan met behulp van 
een computermodel, zoals een PBPK-model, een voorspelling worden gedaan van de 
veranderingen in farmacokinetiek tijdens de zwangerschap.
Het was weliswaar geen onderzoeksvraag van het PANNA-netwerk, maar toch probeer 
ik een optimaal behandelingsregime voor zwangere hiv-geïnfecteerde vrouwen samen 
te stellen. Uit ons onderzoek blijkt dat tenofovir en emtricitabine de placenta goed 
passeren en over het algemeen veilig waren en daarom een goede keus zijn voor een 
NRTI back-bone tijdens de zwangerschap. Bij mogelijk bloed-bloedcontact tijdens de 
bevalling dragen deze middelen bij aan het voorkomen van hiv-infectie van het kind. 
De meest robuuste proteaseremmers, wat farmacokinetische veranderingen betreft, zijn 
atazanavir/r, eenmaal daags 300/10 mg, en darunavir/r 600/100mg tweemaal 
daags. Raltegravir en maraviroc zijn ook een optie, maar hiervan zijn nog maar weinig 
veiligheidsgegevens beschikbaar. Het toevoegen van raltegravir aan de behandeling 
lijkt een goede optie om de viruslast snel te laten dalen tijdens de zwangerschap, 
indien nodig. Raltegravir passeert de placenta goed en het kind is daardoor tijdens 
de bevalling extra goed beschermd tegen infectie. Voor rilpivirine hebben we nog te 
weinig data om conclusies te trekken, dit geldt ook voor de nieuwe middelen die recent 
beschikbaar zijn gekomen.
Ik ben van mening dat efavirenz-gebruik in het eerste trimester van de zwangerschap 
zou moeten worden vermeden vanwege veiligheidsredenen, en omdat in de westerse 
wereld voldoende alternatieven beschikbaar zijn.
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Ik kan concluderen dat de gegevens die worden gegenereerd door het PANNA-netwerk 
kunnen helpen een keuze te maken voor optimale behandeling van hiv-geïnfecteerde 
zwangere vrouwen. Dit wordt bevestigd doordat internationale richtlijnen de resultaten 
uit dit onderzoek hebben opgenomen. Daarnaast hoop ik dat behandelend specia-
listen meer bewust worden van de invloed van zwangerschap op blootstelling aan 
antiretrovirale middelen. Het is belangrijk dat het PANNA-netwerk blijft voortbestaan en 
dat nieuwe antiretrovirale middelen worden toegevoegd aan de lijst van medicatie die 
wordt onderzocht.
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Dankwoord
30 oktober 2007, vandaag precies acht jaar geleden is de basis gelegd voor dit 
promotieonderzoek aan de afdeling apotheek van het UMC St Radboud. De locatie 
was Cinemariënburg (Nijmegen) en aanwezigen waren dr. David Burger en ik (en 
andere filmgasten en cafégangers). Er is veel veranderd sindsdien: UMC St Radboud 
is Radboud universitair medisch centrum geworden, Cinemariënburg is gesloten en dr. 
David Burger is gepromoveerd tot professor David Burger.
David had mij uitgenodigd voor een informeel, oriënterend gesprek over een mogelijke 
functie als researchassistente in de apotheek. David en ik kenden elkaar van een aantal 
klinische onderzoeken die ik vanuit Farma Research BV had gecoördineerd. Naast het 
werk als researchassistente hebben we ook gesproken over ‘een eigen onderzoek’. 
Dat leek mij wel leuk en spannend, en zo is het gekomen. In februari 2008 ben ik in 
de apotheek begonnen als researchassistente. Vrij snel zijn we het PANNA-onderzoek 
gaan opzetten. Ik had veel ervaring met kleinschalige onderzoeken met gezonde proef-
personen; het opzetten van een internationaal netwerk bleek andere koek. Gelukkig 
was er al een soortgelijk onderzoek opgestart: SARA, dat is beschreven in hoofdstuk 
3 van dit proefschrift, en wat een mooie basis was voor het PANNA-onderzoek. De 
onderzoekers die we hebben benaderd, hadden gelukkig research-nurses of -coördi-
natoren in dienst die mij uitgebreid hebben geholpen met alle logistieke uitdagingen. 
De Europese clinical trials directive wordt namelijk in alle landen net iets anders geïn-
terpreteerd.
De onderzoekers bleken enthousiast en dachten heel goed mee. We bleken infectiolo-
gen, farmacologen, kinderartsen en gynaecologen aan boord te hebben. Dat was een 
goede mix om een mooi onderzoek op te zetten. Met enthousiasme en kennis kom je 
een heel eind, maar aan dit soort onderzoeken hangt ook een kostenplaatje. NEAT/
Penta heeft de eerste financiële injectie gegeven en gaat daar nog steeds mee door. 
Daarnaast was Merck onze eerste partner uit de categorie farmaceutische industrie. 
Later volgden BMS, Janssen Research BV en recent ViiV Healthcare. Het hele PAN-
NA-netwerk is erg blij met deze financiële ondersteuning.
Het PANNA-onderzoek, maar ook het SARA-onderzoek en de onderzoeken die in 
dit proefschrift zijn beschreven, kwamen tot stand door een intensieve, internationale 
samenwerking. Het is niet voor niets een netwerk. Ik kon dit niet alleen en ben veel 
personen dankbaar. 
Allereerst wil ik de dames die hebben deelgenomen aan dit onderzoek bedanken. Ik 
realiseer me dat zwanger zijn en hiv-geïnfecteerd een belastende situatie is. Meedoen 
met een onderzoek is dan misschien niet het eerste waar je op zit te wachten. Bij een 
aantal deelneemsters is de diagnose hiv pas in de zwangerschap gesteld, voor hen 
heb ik extra veel respect omdat ze ondanks deze moeilijke tijd hun medewerking wilden 
verlenen. Tijdens het onderzoek bleek dat de motivatie voor het terugkomen naar het 
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ziekenhuis voor de postpartum curve moeilijk was: net moeder en dan na 4-6 weken 
weer een dag in het ziekenhuis doorbrengen. Dat is niet zo eenvoudig te regelen. 
De onderzoekers en hun team hebben geprobeerd het zo eenvoudig en aangenaam 
mogelijk te maken. Meestal konden de baby’s mee naar het ziekenhuis, en werd voor 
andere kinderen opvang betaald. Zonder de medewerking van deze zwangere dames 
was er geen PANNA-onderzoek geweest. Heel hartelijk bedankt!
Professor David Burger – mijn promotor en al een aantal jaren kantoorkamergenoot – je 
zegt altijd dat ik jouw steun en toeverlaat ben, maar dat geldt ook andersom. Zonder 
jou was het PANNA-onderzoek nooit gestart en was ik niet in het Radboudumc terecht 
gekomen. Ik wil je graag bedanken voor je vertrouwen, hulp, lobby voor financiën, 
kritische blik, geduld en heldere inzichten. Vooral jouw talent om een (volgens mij) groot 
probleem te reduceren tot iets kleins en behapbaars, zonder het te nivelleren, maar 
gewoon door er nuchter naar te kijken, bewonder ik. Ik heb natuurlijk een bevoorrechte 
positie aan het bureau tegenover jou: prangende vragen kon ik altijd stellen, maar 
voor andere promovendi staat jouw (onze) deur ook altijd open. Die open houding 
waardeer ik zeer en die kenmerkt en bepaalt ook de sfeer binnen de vakgroep. We 
hebben samen inmiddels veel congressen bezocht en dat was altijd erg leuk, gezellig 
en leerzaam. Naast het werk blijkt er nog een ander leven te zijn waar je ook graag 
collega’s in betrekt: filmclub, wandeltochten, de Parade en niet te vergeten de thuiswed-
strijden van NEC. Ook daarvoor wil ik je graag bedanken: mijn eerste voetbalwedstrijd 
in een echt stadion was een mooie ervaring. Ik ga graag weer een keer mee en dan 
maar hopen dat ik een echte panna zie.
De leden van de manuscriptcommissie, prof. Ronald de Groot, prof. Fred Lotgering en 
prof. Catherijne Knibbe, wil ik hartelijk danken voor hun snelle en goede beoordeling 
van het manuscript en voor hun mooie woorden.
Dr. Jet Gisolf, opponent en celliste: fijn dat je mijn opponent wilt zijn vandaag. Ik ben 
benieuwd naar je kritische vragen!
I would like to thank all investigators, (research) nurses and study coordinators who have 
contributed to the SARA and PANNA studies. It is quite an effort to perform a study 
in pregnant patients, especially to ask the women to participate and convince them to 
return for the postpartum visit. I am very happy with the teams at all sites: you had to 
work very independent, as I was usually not around during the busy PK sampling days. 
I also want to thank you for your hospitality during my monitoring visits, it was always 
enjoyable to be at the sites and check the very well completed CRFs. I always found 
some minor mistakes of course, thanks for that as well. It made my visits worthwhile and 
satisfactory. Without your hard work and enthusiasm these studies would not have been 
the success they are: great team work! Special thanks to all investigators who gave 
valuable input in the study protocol as well as the papers we have produced from the 
PANNA study. I hope that all of you will continue to be a member of the PANNA family 
in the future!
A very important person for me and PANNA is Carlo Giaquinto, who believed in the 
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PANNA study from day-1 onwards. I remember our first encounter in a restaurant in 
Paris, where you promised to pay my salary as a coordinator of the PANNA study. 
Thank you very much for your support and for the opportunity to present the PANNA 
study in San Servolo at the bi-annual PENTA meeting and also for being here today and 
asking relevant questions.
Another member of the PANNA family I would like to thank especially is professor 
Graham Taylor who reviewed the introduction and general discussion of this thesis. I 
asked to do an English language check, but for a genuine professor it is impossible not 
to comment on the content, which is greatly appreciated. Dear Graham: I am looking 
forward to our next jazz concert visit, wherever in the world.
I also want to thank our friends of the IMPAACT group with whom we started a fruitful 
collaboration two years ago. Dear dr. Mark Mirochnick and dr. Brookie Best, thank you 
very much for your open mind and making the collaboration possible and a success. I 
am very happy that we can work together and not approach each other as competitors. 
I am looking forward to work on our future joint papers.
Jasper van der Lugt, met wie ik de resultaten van het SARA-onderzoek heb geanaly-
seerd en gedocumenteerd, wil ik bedanken voor de korte, maar prettige samenwerking. 
Meestal op afstand, in Bangkok, maar het was ook erg gezellig als je ons in Nijmegen 
kwam bezoeken.
Naast de collega’s in het buitenland wil ook de collega’s in Nijmegen bedanken: aller-
eerst Remco de Jong, afdelingshoofd van de Apotheek van het Radboudumc, voor het 
mogelijk maken van dit promotietraject binnen de afdeling en voor de bijdrage aan de 
uitgave van dit proefschrift.
Professor Chiel Hekster, beste Chiel, de eerste jaren dat ik in de Apotheek werkte (en 
jouw laatste jaren) deelden wij een werkkamer. Dat heeft geleid tot een bijzondere 
vriendschap, we hebben nog steeds vrij intensief contact over jouw website, mijn mu-
ziekprojecten maar ook over het leven in het algemeen. Je bent altijd erg geïnteresseerd 
geweest in mijn promotieonderzoek en hield nauwkeurig mijn publicaties bij. Ik wed dat 
jij weet wat mijn H-index is! Je meldde je dan ook zelf al vroeg aan om te opponeren 
bij mijn verdediging, natuurlijk was ik daar niet tegen. Ik heb je gevraagd een schilderij 
te maken voor het omslag van dit proefschrift en ik was zeer vereerd en blij dat je dat 
wilde doen. Ik hoop dat jij ook blij bent met het resultaat.
Monique Roukens wil ik speciaal bedanken, jij bent, naast David, mijn steun en toever-
laat in de Apotheek. Als er iets moet gebeuren voor het PANNA-onderzoek sta je altijd 
meteen klaar, maakt niet uit wat of wanneer. Je levert goed werk, bent precies en snel, 
ik ben erg blij met je!
Ik heb natuurlijk een beetje een rare positie in het groepje promovendi. Het grootste 
deel van mijn baan is het ondersteunen van jullie allen. Dat deed ik en doe ik nog 
steeds met veel plezier. Maar jullie stonden ook altijd open om mee te helpen denken 
over het PANNA-onderzoek en in de laatste schrijfperiode hebben jullie me behoorlijk 
ontlast. Dank! Ik vond het ook leuk dat ik bij de promovendi die de eindstreep al zijn 
Dankwoord
246 Appendix
gepasseerd paranimf mocht zijn: Matthijs, Nina, Roger, Quirine  en Klaartje. Ik voel me 
zeer vereerd! Maren: hartelijk dank voor het samenwerken aan het raltegravir-artikel, 
dat heeft mij veel werk uit handen genomen. Je hebt er een prachtig stuk van gemaakt 
en het heeft een nog mooiere publicatie opgeleverd! Fijn dat jouw proefschrift nu ook 
klaar is, ik kijk uit naar jouw feestje. Diane en Vincent, jullie zijn ook al bijna klaar 
met het traject, zet hem op! Het is mogelijk! En alle ‘verse’ promovendi: Eline, Lindsey, 
Robert, Lisa, Mette, Elise en Pauline, wat een gezellig en ambitieus clubje zijn jullie, erg 
inspirerend, ook voor de ouderen onder ons. Ik zal jullie graag ondersteunen bij de 
onderzoeken die jullie uitvoeren.
Een speciaal woordje voor Stein, vanaf nu ben ik echt je copromotor. Ik vind het erg 
prettig om met jou te werken, het jonge-honden-enthousiasme werkt aanstekelijk. Je hebt 
een leuke baan met veel mogelijkheden op de twee afdelingen (Apotheek en Farmaco-
logie & Toxicologie). Soms is het wat lastig om de aandacht te verdelen, maar ik denk 
dat je vooral veel voordelen uit de samenwerking kunt halen. Ik heb er alle vertrouwen 
in dat het een prachtig, gevarieerd proefschrift gaat opleveren. Heel veel succes!
De post-docs, of senior onderzoekers, Rob Aarnoutse, Roger Brüggemann, Nielka van 
Erp en Rob ter Heine, wil ik ook bedanken. Jullie leven altijd mee met mijn wel en wee 
als onderzoeker en als researchassistente. Jullie kritische houding bij de voordrachten is 
erg prettig en leerzaam, maar jullie vertrouwen in mijn GCP-kennis is ook erg stimule-
rend. Ik hoop dat ik nog lang met jullie mag samenwerken!
Stagiaire Carlijn dank ik zeer voor jouw bijdrage aan het laatste hoofdstuk van mijn 
proefschrift. Je hebt heel goed werk geleverd en ik vind het bijzonder dat je bent 
gevallen voor het onderwerp ‘medicatiegebruik in de zwangerschap’. Je vervolgstage 
bij het LAREB en de komende stage hebben er allemaal mee te maken. Veel succes 
daarmee en ik kom je vast weer tegen!
En dan prof. Frans Russel en dr. Rick Greupink van de afdeling Farmacologie & Toxicolo-
gie van het Radboudumc. Ik wil jullie bedanken voor de mogelijkheid die jullie hebben 
geboden om een PBPK-model te ontwikkelen. Dit was voor mij geen gesneden koek, 
en de intensieve ondersteuning van Rick heeft mij erg geholpen. Voor jullie beiden is het 
reviewen van het artikel vaak nachtwerk geweest – blijkbaar hebben slimme mensen 
weinig slaap nodig. Ik waardeer jullie uitzonderlijke inzet zeer. Een mooie start van een 
samenwerking die vervolg krijgt in het promotietraject van Stein. Ik hoop nog verder te 
gaan met PBPK modelleren. Het is een interessant, veelbelovend, maar ingewikkeld 
onderwerp.
De analisten van het laboratorium van de Apotheek wil ik bedanken voor het meten van 
de plasmamonsters van het PANNA onderzoek. Khalid verdient een speciaal woord 
van dank voor het coördineren van alle metingen. Sorry dat ik je altijd op je nek zit! 
Maar je werk wordt erg gewaardeerd! Ook Noor wil ik apart bedanken voor het zeer 
consciëntieus opzetten van de analysemethode voor het meten van de vrije concentra-
ties darunavir. Dat was een behoorlijke klus, die volgens mij prima is geslaagd. Veel 
dank voor jouw inzet! Bo, jij hebt ook allerlei klussen uitgevoerd voor het PANNA-on-
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derzoek. We kennen elkaar al heel lang, en ik weet dat ik op je kan bouwen! Hartelijk 
dank.
Graag wil ik alle collega’s uit de Apotheek bedanken voor hun interesse in mijn 
onderzoek. De meesten weten alleen de naam: samples van het PANNA-onderzoek, 
die binnenkomen bij het magazijn. Anderen heb ik wel eens iets verteld in een klinische 
les, blijkbaar deed ik dat zo enthousiast dat ik bekend sta als ‘die vrouw die haar 
werk zo leuk vindt’. Alle ziekenhuisapothekers in opleiding wens ik veel succes met de 
opleiding en ik help jullie graag met het registratieonderzoek als het zo ver is.
Ook mijn familie en vrienden hebben ertoe bijgedragen dat ik hier nu sta en dat er een 
mooi proefschrift ligt. 
Alle muziekvrienden, en dat zijn er echt te veel om allemaal op te noemen, leverden me 
de nodige afleiding, vooral de laatste maanden van het schrijfproces. Het was heerlijk 
om ook een totaal andere bezigheid te hebben naast het schrijven van intelligente 
teksten! Niet alleen het samenspelen, maar ook de drankjes na afloop hielpen erg.
Mijn lieve vriendin Chris wil ik bedanken voor haar steun en luisterend oor. Heel fijn 
om te weten dat ik altijd bij je kan aankloppen met fijne en minder fijne verhalen, dat 
koester ik!
Ingrid wil ik ook bedanken voor de hechte vriendschap, het verzorgen van mijn geluk 
als ik weer eens op congres of monitorbezoek in het buitenland was, en ook voor het 
controleren en aanpassen van de Nederlandse teksten in dit proefschrift. Je kritische 
opmerkingen hebben me erg geholpen. Super bedankt!
Mijn twee paranimfen: Klaartje en Quirine. Fijn en geruststellend dat jullie er bij zijn 
vandaag. Jullie hebben het overleefd, dus dan zal het mij ook wel lukken! Ik wil jullie 
bedanken voor de vriendschap die tussen ons is ontstaan en ik denk nog vaak terug 
aan onze prachtige reis door Afrika. We hebben afgelopen jaren niet alleen tenten, 
maar ook hotelkamers gedeeld als we op congres waren. Dat was altijd een feest! Ik 
mis jullie, ladies! We regelen wel regelmatig een borrel of een etentje!
Lieve Helga, lief zusje, leuk dat je af en toe mee ging op reis, bijvoorbeeld als ik moest 
monitoren in Dublin. Dat was erg gezellig! En ook fijn dat je niet zeurde als ik tijdens 
ons vakantiereisje naar Barcelona ook nog even een dagje ging werken. En natuurlijk 
ook bedankt voor je advies bij het kopen van de promotiejurk.
Lieve pap en mam, jullie hebben dit allemaal mogelijk gemaakt. Ik ben altijd vrij gelaten 
in mijn studiekeuze, werk en andere zaken. Dat heeft me erg zelfstandig gemaakt, of 
misschien is het ook wel andersom: dat ik zelfstandig was (en een tikkeltje eigenwijs) 
en dat jullie me daarom los hebben gelaten. Uiteindelijk heeft het geleid tot dit proef-
schrift en ook het PANNA-netwerk, waar we denk ik wel trots op mogen zijn. Pap, heel 
jammer dat je er niet meer fysiek bij bent, maar in mijn gedachten ben je er wel hoor. 
En zoals een muziekcollega zei na jouw overlijden: vanaf nu heeft hij de beste plek in 
het publiek. Ik zie je al trots glunderen. Heel erg bedankt voor jouw steun. Lieve mam, 
bedankt voor je goede zorgen en interesse in mijn werk. Superfijn dat Helga en jij er 
bij zijn vandaag om dit bijzondere moment mee te maken.
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List of PANNA investigators
Andrea Antinori, IRCSS, Roma, Italy
Ineke van der Ende, Erasmus MC Rotterdam, The Netherlands
Gerd Faetkenheuer, University of Cologne, Cologne, Germany
Carlo Giaquinto, University of Padua, Italy
Yvonne Gilleece, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK
Andrea Gingelmaier, Klinikum der Universität München, Frauenklinik Innenstadt, 
München, Germany
Annette Haberl -  Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany
David Hawkins - Chelsea & Westminster Hospital, London, UK
Carmen Hidalgo Tenorio - Hospital Universitario Virgen de las Nieves Granada, 
Granada, Spain
Jelena Ivanovic, IRCSS, Roma, Italy
Kabamba Kabeya - Saint-Pierre University Hospital, Brussels, Belgium
Marjo van Kasteren -  St Elisabeth Ziekenhuis, Tilburg, The Netherlands
John Lambert, Mater Misericordiae University Hospital Dublin, Ireland
Fyona Lyons, St James’s Hospital Dublin, Ireland
José Moltó, Hospital Universitari Germans Trias I Pujol, Badalona, Spain
Jeannine Nellen, Academisch Medisch Centrum, Amsterdam, The Netherlands
Emanuelle Nicastri, MD, National Institute for Infectious Diseases “L. Spallanzani”, 
Rome,  Italy
Jürgen Rockstroh and Caroline Schwarze-Zander, University of Bonn, Germany
Annemiek de Ruiter, St Thomas’ hospital, London, UK
Tariq Sadiq, Institution for Infection and Immunity, St George’s, University of London, 
London, UK
Graham Taylor - Imperial College Healthcare NHS Trust, London, UK
André van der Ven , Radboud university medical center, Nijmegen, The Netherlands
Katharina Weizsäcker, Klinik für Geburtsmedizin; Charité Universitätsmedizin, Berlin, 
Germany
Chris Wood, North Middlesex Hospital, London, UK
Christoph Wyen, University of Cologne, Cologne, Germany
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